USRE45324E1 - Intermediates for the preparation of analogs of halichondrin B - Google Patents
Intermediates for the preparation of analogs of halichondrin B Download PDFInfo
- Publication number
- USRE45324E1 USRE45324E1 US13/495,909 US200513495909A USRE45324E US RE45324 E1 USRE45324 E1 US RE45324E1 US 200513495909 A US200513495909 A US 200513495909A US RE45324 E USRE45324 E US RE45324E
- Authority
- US
- United States
- Prior art keywords
- vol
- added
- ether
- reaction
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 239000000543 intermediate Substances 0.000 title abstract description 41
- FXNFULJVOQMBCW-VZBLNRDYSA-N halichondrin b Chemical compound O([C@@H]1[C@@H](C)[C@@H]2O[C@@H]3C[C@@]4(O[C@H]5[C@@H](C)C[C@@]6(C[C@@H]([C@@H]7O[C@@H](C[C@@H]7O6)[C@@H](O)C[C@@H](O)CO)C)O[C@H]5C4)O[C@@H]3C[C@@H]2O[C@H]1C[C@@H]1C(=C)[C@H](C)C[C@@H](O1)CC[C@H]1C(=C)C[C@@H](O1)CC1)C(=O)C[C@H](O2)CC[C@H]3[C@H]2[C@H](O2)[C@@H]4O[C@@H]5C[C@@]21O[C@@H]5[C@@H]4O3 FXNFULJVOQMBCW-VZBLNRDYSA-N 0.000 title description 15
- 238000002360 preparation method Methods 0.000 title description 12
- ZBLLGPUWGCOJNG-UHFFFAOYSA-N Halichondrin B Natural products CC1CC2(CC(C)C3OC4(CC5OC6C(CC5O4)OC7CC8OC9CCC%10OC(CC(C(C9)C8=C)C%11%12CC%13OC%14C(OC%15CCC(CC(=O)OC7C6C)OC%15C%14O%11)C%13O%12)CC%10=C)CC3O2)OC%16OC(CC1%16)C(O)CC(O)CO ZBLLGPUWGCOJNG-UHFFFAOYSA-N 0.000 title description 11
- 239000000203 mixture Substances 0.000 claims abstract description 148
- 150000001875 compounds Chemical class 0.000 claims abstract description 104
- -1 arylalkyl ether Chemical compound 0.000 claims description 139
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 32
- 239000002904 solvent Substances 0.000 claims description 25
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims description 22
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 19
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 150000002009 diols Chemical group 0.000 claims description 17
- 125000001931 aliphatic group Chemical group 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 125000005905 mesyloxy group Chemical group 0.000 claims description 12
- 125000005547 pivalate group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 150000005215 alkyl ethers Chemical class 0.000 claims description 10
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 9
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 7
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 7
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical group [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 5
- 150000001241 acetals Chemical class 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 5
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 claims description 4
- ZOJKRWXDNYZASL-NSCUHMNNSA-N (e)-4-methoxybut-2-enoic acid Chemical compound COC\C=C\C(O)=O ZOJKRWXDNYZASL-NSCUHMNNSA-N 0.000 claims description 4
- FFFIRKXTFQCCKJ-UHFFFAOYSA-M 2,4,6-trimethylbenzoate Chemical compound CC1=CC(C)=C(C([O-])=O)C(C)=C1 FFFIRKXTFQCCKJ-UHFFFAOYSA-M 0.000 claims description 4
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 claims description 4
- GPVOTFQILZVCFP-UHFFFAOYSA-N 2-trityloxyacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(=O)O)C1=CC=CC=C1 GPVOTFQILZVCFP-UHFFFAOYSA-N 0.000 claims description 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 claims description 4
- FPHVRPCVNPHPBH-UHFFFAOYSA-N 4-benzylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CC1=CC=CC=C1 FPHVRPCVNPHPBH-UHFFFAOYSA-N 0.000 claims description 4
- JOOXCMJARBKPKM-UHFFFAOYSA-M 4-oxopentanoate Chemical compound CC(=O)CCC([O-])=O JOOXCMJARBKPKM-UHFFFAOYSA-M 0.000 claims description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 4
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 claims description 4
- 229940089960 chloroacetate Drugs 0.000 claims description 4
- RMIODHQZRUFFFF-UHFFFAOYSA-M methoxyacetate Chemical compound COCC([O-])=O RMIODHQZRUFFFF-UHFFFAOYSA-M 0.000 claims description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 4
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 claims description 4
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 claims description 4
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 3
- 150000005676 cyclic carbonates Chemical class 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- PWAPCRSSMCLZHG-UHFFFAOYSA-N cyclopentylidene Chemical group [C]1CCCC1 PWAPCRSSMCLZHG-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 2
- VAYTZRYEBVHVLE-UHFFFAOYSA-N 1,3-dioxol-2-one Chemical compound O=C1OC=CO1 VAYTZRYEBVHVLE-UHFFFAOYSA-N 0.000 claims 1
- PGTRXPWCFSKHIL-UHFFFAOYSA-N 2-(benzenesulfonyl)ethyl hydrogen carbonate Chemical compound OC(=O)OCCS(=O)(=O)C1=CC=CC=C1 PGTRXPWCFSKHIL-UHFFFAOYSA-N 0.000 claims 1
- LDZNCSVWVMBVST-UHFFFAOYSA-N 2-trimethylsilylethyl hydrogen carbonate Chemical compound C[Si](C)(C)CCOC(O)=O LDZNCSVWVMBVST-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- IEPBPSSCIZTJIF-UHFFFAOYSA-N bis(2,2,2-trichloroethyl) carbonate Chemical compound ClC(Cl)(Cl)COC(=O)OCC(Cl)(Cl)Cl IEPBPSSCIZTJIF-UHFFFAOYSA-N 0.000 claims 1
- JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 claims 1
- JZUVESQYEHERMD-UHFFFAOYSA-N bis[(4-nitrophenyl)methyl] carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)OCC1=CC=C([N+]([O-])=O)C=C1 JZUVESQYEHERMD-UHFFFAOYSA-N 0.000 claims 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 claims 1
- FGIVSGPRGVABAB-UHFFFAOYSA-N fluoren-9-ylmethyl hydrogen carbonate Chemical compound C1=CC=C2C(COC(=O)O)C3=CC=CC=C3C2=C1 FGIVSGPRGVABAB-UHFFFAOYSA-N 0.000 claims 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 claims 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 claims 1
- LGSAOJLQTXCYHF-UHFFFAOYSA-N tri(propan-2-yl)-tri(propan-2-yl)silyloxysilane Chemical compound CC(C)[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)C(C)C LGSAOJLQTXCYHF-UHFFFAOYSA-N 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 230000002062 proliferating effect Effects 0.000 abstract description 2
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 204
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 199
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 176
- 238000006243 chemical reaction Methods 0.000 description 170
- 239000000243 solution Substances 0.000 description 165
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 137
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 135
- 239000010410 layer Substances 0.000 description 121
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 92
- 239000012044 organic layer Substances 0.000 description 87
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 85
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 70
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 67
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 58
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 51
- 239000012267 brine Substances 0.000 description 49
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 41
- 238000000034 method Methods 0.000 description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 31
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 0 [1*]C1C(CC(C)CC)OC(CC(O)C(=C)C(C)CC(C)CCC2OC(CCCC)CC2=C)C1CS(=O)(=O)C1=CC=CC=C1 Chemical compound [1*]C1C(CC(C)CC)OC(CC(O)C(=C)C(C)CC(C)CCC2OC(CCCC)CC2=C)C1CS(=O)(=O)C1=CC=CC=C1 0.000 description 30
- 235000019439 ethyl acetate Nutrition 0.000 description 30
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 30
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 29
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 29
- 238000003756 stirring Methods 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- 239000000284 extract Substances 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 239000000706 filtrate Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 25
- 230000002829 reductive effect Effects 0.000 description 25
- 239000000725 suspension Substances 0.000 description 25
- 239000007787 solid Substances 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- 235000017557 sodium bicarbonate Nutrition 0.000 description 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 20
- 238000001914 filtration Methods 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- 239000000377 silicon dioxide Substances 0.000 description 18
- 229910052681 coesite Inorganic materials 0.000 description 17
- 229910052906 cristobalite Inorganic materials 0.000 description 17
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- 229910052682 stishovite Inorganic materials 0.000 description 17
- 229910052905 tridymite Inorganic materials 0.000 description 17
- 239000012065 filter cake Substances 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 16
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 125000006239 protecting group Chemical group 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 239000012298 atmosphere Substances 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 13
- 238000004587 chromatography analysis Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 12
- 238000005192 partition Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 11
- 239000002244 precipitate Substances 0.000 description 11
- 239000012043 crude product Substances 0.000 description 10
- 238000004821 distillation Methods 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 8
- 125000005843 halogen group Chemical group 0.000 description 8
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 8
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 8
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000011065 in-situ storage Methods 0.000 description 7
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 7
- 239000011736 potassium bicarbonate Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 7
- AAWZDTNXLSGCEK-WYWMIBKRSA-N (-)-quinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1O AAWZDTNXLSGCEK-WYWMIBKRSA-N 0.000 description 6
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 6
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 6
- 239000012230 colorless oil Substances 0.000 description 6
- 150000002170 ethers Chemical class 0.000 description 6
- NTNUDYROPUKXNA-UHFFFAOYSA-N methyl 2-(triphenyl-$l^{5}-phosphanylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC)C1=CC=CC=C1 NTNUDYROPUKXNA-UHFFFAOYSA-N 0.000 description 6
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 6
- 238000010626 work up procedure Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229910021554 Chromium(II) chloride Inorganic materials 0.000 description 5
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- XBWRJSSJWDOUSJ-UHFFFAOYSA-L chromium(ii) chloride Chemical compound Cl[Cr]Cl XBWRJSSJWDOUSJ-UHFFFAOYSA-L 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 description 5
- 125000002346 iodo group Chemical group I* 0.000 description 5
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 5
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 5
- 125000004043 oxo group Chemical group O=* 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000019345 sodium thiosulphate Nutrition 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 125000003107 substituted aryl group Chemical group 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000010533 azeotropic distillation Methods 0.000 description 4
- 239000012455 biphasic mixture Substances 0.000 description 4
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 239000013058 crude material Substances 0.000 description 4
- 239000010779 crude oil Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 235000010265 sodium sulphite Nutrition 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- 229910052717 sulfur Chemical group 0.000 description 4
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- MBMQEIFVQACCCH-QBODLPLBSA-N zearalenone Chemical compound O=C1O[C@@H](C)CCCC(=O)CCC\C=C\C2=CC(O)=CC(O)=C21 MBMQEIFVQACCCH-QBODLPLBSA-N 0.000 description 4
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- SOGFSQSGBFDQFA-OFNDNPAQSA-N chembl185856 Chemical compound C([C@H]1CC[C@@H]2OC3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CO)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 SOGFSQSGBFDQFA-OFNDNPAQSA-N 0.000 description 3
- 229940126208 compound 22 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- LDHQCZJRKDOVOX-NSCUHMNNSA-M crotonate Chemical compound C\C=C\C([O-])=O LDHQCZJRKDOVOX-NSCUHMNNSA-M 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 150000004675 formic acid derivatives Chemical class 0.000 description 3
- 239000008241 heterogeneous mixture Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000003871 sulfonates Chemical class 0.000 description 3
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 3
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 3
- OOKAXSHFTDPZHP-UHFFFAOYSA-N (1-bromo-2-methyl-1-oxopropan-2-yl) acetate Chemical compound CC(=O)OC(C)(C)C(Br)=O OOKAXSHFTDPZHP-UHFFFAOYSA-N 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- YMFWYDYJHRGGPF-UHFFFAOYSA-N 2,3-dibromoprop-1-ene Chemical compound BrCC(Br)=C YMFWYDYJHRGGPF-UHFFFAOYSA-N 0.000 description 2
- OGLCQHRZUSEXNB-UHFFFAOYSA-N 2-Pinene-9, 10-diol Natural products OC1C(=O)OC2C(O)C(O)OC21 OGLCQHRZUSEXNB-UHFFFAOYSA-N 0.000 description 2
- FKXCNOSKBLGEMQ-UHFFFAOYSA-N 2-bromoethenyl(trimethyl)silane Chemical group C[Si](C)(C)C=CBr FKXCNOSKBLGEMQ-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical group CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PJQUDRJHWUHSGO-UHFFFAOYSA-N D-Glucurono-6,3-lactone Natural products OC(=O)CCCCCCCC1CCC(CC(O)=O)O1 PJQUDRJHWUHSGO-UHFFFAOYSA-N 0.000 description 2
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 description 2
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 101150026303 HEX1 gene Proteins 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- LUSRAIIDHYLWDQ-BKISDOJLSA-N [H][C@@]12CCC3CC(=O)C[C@H]4[C@H](CC5O[C@@H](CCC6O[C@@H](CCC(=O)/C=C/[C@H](O[Si](C)(C)C(C)(C)C)[C@H](O1)[C@@H](C)[C@@H](C)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](C)CC)[C@@H]4C.[H][C@@]12CCC3CC(=O)C[C@H]4[C@H](CC5O[C@@H](CCC6O[C@@H](CCC(O)/C=C/[C@H](O[Si](C)(C)C(C)(C)C)[C@H](O1)[C@@H](C)[C@@H](C)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](C)CC)[C@@H]4C Chemical compound [H][C@@]12CCC3CC(=O)C[C@H]4[C@H](CC5O[C@@H](CCC6O[C@@H](CCC(=O)/C=C/[C@H](O[Si](C)(C)C(C)(C)C)[C@H](O1)[C@@H](C)[C@@H](C)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](C)CC)[C@@H]4C.[H][C@@]12CCC3CC(=O)C[C@H]4[C@H](CC5O[C@@H](CCC6O[C@@H](CCC(O)/C=C/[C@H](O[Si](C)(C)C(C)(C)C)[C@H](O1)[C@@H](C)[C@@H](C)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](C)CC)[C@@H]4C LUSRAIIDHYLWDQ-BKISDOJLSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 2
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 150000002118 epoxides Chemical group 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 2
- DJXDHDYQDMVTPZ-UHFFFAOYSA-N methyl 3-trimethylsilylpent-4-enoate Chemical compound COC(=O)CC(C=C)[Si](C)(C)C DJXDHDYQDMVTPZ-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- UAWABSHMGXMCRK-UHFFFAOYSA-L samarium(ii) iodide Chemical compound I[Sm]I UAWABSHMGXMCRK-UHFFFAOYSA-L 0.000 description 2
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 2
- 239000001433 sodium tartrate Substances 0.000 description 2
- 229960002167 sodium tartrate Drugs 0.000 description 2
- 235000011004 sodium tartrates Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- PDVFSPNIEOYOQL-UHFFFAOYSA-N (4-methylphenyl)sulfonyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OS(=O)(=O)C1=CC=C(C)C=C1 PDVFSPNIEOYOQL-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- ARCFYUDCVYJQRN-KGHNJIHGSA-N 1,4-bis[(r)-[(2r,4s,5s)-5-ethyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methoxy]anthracene-9,10-dione Chemical compound C1=C(OC)C=C2C([C@@H](OC=3C=4C(=O)C5=CC=CC=C5C(=O)C=4C(O[C@@H]([C@@H]4N5CC[C@H]([C@@H](C5)CC)C4)C=4C5=CC(OC)=CC=C5N=CC=4)=CC=3)[C@H]3C[C@@H]4CCN3C[C@H]4CC)=CC=NC2=C1 ARCFYUDCVYJQRN-KGHNJIHGSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- SYZRZLUNWVNNNV-UHFFFAOYSA-N 2-bromoacetyl chloride Chemical compound ClC(=O)CBr SYZRZLUNWVNNNV-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- 241000726101 Axinella Species 0.000 description 1
- INEMBLIDDSFTPR-OTCIIXPJSA-N B.C.C.C=O.CC1=CC(C)=C(S(=O)(=O)NN)C(C)=C1.CCO.CCO.[H][C@]12CC[C@H](CCC)O[C@@]1(C=O)C[C@H](C#C)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](C#C)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](C#CCO)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCO)O2.[H][C@]12CC[C@H](CCC)O[C@@]13C[C@@]([H])(O2)C(=O)C1O[C@@H]13.[H][C@]12CC[C@H](CCC)O[C@@]13C[C@@]([H])(O2)C(O)C1O[C@@H]13.[H][C@]12CC[C@H](CCC)O[C@]13C=CC(O)[C@@]([H])(C3)O2.[NaH] Chemical compound B.C.C.C=O.CC1=CC(C)=C(S(=O)(=O)NN)C(C)=C1.CCO.CCO.[H][C@]12CC[C@H](CCC)O[C@@]1(C=O)C[C@H](C#C)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](C#C)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](C#CCO)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCO)O2.[H][C@]12CC[C@H](CCC)O[C@@]13C[C@@]([H])(O2)C(=O)C1O[C@@H]13.[H][C@]12CC[C@H](CCC)O[C@@]13C[C@@]([H])(O2)C(O)C1O[C@@H]13.[H][C@]12CC[C@H](CCC)O[C@]13C=CC(O)[C@@]([H])(C3)O2.[NaH] INEMBLIDDSFTPR-OTCIIXPJSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- HBNQXBUVGOGNNE-RGRQVADUSA-N C.C.O=C=O.O=C=O.[H][C@]12CC[C@H](CC)O[C@]13CC1OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CC)O[C@]13C[C@@H](O)C(O)[C@@]([H])(C3)O2 Chemical compound C.C.O=C=O.O=C=O.[H][C@]12CC[C@H](CC)O[C@]13CC1OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CC)O[C@]13C[C@@H](O)C(O)[C@@]([H])(C3)O2 HBNQXBUVGOGNNE-RGRQVADUSA-N 0.000 description 1
- XIGDMBKPUHFQKO-PMJSRTKNSA-N C.C.O=C=O.[H][C@@]12C[C@@](O)(C[C@H]3OC4(CCCCC4)OC31)C(=O)O2.[H][C@]1(O)C[C@@H](O)[C@@H](O)[C@H](O)C1 Chemical compound C.C.O=C=O.[H][C@@]12C[C@@](O)(C[C@H]3OC4(CCCCC4)OC31)C(=O)O2.[H][C@]1(O)C[C@@H](O)[C@@H](O)[C@H](O)C1 XIGDMBKPUHFQKO-PMJSRTKNSA-N 0.000 description 1
- HUMBGUAITWEHGB-OMEITMGVSA-N C.C=C(C)C(C)C[C@H](C)CCC1O[C@@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)CC1=C.C=C(C)C(C)C[C@H](O)CCC1O[C@@H](CCCO)CC1=C Chemical compound C.C=C(C)C(C)C[C@H](C)CCC1O[C@@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)CC1=C.C=C(C)C(C)C[C@H](O)CCC1O[C@@H](CCCO)CC1=C HUMBGUAITWEHGB-OMEITMGVSA-N 0.000 description 1
- ZNEJRJAWPSHFMX-BAJWRBODSA-N C.C=C(C)C(C)C[C@H](C)CCC1O[C@@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)CC1=C.C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)OC1CC[C@@H](C)CC(C)C(C)=O Chemical compound C.C=C(C)C(C)C[C@H](C)CCC1O[C@@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)CC1=C.C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)OC1CC[C@@H](C)CC(C)C(C)=O ZNEJRJAWPSHFMX-BAJWRBODSA-N 0.000 description 1
- FURNXVCKNCPMGH-MAMSWXILSA-N C.C=C(OS(=O)(=O)C(F)(F)F)C(C)C[C@H](O)CCC1O[C@@H](CCCO)CC1=C.C=C1C[C@H](CCCO)O[C@H]1CC[C@@H](O)C[C@@H](C)C(=C)OS(=O)(=O)C(F)(F)F Chemical compound C.C=C(OS(=O)(=O)C(F)(F)F)C(C)C[C@H](O)CCC1O[C@@H](CCCO)CC1=C.C=C1C[C@H](CCCO)O[C@H]1CC[C@@H](O)C[C@@H](C)C(=C)OS(=O)(=O)C(F)(F)F FURNXVCKNCPMGH-MAMSWXILSA-N 0.000 description 1
- XNVIOJJXBDIVJY-VEGPEHBUSA-N C.C=C1C[C@H](CCCO)O[C@H]1CC[C@@H](O)C[C@@H](C)C(=C)C.C=C1C[C@H](CCCOC(=O)C(C)(C)C)O[C@H]1CC[C@@H](O)C[C@@H](C)C(=C)C Chemical compound C.C=C1C[C@H](CCCO)O[C@H]1CC[C@@H](O)C[C@@H](C)C(=C)C.C=C1C[C@H](CCCOC(=O)C(C)(C)C)O[C@H]1CC[C@@H](O)C[C@@H](C)C(=C)C XNVIOJJXBDIVJY-VEGPEHBUSA-N 0.000 description 1
- HEIGRAOEPFLDJJ-AWHLDLKRSA-N C.C=CC[C@@H]1O[C@H](C[C@@H](CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C[C@H]1[C@@H](C[C@@H](CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)O[C@@H](CC=O)[C@@H]1CS(=O)(=O)C1=CC=CC=C1 Chemical compound C.C=CC[C@@H]1O[C@H](C[C@@H](CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C[C@H]1[C@@H](C[C@@H](CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)O[C@@H](CC=O)[C@@H]1CS(=O)(=O)C1=CC=CC=C1 HEIGRAOEPFLDJJ-AWHLDLKRSA-N 0.000 description 1
- XLFMWNFHWKWJNP-QLYMZZJJSA-N C.CC(=O)OC(C)(C)C(=O)Br.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](O)C3O)O1.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H](Br)[C@H]3OC(C)=O)O1 Chemical compound C.CC(=O)OC(C)(C)C(=O)Br.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](O)C3O)O1.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H](Br)[C@H]3OC(C)=O)O1 XLFMWNFHWKWJNP-QLYMZZJJSA-N 0.000 description 1
- JVNCNHCOPYWHLG-UHFFFAOYSA-N C.CC1=C2NC(=O)OC(=O)C2=CC=C1.CC1=CC=CC(C(=O)O)=C1N.O=C(OC(Cl)(Cl)Cl)Cl1Cl2Cl3OC312 Chemical compound C.CC1=C2NC(=O)OC(=O)C2=CC=C1.CC1=CC=CC(C(=O)O)=C1N.O=C(OC(Cl)(Cl)Cl)Cl1Cl2Cl3OC312 JVNCNHCOPYWHLG-UHFFFAOYSA-N 0.000 description 1
- BNQHFYAINVVXHT-LVZIGJPPSA-N C.CCC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](C)[C@H]3C)O1.CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](C)[C@H]3C)O1.C[C@@H]1C[C@]23C[C@@H](O[C@H]2CC[C@H](CCO)O3)[C@@H]1C.N#C[K].O=C=O.[C-4].[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](C)[C@H]3C)O1.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](O)[C@H]3O)O1.[CH-3].[CH2-2].[CH3-] Chemical compound C.CCC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](C)[C@H]3C)O1.CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](C)[C@H]3C)O1.C[C@@H]1C[C@]23C[C@@H](O[C@H]2CC[C@H](CCO)O3)[C@@H]1C.N#C[K].O=C=O.[C-4].[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](C)[C@H]3C)O1.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](O)[C@H]3O)O1.[CH-3].[CH2-2].[CH3-] BNQHFYAINVVXHT-LVZIGJPPSA-N 0.000 description 1
- RXYDJPZAIQZXDC-LMFNJBLNSA-N C.ClCCl.[H][C@]12CC[C@H](CCC)O[C@]13CC1OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CCO)O[C@]13CC1OC1[C@@]([H])(C3)O2 Chemical compound C.ClCCl.[H][C@]12CC[C@H](CCC)O[C@]13CC1OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CCO)O[C@]13CC1OC1[C@@]([H])(C3)O2 RXYDJPZAIQZXDC-LMFNJBLNSA-N 0.000 description 1
- DXOLFXLLGHCBJX-QHQHGPNMSA-N C.O=C=O.[H][C@]12CC[C@H](CC)O[C@]13CC1OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CCO)O[C@]13CC1OC1[C@@]([H])(C3)O2 Chemical compound C.O=C=O.[H][C@]12CC[C@H](CC)O[C@]13CC1OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CCO)O[C@]13CC1OC1[C@@]([H])(C3)O2 DXOLFXLLGHCBJX-QHQHGPNMSA-N 0.000 description 1
- FNYSNJCNSMURHQ-ZLNGWWRKSA-N C.[2H]B[U].[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C=C[C@H]3OC(C)=O)O1.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H](Br)[C@H]3OC(C)=O)O1 Chemical compound C.[2H]B[U].[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C=C[C@H]3OC(C)=O)O1.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H](Br)[C@H]3OC(C)=O)O1 FNYSNJCNSMURHQ-ZLNGWWRKSA-N 0.000 description 1
- WSTFTTCADMRXJV-ZQGGXLJUSA-N C.[H][C@]12CC[C@H](CCC)O[C@]13C=CC(O)[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CCC)O[C@]13CC1OC1[C@@]([H])(C3)O2 Chemical compound C.[H][C@]12CC[C@H](CCC)O[C@]13C=CC(O)[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CCC)O[C@]13CC1OC1[C@@]([H])(C3)O2 WSTFTTCADMRXJV-ZQGGXLJUSA-N 0.000 description 1
- ZGUJPVBSBJZTAI-UHFFFAOYSA-N C1=COCC1.C=C(Br)CBr.C=C(Br)CC(O)CCCO.OC1CCCO1 Chemical compound C1=COCC1.C=C(Br)CBr.C=C(Br)CC(O)CCCO.OC1CCCO1 ZGUJPVBSBJZTAI-UHFFFAOYSA-N 0.000 description 1
- NPIMEGCQVJUSBD-QGESBSACSA-N C1CCOC1.C=CC(CC)[Si](C)(C)C.O=C=O.O=C=O.O=C=O.O=C=O.O=S(=O)(O)O.[H][C@@]12C[C@@](C)(C[C@H]3OC4(CCCCC4)O[C@H]31)C(=O)O2.[H][C@@]12C[C@@](C)(C[C@H]3OC4(CCCCC4)O[C@H]31)C(O)O2.[H][C@@]12C[C@@](C)(C[C@H]3OC4(CCCCC4)O[C@H]31)C(O)O2.[H][C@@]12C[C@@](C)(C[C@H]3OC4(CCCCC4)O[C@H]31)C(OC(C)=O)O2.[H][C@@]12C[C@@](C)(C[C@H]3OC4(CCCCC4)O[C@H]31)[C@H](C/C=C/CC)O2.[H][C@@]12C[C@@](O)(C[C@H]3OC4(CCCCC4)O[C@H]31)C(=O)O2.[H][C@]1(O)C[C@@H](O)[C@@H](O)[C@H](O)C1.[H][C@]12CC[C@H](CC)O[C@]13C[C@H]1OC4(CCCCC4)OC1[C@@]([H])(C3)O2 Chemical compound C1CCOC1.C=CC(CC)[Si](C)(C)C.O=C=O.O=C=O.O=C=O.O=C=O.O=S(=O)(O)O.[H][C@@]12C[C@@](C)(C[C@H]3OC4(CCCCC4)O[C@H]31)C(=O)O2.[H][C@@]12C[C@@](C)(C[C@H]3OC4(CCCCC4)O[C@H]31)C(O)O2.[H][C@@]12C[C@@](C)(C[C@H]3OC4(CCCCC4)O[C@H]31)C(O)O2.[H][C@@]12C[C@@](C)(C[C@H]3OC4(CCCCC4)O[C@H]31)C(OC(C)=O)O2.[H][C@@]12C[C@@](C)(C[C@H]3OC4(CCCCC4)O[C@H]31)[C@H](C/C=C/CC)O2.[H][C@@]12C[C@@](O)(C[C@H]3OC4(CCCCC4)O[C@H]31)C(=O)O2.[H][C@]1(O)C[C@@H](O)[C@@H](O)[C@H](O)C1.[H][C@]12CC[C@H](CC)O[C@]13C[C@H]1OC4(CCCCC4)OC1[C@@]([H])(C3)O2 NPIMEGCQVJUSBD-QGESBSACSA-N 0.000 description 1
- PPXQWIVDHGKOGJ-GDFMJWNDSA-N C1CCOC1.CCCC1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1.CCN(CC)CC.CCN(CC)CC.OCCC1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1 Chemical compound C1CCOC1.CCCC1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1.CCN(CC)CC.CCN(CC)CC.OCCC1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1 PPXQWIVDHGKOGJ-GDFMJWNDSA-N 0.000 description 1
- ACVIPJIDIUTOPU-GMVHEEFESA-N C1CCOC1.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCC(=O)OC)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CO)C[C@H](CCC(=O)OC)O2 Chemical compound C1CCOC1.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCC(=O)OC)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CO)C[C@H](CCC(=O)OC)O2 ACVIPJIDIUTOPU-GMVHEEFESA-N 0.000 description 1
- KHAAMPFEWYCJPR-UHFFFAOYSA-N C=C(Br)CC(O)CCCO.C=C(Br)CC(O)CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound C=C(Br)CC(O)CCCO.C=C(Br)CC(O)CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C KHAAMPFEWYCJPR-UHFFFAOYSA-N 0.000 description 1
- AISUMUZBFLIFED-DCSCKUOQSA-N C=C(Br)CC(O)CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.C=C(Br)C[C@@H](O)CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.C=C(Br)C[C@H](O)CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound C=C(Br)CC(O)CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.C=C(Br)C[C@@H](O)CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.C=C(Br)C[C@H](O)CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C AISUMUZBFLIFED-DCSCKUOQSA-N 0.000 description 1
- AEFBCSUJZFVQBU-MPXMCKNUSA-N C=C(Br)C[C@@H](CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)OS(=O)(=O)C1=CC=C(C)C=C1.C=C(Br)C[C@H](O)CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound C=C(Br)C[C@@H](CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)OS(=O)(=O)C1=CC=C(C)C=C1.C=C(Br)C[C@H](O)CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C AEFBCSUJZFVQBU-MPXMCKNUSA-N 0.000 description 1
- WXHIAGIYTIKIHG-BIEKQKMCSA-N C=C(Br)C[C@@H](CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)OS(=O)(=O)C1=CC=C(C)C=C1.C=C(C[C@@H](CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)OS(=O)(=O)C1=CC=C(C)C=C1)[C@@H](O)CC[C@@H](C)CC(C)C(=O)N(C)OC.C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)OC1CC[C@@H](C)CC(C)C(=O)N(C)OC.CC1=CC=CC(C2=NC(C(C)C)CO2)=C1NS(C)(=O)=O.[H]C(=O)CC[C@H](CC(C)C(=O)N(C)OC)O[Si](C)(C)C(C)(C)C Chemical compound C=C(Br)C[C@@H](CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)OS(=O)(=O)C1=CC=C(C)C=C1.C=C(C[C@@H](CCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)OS(=O)(=O)C1=CC=C(C)C=C1)[C@@H](O)CC[C@@H](C)CC(C)C(=O)N(C)OC.C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)OC1CC[C@@H](C)CC(C)C(=O)N(C)OC.CC1=CC=CC(C2=NC(C(C)C)CO2)=C1NS(C)(=O)=O.[H]C(=O)CC[C@H](CC(C)C(=O)N(C)OC)O[Si](C)(C)C(C)(C)C WXHIAGIYTIKIHG-BIEKQKMCSA-N 0.000 description 1
- KQOIZTRZIRVCQH-WNFOGAQKSA-N C=C(Br)C[C@@H](CCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)OC(=O)C1=CC=C([N+](=O)[O-])C=C1.C=C(Br)C[C@H](O)CCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound C=C(Br)C[C@@H](CCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)OC(=O)C1=CC=C([N+](=O)[O-])C=C1.C=C(Br)C[C@H](O)CCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C KQOIZTRZIRVCQH-WNFOGAQKSA-N 0.000 description 1
- DSCRUYZRZDQACZ-IBGZPJMESA-N C=C(Br)C[C@@H](O)CCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound C=C(Br)C[C@@H](O)CCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C DSCRUYZRZDQACZ-IBGZPJMESA-N 0.000 description 1
- HRRPBWOKMUTPPL-MRVPVSSYSA-N C=C(Br)C[C@H](C)CCCC Chemical compound C=C(Br)C[C@H](C)CCCC HRRPBWOKMUTPPL-MRVPVSSYSA-N 0.000 description 1
- XTVLBIXDEYVNMU-UOFXJQDPSA-N C=C(Br)C[C@H](C)CCCC.C=C(C[C@H](C)CCCC)C(O)CCC(C)CC(C)C(=O)N(C)OC.C=C1C[C@H](CCCC)CC1CCC(C)CC(C)C(=O)N(C)OC.CCCC(C)CC(C)C(=O)N(C)OC.[F-2] Chemical compound C=C(Br)C[C@H](C)CCCC.C=C(C[C@H](C)CCCC)C(O)CCC(C)CC(C)C(=O)N(C)OC.C=C1C[C@H](CCCC)CC1CCC(C)CC(C)C(=O)N(C)OC.CCCC(C)CC(C)C(=O)N(C)OC.[F-2] XTVLBIXDEYVNMU-UOFXJQDPSA-N 0.000 description 1
- LKCCWQYIQLEQIE-UHFFFAOYSA-N C=C(C)C(C)CC(C)CCC1OC(CCCC)cc1c Chemical compound C=C(C)C(C)CC(C)CCC1OC(CCCC)cc1c LKCCWQYIQLEQIE-UHFFFAOYSA-N 0.000 description 1
- LKCCWQYIQLEQIE-YDXUJSMASA-N C=C(C)[C@H](C)CC(C)CCC1O[C@@H](CCCC)cc1c Chemical compound C=C(C)[C@H](C)CC(C)CCC1O[C@@H](CCCC)cc1c LKCCWQYIQLEQIE-YDXUJSMASA-N 0.000 description 1
- KJQFTHCIYJGWFW-ZJJSSMGNSA-N C=C1C[C@@H]2CC[C@@]34C[C@]5(C)O[C@H]6[C@@H](O3)C3OC(CCC3O[C@H]6C5O4)CC(=O)C[C@H]3[C@H](CC4O[C@@H](CCC1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3C Chemical compound C=C1C[C@@H]2CC[C@@]34C[C@]5(C)O[C@H]6[C@@H](O3)C3OC(CCC3O[C@H]6C5O4)CC(=O)C[C@H]3[C@H](CC4O[C@@H](CCC1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3C KJQFTHCIYJGWFW-ZJJSSMGNSA-N 0.000 description 1
- PBJISWJLSMXGJR-QVNDSAPHSA-N C=C1C[C@H](CCC=O)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2C(C(=O)CC2CCC3O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](C)[C@@H](C)C3O2)S(=O)(=O)C2=CC=CC=C2)O1.C=C1C[C@H](CCC=O)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2CC(=O)CC2CCC3O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](C)[C@@H](C)C3O2)O1 Chemical compound C=C1C[C@H](CCC=O)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2C(C(=O)CC2CCC3O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](C)[C@@H](C)C3O2)S(=O)(=O)C2=CC=CC=C2)O1.C=C1C[C@H](CCC=O)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2CC(=O)CC2CCC3O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](C)[C@@H](C)C3O2)O1 PBJISWJLSMXGJR-QVNDSAPHSA-N 0.000 description 1
- NTFRASLIVFXZOB-YWAKIELFSA-N C=C1C[C@H](CCC=O)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2C(C(O)CC2CCC3O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](C)[C@@H](C)C3O2)S(=O)(=O)C2=CC=CC=C2)O1.C=C1C[C@H](CCCO)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2C(C(O)CC2CCC3O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](C)[C@@H](C)C3O2)S(=O)(=O)C2=CC=CC=C2)O1 Chemical compound C=C1C[C@H](CCC=O)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2C(C(O)CC2CCC3O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](C)[C@@H](C)C3O2)S(=O)(=O)C2=CC=CC=C2)O1.C=C1C[C@H](CCCO)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2C(C(O)CC2CCC3O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](C)[C@@H](C)C3O2)S(=O)(=O)C2=CC=CC=C2)O1 NTFRASLIVFXZOB-YWAKIELFSA-N 0.000 description 1
- DJJYYLCUWWANLT-YKWDICOMSA-N C=C1C[C@H](CCCC)OC1CC[C@@H](C)CC(C)C(=O)N(C)OC Chemical compound C=C1C[C@H](CCCC)OC1CC[C@@H](C)CC(C)C(=O)N(C)OC DJJYYLCUWWANLT-YKWDICOMSA-N 0.000 description 1
- DZXXLRNYAJKNJU-MZZIJBNTSA-N C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(=C)OS(=O)(=O)C(F)(F)F.C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(C)=O Chemical compound C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(=C)OS(=O)(=O)C(F)(F)F.C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(C)=O DZXXLRNYAJKNJU-MZZIJBNTSA-N 0.000 description 1
- QGDUWTWVYNGZSG-YWXGDUOGSA-N C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(=C)OS(=O)(=O)C(F)(F)F.C=C1C[C@H](CCCO)OC1CC[C@@H](O)C[C@@H](C)C(=C)OS(=O)(=O)C(F)(F)F Chemical compound C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(=C)OS(=O)(=O)C(F)(F)F.C=C1C[C@H](CCCO)OC1CC[C@@H](O)C[C@@H](C)C(=C)OS(=O)(=O)C(F)(F)F QGDUWTWVYNGZSG-YWXGDUOGSA-N 0.000 description 1
- KZUKPGUPFNNMHZ-KRMCGNKASA-N C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(=O)N(C)OC.C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(C)=O Chemical compound C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(=O)N(C)OC.C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(C)=O KZUKPGUPFNNMHZ-KRMCGNKASA-N 0.000 description 1
- WUFHPZJQOBTGEU-GODJBBRCSA-N C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(=O)N(C)OC.C=C1C[C@H](CCCC)OC1CC[C@@H]1C[C@@H](C)C(=O)O1 Chemical compound C=C1C[C@H](CCCC)OC1CC[C@@H](C)C[C@@H](C)C(=O)N(C)OC.C=C1C[C@H](CCCC)OC1CC[C@@H]1C[C@@H](C)C(=O)O1 WUFHPZJQOBTGEU-GODJBBRCSA-N 0.000 description 1
- PIPANGYWRUFPTI-BYPXCTEESA-N C=C1C[C@H](CCCC)OC1CC[C@@H]1CCC(=O)O1.C=C1C[C@H](CCCC)OC1CC[C@@H]1C[C@@H](C)C(=O)O1 Chemical compound C=C1C[C@H](CCCC)OC1CC[C@@H]1CCC(=O)O1.C=C1C[C@H](CCCC)OC1CC[C@@H]1C[C@@H](C)C(=O)O1 PIPANGYWRUFPTI-BYPXCTEESA-N 0.000 description 1
- WUQSVHXKLQZTSG-LASTUSRZSA-N C=C1C[C@H](CCCC)OC1CC[C@@H]1CCC(=O)O1.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCCC)O2 Chemical compound C=C1C[C@H](CCCC)OC1CC[C@@H]1CCC(=O)O1.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCCC)O2 WUQSVHXKLQZTSG-LASTUSRZSA-N 0.000 description 1
- WTCKUWFGEBTIEH-NWXOVYKASA-N C=C1C[C@H](CCCC)OC1CC[C@H](C[C@@H](C)C(=C)C(O)C[C@@H]1OC(CC(C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O Chemical compound C=C1C[C@H](CCCC)OC1CC[C@H](C[C@@H](C)C(=C)C(O)C[C@@H]1OC(CC(C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O WTCKUWFGEBTIEH-NWXOVYKASA-N 0.000 description 1
- WTCKUWFGEBTIEH-ZQGRCETJSA-N C=C1C[C@H](CCCC)OC1CC[C@H](C[C@@H](C)C(=C)[C@@H](O)C[C@@H]1OC(C[C@H](C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O Chemical compound C=C1C[C@H](CCCC)OC1CC[C@H](C[C@@H](C)C(=C)[C@@H](O)C[C@@H]1OC(C[C@H](C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O WTCKUWFGEBTIEH-ZQGRCETJSA-N 0.000 description 1
- WTCKUWFGEBTIEH-AZDSRTPOSA-N C=C1C[C@H](CCCC)OC1CC[C@H](C[C@@H](C)C(=C)[C@H](O)C[C@@H]1OC(C[C@H](C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O Chemical compound C=C1C[C@H](CCCC)OC1CC[C@H](C[C@@H](C)C(=C)[C@H](O)C[C@@H]1OC(C[C@H](C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O WTCKUWFGEBTIEH-AZDSRTPOSA-N 0.000 description 1
- MEERGUJXTKBTAC-LDGVPRMTSA-N C=C1C[C@H](CCCO)OC1CC[C@@H]1CCC(=O)O1.C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)OC1CC[C@@H]1CCC(=O)O1.ClCCl Chemical compound C=C1C[C@H](CCCO)OC1CC[C@@H]1CCC(=O)O1.C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)OC1CC[C@@H]1CCC(=O)O1.ClCCl MEERGUJXTKBTAC-LDGVPRMTSA-N 0.000 description 1
- JOHWMSPPAHFQHA-GUPJQSDDSA-N C=C1C[C@H](CCCO)OC1CC[C@@H]1CCC(=O)O1.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCCO)O2 Chemical compound C=C1C[C@H](CCCO)OC1CC[C@@H]1CCC(=O)O1.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCCO)O2 JOHWMSPPAHFQHA-GUPJQSDDSA-N 0.000 description 1
- BRFPTCZXSPEIJK-UQOPPNBTSA-N C=C1C[C@H](CCCO)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](C)[C@H]2CS(=O)(=O)C2=CC=CC=C2)O1.C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](C)[C@H]2CS(=O)(=O)C2=CC=CC=C2)O1.ClCCl Chemical compound C=C1C[C@H](CCCO)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](C)[C@H]2CS(=O)(=O)C2=CC=CC=C2)O1.C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](C)[C@H]2CS(=O)(=O)C2=CC=CC=C2)O1.ClCCl BRFPTCZXSPEIJK-UQOPPNBTSA-N 0.000 description 1
- ZDVUVGYKPFXIRD-SJEWZGLTSA-N C=C1C[C@H](CCCO)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](C)[C@H]2CS(=O)(=O)C2=CC=CC=C2)O1.[H]C(=O)C[C@H]1CC[C@]2([H])O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@]2([H])O1.[H][C@]12CCC(CC(O)C([C@H]3[C@H](CC4O[C@@H](CCC5O[C@@H](CCCO)CC5=C)C[C@@H](C)C4=C)O[C@H](C[C@H](C)CC)[C@@H]3C)S(=O)(=O)C3=CC=CC=C3)O[C@]1([H])[C@H](C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)O2 Chemical compound C=C1C[C@H](CCCO)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](C)[C@H]2CS(=O)(=O)C2=CC=CC=C2)O1.[H]C(=O)C[C@H]1CC[C@]2([H])O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@]2([H])O1.[H][C@]12CCC(CC(O)C([C@H]3[C@H](CC4O[C@@H](CCC5O[C@@H](CCCO)CC5=C)C[C@@H](C)C4=C)O[C@H](C[C@H](C)CC)[C@@H]3C)S(=O)(=O)C3=CC=CC=C3)O[C@]1([H])[C@H](C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)O2 ZDVUVGYKPFXIRD-SJEWZGLTSA-N 0.000 description 1
- IGMKDVCXCUWNFY-IVCFKWPJSA-N C=C1C[C@H](CCCO)O[C@H]1CCC1CCC(=O)O1.C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[C@H]1CCC1CCC(=O)O1.CC(C)(C)[Si](Cl)(C1=CC=CC=C1)C1=CC=CC=C1.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCCO)O2 Chemical compound C=C1C[C@H](CCCO)O[C@H]1CCC1CCC(=O)O1.C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)O[C@H]1CCC1CCC(=O)O1.CC(C)(C)[Si](Cl)(C1=CC=CC=C1)C1=CC=CC=C1.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCCO)O2 IGMKDVCXCUWNFY-IVCFKWPJSA-N 0.000 description 1
- XITSKHVDTAHPKY-LVQIRKBHSA-M C=C1C[C@H](CCCO)O[C@H]1CC[C@@H](O)C[C@@H](C)C(=C)C.CC(C)[C@H](C)CC(O)CCC1OC2C[C@@]1(O)C[C@H]1OC(C)(C)O[C@H]21.CC(C)[C@H](C)CC1CC[C@@H]2OC3C[C@]2(C[C@H]2OC(C)(C)O[C@H]32)O1.CC(C)[C@H](C)CC=O.CC(C)[C@H](C)C[C@]1(O)CC[C@@H]2OC3C[C@]2(C[C@H]2OC(C)(C)O[C@H]32)O1.CC1(C)O[C@@H]2C[C@]3(O)CC(O[C@H]3CCI)[C@H]2O1.CC1(C)O[C@@H]2C[C@]3(O)CC(O[C@H]3CCO)[C@H]2O1.CC1(C)O[C@@H]2C[C@]34CC(O[C@H]3CC(=O)O4)[C@H]2O1.CC1=CC=C(S(=O)(=O)Cl)C=C1.CCC[C@@H]1OC2C[C@@]1(O)C[C@H]1OC(C)(C)O[C@H]21.CCOCC.CC[SiH](CC)CC.FB(F)F.[Na]I Chemical compound C=C1C[C@H](CCCO)O[C@H]1CC[C@@H](O)C[C@@H](C)C(=C)C.CC(C)[C@H](C)CC(O)CCC1OC2C[C@@]1(O)C[C@H]1OC(C)(C)O[C@H]21.CC(C)[C@H](C)CC1CC[C@@H]2OC3C[C@]2(C[C@H]2OC(C)(C)O[C@H]32)O1.CC(C)[C@H](C)CC=O.CC(C)[C@H](C)C[C@]1(O)CC[C@@H]2OC3C[C@]2(C[C@H]2OC(C)(C)O[C@H]32)O1.CC1(C)O[C@@H]2C[C@]3(O)CC(O[C@H]3CCI)[C@H]2O1.CC1(C)O[C@@H]2C[C@]3(O)CC(O[C@H]3CCO)[C@H]2O1.CC1(C)O[C@@H]2C[C@]34CC(O[C@H]3CC(=O)O4)[C@H]2O1.CC1=CC=C(S(=O)(=O)Cl)C=C1.CCC[C@@H]1OC2C[C@@]1(O)C[C@H]1OC(C)(C)O[C@H]21.CCOCC.CC[SiH](CC)CC.FB(F)F.[Na]I XITSKHVDTAHPKY-LVQIRKBHSA-M 0.000 description 1
- ARXLRAIBKURVOM-JADXMKSLSA-N C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CCC(C)C[C@@H](C)C(=C)C.C=C1C[C@H](CCCOC(=O)C2=CC=CC=C2)OC1CCC(C)C[C@@H](C)C(=C)C Chemical compound C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CCC(C)C[C@@H](C)C(=C)C.C=C1C[C@H](CCCOC(=O)C2=CC=CC=C2)OC1CCC(C)C[C@@H](C)C(=C)C ARXLRAIBKURVOM-JADXMKSLSA-N 0.000 description 1
- DOPRBNBMYVMPCY-XCJYIKEJSA-N C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@@H](C)C[C@@H](C)C(=C)C(O)C[C@@H]1O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2CS(=O)(=O)C2=CC=CC=C2)O1.C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2CS(=O)(=O)C2=CC=CC=C2)O1 Chemical compound C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@@H](C)C[C@@H](C)C(=C)C(O)C[C@@H]1O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2CS(=O)(=O)C2=CC=CC=C2)O1.C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H]1C[C@@H](C)C(=C)C(C[C@@H]2O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]2CS(=O)(=O)C2=CC=CC=C2)O1 DOPRBNBMYVMPCY-XCJYIKEJSA-N 0.000 description 1
- VETODNGQDFPZEJ-NPTHLOCCSA-N C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@@H](C)C[C@@H](C)C(=C)C.C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@@H](C)C[C@@H](C)C(=C)C(O)C[C@@H]1O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]1CS(=O)(=O)C1=CC=CC=C1.CC1=CC=CC(C2=N[C@@H](C(C)C)CO2)=C1NS(C)(=O)=O.CC[C@@H](C)C[C@H]1O[C@@H](CC=O)[C@H](CS(=O)(=O)C2=CC=CC=C2)[C@H]1OC Chemical compound C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@@H](C)C[C@@H](C)C(=C)C.C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@@H](C)C[C@@H](C)C(=C)C(O)C[C@@H]1O[C@H](C[C@H](C)CC)[C@H](OC)[C@H]1CS(=O)(=O)C1=CC=CC=C1.CC1=CC=CC(C2=N[C@@H](C(C)C)CO2)=C1NS(C)(=O)=O.CC[C@@H](C)C[C@H]1O[C@@H](CC=O)[C@H](CS(=O)(=O)C2=CC=CC=C2)[C@H]1OC VETODNGQDFPZEJ-NPTHLOCCSA-N 0.000 description 1
- UVQWKCUNBZBQLA-BUUWAUDMSA-N C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H](C[C@@H](C)C(=C)C(O)C[C@@H]1OC(CC(C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O Chemical compound C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H](C[C@@H](C)C(=C)C(O)C[C@@H]1OC(CC(C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O UVQWKCUNBZBQLA-BUUWAUDMSA-N 0.000 description 1
- UVQWKCUNBZBQLA-IDBDEUJNSA-N C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H](C[C@@H](C)C(=C)C(O)C[C@@H]1OC(C[C@H](C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O Chemical compound C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H](C[C@@H](C)C(=C)C(O)C[C@@H]1OC(C[C@H](C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O UVQWKCUNBZBQLA-IDBDEUJNSA-N 0.000 description 1
- UVQWKCUNBZBQLA-PCBHFSGKSA-N C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H](C[C@@H](C)C(=C)[C@@H](O)C[C@@H]1OC(C[C@H](C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O Chemical compound C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H](C[C@@H](C)C(=C)[C@@H](O)C[C@@H]1OC(C[C@H](C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O UVQWKCUNBZBQLA-PCBHFSGKSA-N 0.000 description 1
- UVQWKCUNBZBQLA-WKVDOFKLSA-N C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H](C[C@@H](C)C(=C)[C@H](O)C[C@@H]1OC(C[C@H](C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O Chemical compound C=C1C[C@H](CCCOC(=O)C(C)(C)C)OC1CC[C@H](C[C@@H](C)C(=C)[C@H](O)C[C@@H]1OC(C[C@H](C)CC)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1)OS(C)(=O)=O UVQWKCUNBZBQLA-WKVDOFKLSA-N 0.000 description 1
- LSPRPCZGYUDOBA-HGVFESIASA-M C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)OC1CC[C@@H](C)CC(C)C(=O)N(C)OC.C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)OC1CC[C@@H](C)CC(C)C(C)=O.C[Mg]Cl Chemical compound C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)OC1CC[C@@H](C)CC(C)C(=O)N(C)OC.C=C1C[C@H](CCCO[Si](C2=CC=CC=C2)(C2=CC=CC=C2)C(C)(C)C)OC1CC[C@@H](C)CC(C)C(C)=O.C[Mg]Cl LSPRPCZGYUDOBA-HGVFESIASA-M 0.000 description 1
- CFBROBOZAHBHTK-QMPDRDCZSA-N C=CC(CC)[Si](C)(C)C.O=C=O.O=C=O.[H][C@@]1([C@@H](COC(C)=O)OC(C)=O)O[C@@H](C)[C@H](C)[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@@H](COC(C)=O)OC(C)=O)O[C@@H](C/C=C/CC)[C@H](C)[C@@H]2OC3(CCCCC3)OC21 Chemical compound C=CC(CC)[Si](C)(C)C.O=C=O.O=C=O.[H][C@@]1([C@@H](COC(C)=O)OC(C)=O)O[C@@H](C)[C@H](C)[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@@H](COC(C)=O)OC(C)=O)O[C@@H](C/C=C/CC)[C@H](C)[C@@H]2OC3(CCCCC3)OC21 CFBROBOZAHBHTK-QMPDRDCZSA-N 0.000 description 1
- BGIQHPUKAZCGMB-ZWTDDQOVSA-N C=CCC[C@@H]1CC(C)C(=O)O1.C=CCC[C@@H]1CCC(=O)O1 Chemical compound C=CCC[C@@H]1CC(C)C(=O)O1.C=CCC[C@@H]1CCC(=O)O1 BGIQHPUKAZCGMB-ZWTDDQOVSA-N 0.000 description 1
- JVFQWUQDTGNMGE-ZMHYYLQSSA-N C=CCC[C@@H]1CC(C)C(=O)O1.C=CCC[C@H](CC(C)C(=O)N(C)OC)O[Si](C)(C)C(C)(C)C Chemical compound C=CCC[C@@H]1CC(C)C(=O)O1.C=CCC[C@H](CC(C)C(=O)N(C)OC)O[Si](C)(C)C(C)(C)C JVFQWUQDTGNMGE-ZMHYYLQSSA-N 0.000 description 1
- IOYGCBPAMWUWHJ-SUSPOVHDSA-N C=CCC[C@@H]1CCC(=O)O1.C=CCC[C@@H]1CO1 Chemical compound C=CCC[C@@H]1CCC(=O)O1.C=CCC[C@@H]1CO1 IOYGCBPAMWUWHJ-SUSPOVHDSA-N 0.000 description 1
- CBHSWCWATHOCMF-CFTBCDAESA-N C=CCC[C@H](CC(C)C(=O)N(C)OC)O[Si](C)(C)C(C)(C)C.[H]C(=O)CC[C@H](CC(C)C(=O)N(C)OC)O[Si](C)(C)C(C)(C)C Chemical compound C=CCC[C@H](CC(C)C(=O)N(C)OC)O[Si](C)(C)C(C)(C)C.[H]C(=O)CC[C@H](CC(C)C(=O)N(C)OC)O[Si](C)(C)C(C)(C)C CBHSWCWATHOCMF-CFTBCDAESA-N 0.000 description 1
- ZYFFQGKKUPQCFG-LHVRFMFLSA-N C=CC[C@@H]1O[C@H](CC(O)CO)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=CC[C@@H]1O[C@H](CC2COC(C)(C)O2)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1 Chemical compound C=CC[C@@H]1O[C@H](CC(O)CO)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=CC[C@@H]1O[C@H](CC2COC(C)(C)O2)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1 ZYFFQGKKUPQCFG-LHVRFMFLSA-N 0.000 description 1
- ANYJFBDXHBGKEP-BGWQVRTCSA-N C=CC[C@@H]1O[C@H](CC(O)CO)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@@H](CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1.[2H]CF Chemical compound C=CC[C@@H]1O[C@H](CC(O)CO)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@@H](CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1.[2H]CF ANYJFBDXHBGKEP-BGWQVRTCSA-N 0.000 description 1
- QVOBWWMIKAWAMD-OHTIZJFXSA-N C=CC[C@@H]1O[C@H](CC2COC(C)(C)O2)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=CC[C@@H]1O[C@H](CC2COC(C)(C)O2)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1 Chemical compound C=CC[C@@H]1O[C@H](CC2COC(C)(C)O2)[C@H](C)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=CC[C@@H]1O[C@H](CC2COC(C)(C)O2)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1 QVOBWWMIKAWAMD-OHTIZJFXSA-N 0.000 description 1
- PYFBZWBWSHBQSJ-JKEHNMNFSA-N C=CC[C@@H]1O[C@H](CC2COC(C)(C)O2)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@H](O)CO)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1 Chemical compound C=CC[C@@H]1O[C@H](CC2COC(C)(C)O2)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@H](O)CO)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1 PYFBZWBWSHBQSJ-JKEHNMNFSA-N 0.000 description 1
- BWBJZNZBKWPLCN-GVHWTRHRSA-N C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)C1=CC1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)C1=O.O=S=O Chemical compound C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)C1=CC1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)C1=O.O=S=O BWBJZNZBKWPLCN-GVHWTRHRSA-N 0.000 description 1
- DASJWFXCGKHVCA-BDKPAESXSA-N C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)C1=CC1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](O)C1=CC1=CC=CC=C1.O=S=O.O=S=O Chemical compound C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)C1=CC1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](O)C1=CC1=CC=CC=C1.O=S=O.O=S=O DASJWFXCGKHVCA-BDKPAESXSA-N 0.000 description 1
- UMLDWIRPZFTWOK-QHAALSNXSA-N C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)C1=O.C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)[C@H]1O Chemical compound C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)C1=O.C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)[C@H]1O UMLDWIRPZFTWOK-QHAALSNXSA-N 0.000 description 1
- GRHIKYIBEVWAEH-SQLDGXFYSA-N C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)[C@H]1O.C[C@@H]1C2OC(C)(C)O[C@H]2O[C@@H]1CC(COC(=O)C1=CC=CC=C1)OC(=O)C1=CC=CC=C1 Chemical compound C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](C)[C@H]1O.C[C@@H]1C2OC(C)(C)O[C@H]2O[C@@H]1CC(COC(=O)C1=CC=CC=C1)OC(=O)C1=CC=CC=C1 GRHIKYIBEVWAEH-SQLDGXFYSA-N 0.000 description 1
- ZHCLUJJMEXUKJH-PQOOAYDYSA-N C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](O)C1=CC1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1.O=S=O Chemical compound C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](O)C1=CC1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1.O=S=O ZHCLUJJMEXUKJH-PQOOAYDYSA-N 0.000 description 1
- MUJCMGCVSLUNAT-SXBOFTGMSA-N C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@H](O)CO)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1 Chemical compound C=CC[C@@H]1O[C@H](C[C@@H](COC(=O)C2=CC=CC=C2)OC(=O)C2=CC=CC=C2)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C=CC[C@@H]1O[C@H](C[C@H](O)CO)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1 MUJCMGCVSLUNAT-SXBOFTGMSA-N 0.000 description 1
- RAYFWUZLNNVBHZ-OVQHTUKZSA-N C=CC[C@@H]1O[C@H](C[C@H](O)CO)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C[C@H]1[C@@H](C[C@@H](CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)O[C@@H](CC=O)[C@@H]1CS(=O)(=O)C1=CC=CC=C1 Chemical compound C=CC[C@@H]1O[C@H](C[C@H](O)CO)[C@H](O)[C@H]1CS(=O)(=O)C1=CC=CC=C1.C[C@H]1[C@@H](C[C@@H](CO[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)O[C@@H](CC=O)[C@@H]1CS(=O)(=O)C1=CC=CC=C1 RAYFWUZLNNVBHZ-OVQHTUKZSA-N 0.000 description 1
- ALWFJUOVOQKBSD-LYORPHISSA-N C=CC[C@H]1O[C@@H]2OC(C)(C)OC2[C@H]1C.C=CC[C@H]1O[C@@H]2OC(C)(C)OC2[C@H]1O Chemical compound C=CC[C@H]1O[C@@H]2OC(C)(C)OC2[C@H]1C.C=CC[C@H]1O[C@@H]2OC(C)(C)OC2[C@H]1O ALWFJUOVOQKBSD-LYORPHISSA-N 0.000 description 1
- XVVRJKZSZIHDBH-QZVXYJKMSA-N C=CC[C@H]1O[C@@H]2OC(C)(C)OC2[C@H]1C.C[C@@H]1C2OC(C)(C)O[C@H]2O[C@@H]1CC(O)CO Chemical compound C=CC[C@H]1O[C@@H]2OC(C)(C)OC2[C@H]1C.C[C@@H]1C2OC(C)(C)O[C@H]2O[C@@H]1CC(O)CO XVVRJKZSZIHDBH-QZVXYJKMSA-N 0.000 description 1
- PIIAFTIASSUDRY-LAKDDCHWSA-N C=CC[C@H]1O[C@@H]2OC(C)(C)OC2[C@H]1O.CC1(C)OC2[C@@H](O)[C@@H](CC(O)C[Si](C)(C)C)O[C@@H]2O1 Chemical compound C=CC[C@H]1O[C@@H]2OC(C)(C)OC2[C@H]1O.CC1(C)OC2[C@@H](O)[C@@H](CC(O)C[Si](C)(C)C)O[C@@H]2O1 PIIAFTIASSUDRY-LAKDDCHWSA-N 0.000 description 1
- LTZNDORXSGXGSM-QMAPNNFKSA-N C=O.C=O.CC1=CC(C)=C(S(=O)(=O)NN)C(C)=C1.O=C=O.O=C=O.O=C=O.O=C=O.O=C=O.[H]C[C@H]1CC[C@]2([H])O[C@@H](C#C)C[C@]2(C=O)O1.[H]C[C@H]1CC[C@]2([H])O[C@]3([H])C[C@@]2(O1)[C@H]1OC1C3=O.[H]C[C@H]1CC[C@]2([H])O[C@]3([H])C[C@@]2(O1)[C@H]1OC1C3O.[H]C[C@H]1CC[C@]2([H])O[C@]3([H])C[C@]2(C=CC3O)O1.[H]C[C@H]1CC[C@]2([H])O[C@]3([H])C[C@]2(C[C@H]2OC23)O1.[H][C@]12CC[C@H](CC)O[C@]13C[C@H]1OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](C#C)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](C#CCO)O2.[H][C@]12CC[C@H](CCO)O[C@@]1(CO)C[C@H](C#C)O2 Chemical compound C=O.C=O.CC1=CC(C)=C(S(=O)(=O)NN)C(C)=C1.O=C=O.O=C=O.O=C=O.O=C=O.O=C=O.[H]C[C@H]1CC[C@]2([H])O[C@@H](C#C)C[C@]2(C=O)O1.[H]C[C@H]1CC[C@]2([H])O[C@]3([H])C[C@@]2(O1)[C@H]1OC1C3=O.[H]C[C@H]1CC[C@]2([H])O[C@]3([H])C[C@@]2(O1)[C@H]1OC1C3O.[H]C[C@H]1CC[C@]2([H])O[C@]3([H])C[C@]2(C=CC3O)O1.[H]C[C@H]1CC[C@]2([H])O[C@]3([H])C[C@]2(C[C@H]2OC23)O1.[H][C@]12CC[C@H](CC)O[C@]13C[C@H]1OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](C#C)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](C#CCO)O2.[H][C@]12CC[C@H](CCO)O[C@@]1(CO)C[C@H](C#C)O2 LTZNDORXSGXGSM-QMAPNNFKSA-N 0.000 description 1
- MVSVCRLBEZHLRM-IBLUKRHDSA-N CC(C)(OC12)OC1OC(CSCO)[C@@H]2OCc1ccccc1 Chemical compound CC(C)(OC12)OC1OC(CSCO)[C@@H]2OCc1ccccc1 MVSVCRLBEZHLRM-IBLUKRHDSA-N 0.000 description 1
- KILVOIFXRMXFLE-GGZOMVNGSA-N CC(C)(O[C@@H]1C[C@@]2(CC3)O4)O[C@@]13OC2=CC4=O Chemical compound CC(C)(O[C@@H]1C[C@@]2(CC3)O4)O[C@@]13OC2=CC4=O KILVOIFXRMXFLE-GGZOMVNGSA-N 0.000 description 1
- APMMJXKLGFDQAN-UHFFFAOYSA-N CC(C)C(N)CO.CC1=C2NC(=O)OC(=O)C2=CC=C1.CC1=CC=CC(C(=O)CC(CO)C(C)C)=C1N Chemical compound CC(C)C(N)CO.CC1=C2NC(=O)OC(=O)C2=CC=C1.CC1=CC=CC(C(=O)CC(CO)C(C)C)=C1N APMMJXKLGFDQAN-UHFFFAOYSA-N 0.000 description 1
- GJANFRWEUSQOLL-OPVBDZBXSA-N CC1(C)OC2[C@@H](O)[C@@H](CC(O)C[Si](C)(C)C)O[C@@H]2O1.CC1(C)OC2[C@H]3OC(O)CC3O[C@@H]2O1 Chemical compound CC1(C)OC2[C@@H](O)[C@@H](CC(O)C[Si](C)(C)C)O[C@@H]2O1.CC1(C)OC2[C@H]3OC(O)CC3O[C@@H]2O1 GJANFRWEUSQOLL-OPVBDZBXSA-N 0.000 description 1
- FGBOONLIIQJUCC-GABGXHNOSA-N CC1(C)OC2[C@H]3C[C@@](O)(C[C@H]2O1)C(=O)O3.CC1(C)OC2[C@H]3C[C@@](OC(=O)CBr)(C[C@H]2O1)C(=O)O3 Chemical compound CC1(C)OC2[C@H]3C[C@@](O)(C[C@H]2O1)C(=O)O3.CC1(C)OC2[C@H]3C[C@@](OC(=O)CBr)(C[C@H]2O1)C(=O)O3 FGBOONLIIQJUCC-GABGXHNOSA-N 0.000 description 1
- IXAUCMYJKILEFO-FDIVRGOESA-N CC1(C)OC2[C@H]3C[C@@](OC(=O)CBr)(C[C@H]2O1)C(=O)O3.CC1(C)OC2[C@H]3C[C@]4(C[C@H]2O1)OC(=O)C=C4O3 Chemical compound CC1(C)OC2[C@H]3C[C@@](OC(=O)CBr)(C[C@H]2O1)C(=O)O3.CC1(C)OC2[C@H]3C[C@]4(C[C@H]2O1)OC(=O)C=C4O3 IXAUCMYJKILEFO-FDIVRGOESA-N 0.000 description 1
- QYUQTICUUVJGME-JGWOFTGSSA-N CC1(C)OC2[C@H]3C[C@]4(C[C@H]2O1)OC(=O)C=C4O3.CC1(C)OC2[C@H]3C[C@]4(C[C@H]2O1)OC(=O)C[C@@H]4O3 Chemical compound CC1(C)OC2[C@H]3C[C@]4(C[C@H]2O1)OC(=O)C=C4O3.CC1(C)OC2[C@H]3C[C@]4(C[C@H]2O1)OC(=O)C[C@@H]4O3 QYUQTICUUVJGME-JGWOFTGSSA-N 0.000 description 1
- IHIMXWLXHDQZTP-QHSOEMHCSA-N CC1(C)OC2[C@H]3OC(=O)CC3O[C@@H]2O1.CC1(C)OC2[C@H]3OC(O)CC3O[C@@H]2O1 Chemical compound CC1(C)OC2[C@H]3OC(=O)CC3O[C@@H]2O1.CC1(C)OC2[C@H]3OC(O)CC3O[C@@H]2O1 IHIMXWLXHDQZTP-QHSOEMHCSA-N 0.000 description 1
- PRAONILWOQMROI-WAWZUAPZSA-N CC1(C)OC2[C@H]3OC(=O)CC3O[C@@H]2O1.[H][C@]12O[C@@H]3OC(C)(C)OC3[C@@]1([H])OC(=O)[C@@H]2Cl Chemical compound CC1(C)OC2[C@H]3OC(=O)CC3O[C@@H]2O1.[H][C@]12O[C@@H]3OC(C)(C)OC3[C@@]1([H])OC(=O)[C@@H]2Cl PRAONILWOQMROI-WAWZUAPZSA-N 0.000 description 1
- QFIMLPNKOBXEAK-PNFUHCLESA-N CC1(C)O[C@@H]([C@@H](C[C@]2(C3)OC(CBr)=O)OC2=O)[C@@H]3O1 Chemical compound CC1(C)O[C@@H]([C@@H](C[C@]2(C3)OC(CBr)=O)OC2=O)[C@@H]3O1 QFIMLPNKOBXEAK-PNFUHCLESA-N 0.000 description 1
- YAWGDZNAIADXRQ-UHFFFAOYSA-N CC1=C(NS(C)(=O)=O)C(C2=NC(C(C)C)CO2)=CC=C1.CC1=CC=CC(C(=O)CC(CO)C(C)C)=C1N Chemical compound CC1=C(NS(C)(=O)=O)C(C2=NC(C(C)C)CO2)=CC=C1.CC1=CC=CC(C(=O)CC(CO)C(C)C)=C1N YAWGDZNAIADXRQ-UHFFFAOYSA-N 0.000 description 1
- BPCWLBDSTRFQOI-KYFZBXIBSA-N CC1C2C[C@]3(C[C@H]1C)OC(=O)cc3O2 Chemical compound CC1C2C[C@]3(C[C@H]1C)OC(=O)cc3O2 BPCWLBDSTRFQOI-KYFZBXIBSA-N 0.000 description 1
- FJGXOLLJOOHFDE-PPHUBBTKSA-N CC1C2C[C@]3(C[C@H]1C)O[W]cc3O2 Chemical compound CC1C2C[C@]3(C[C@H]1C)O[W]cc3O2 FJGXOLLJOOHFDE-PPHUBBTKSA-N 0.000 description 1
- FJGXOLLJOOHFDE-UHFFFAOYSA-N CC1CC23CC(Oc2c[W]O3)C1C Chemical compound CC1CC23CC(Oc2c[W]O3)C1C FJGXOLLJOOHFDE-UHFFFAOYSA-N 0.000 description 1
- FMUBVSCIZTYWPU-MFUINJGTSA-N CC=C[C@@H]1OC2(CCCCC2)OC1[C@@H](O)C1COC2(CCCCC2)O1.[H][C@@]1([C@H]2COC3(CCCCC3)O2)OC(O)[C@@H]2OC3(CCCCC3)OC21 Chemical compound CC=C[C@@H]1OC2(CCCCC2)OC1[C@@H](O)C1COC2(CCCCC2)O1.[H][C@@]1([C@H]2COC3(CCCCC3)O2)OC(O)[C@@H]2OC3(CCCCC3)OC21 FMUBVSCIZTYWPU-MFUINJGTSA-N 0.000 description 1
- SYHWHJUJOAKWSH-WNRGRERSSA-N CC=C[C@@H]1OC2(CCCCC2)OC1[C@@H](O)C1COC2(CCCCC2)O1.[H][C@@]1([C@H]2COC3(CCCCC3)O2)O[C@@H](O)[C@H](O)[C@@H]2OC3(CCCCC3)OC21 Chemical compound CC=C[C@@H]1OC2(CCCCC2)OC1[C@@H](O)C1COC2(CCCCC2)O1.[H][C@@]1([C@H]2COC3(CCCCC3)O2)O[C@@H](O)[C@H](O)[C@@H]2OC3(CCCCC3)OC21 SYHWHJUJOAKWSH-WNRGRERSSA-N 0.000 description 1
- BDWMWLGSMODTOK-XLAKAHIMSA-N CCC(C)C[C@H]1O[C@@H]2OC(C)(C)OC2[C@H]1C.C[C@@H]1C2OC(C)(C)O[C@H]2O[C@@H]1CC(O)CO Chemical compound CCC(C)C[C@H]1O[C@@H]2OC(C)(C)OC2[C@H]1C.C[C@@H]1C2OC(C)(C)O[C@H]2O[C@@H]1CC(O)CO BDWMWLGSMODTOK-XLAKAHIMSA-N 0.000 description 1
- PWSPFYHKVXVCPN-UHFFFAOYSA-N CCCC(C)CC(C)C(=O)N(C)OC Chemical compound CCCC(C)CC(C)C(=O)N(C)OC PWSPFYHKVXVCPN-UHFFFAOYSA-N 0.000 description 1
- PWSPFYHKVXVCPN-YHMJZVADSA-N CCC[C@@H](C)CC(C)C(=O)N(C)OC Chemical compound CCC[C@@H](C)CC(C)C(=O)N(C)OC PWSPFYHKVXVCPN-YHMJZVADSA-N 0.000 description 1
- JLVHHOYHVSKJDD-KWRVWLJBSA-N CCC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1.N#C[K].[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1 Chemical compound CCC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1.N#C[K].[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1 JLVHHOYHVSKJDD-KWRVWLJBSA-N 0.000 description 1
- ZKGQGLWFUGYPLI-LCFWUDGRSA-N CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1.O=C=O.OCC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1 Chemical compound CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1.O=C=O.OCC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1 ZKGQGLWFUGYPLI-LCFWUDGRSA-N 0.000 description 1
- ONIXYPVZAGDBPB-IYYFACDCSA-N CO.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CO)C[C@H](/C=C/C(=O)OC)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CO)C[C@H](CCC(=O)OC)O2 Chemical compound CO.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CO)C[C@H](/C=C/C(=O)OC)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CO)C[C@H](CCC(=O)OC)O2 ONIXYPVZAGDBPB-IYYFACDCSA-N 0.000 description 1
- SAVGEESYJIZSPR-LQFDUZRDSA-N C[Si](C)(C)C=CBr.O=C=O.O=C=O.[H]C(=O)[C@]1([H])O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1(C(O)/C=C/[Si](C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21 Chemical compound C[Si](C)(C)C=CBr.O=C=O.O=C=O.[H]C(=O)[C@]1([H])O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1(C(O)/C=C/[Si](C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21 SAVGEESYJIZSPR-LQFDUZRDSA-N 0.000 description 1
- 241001554545 Carteris Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 238000005704 Eschenmoser-Tanabe fragmentation reaction Methods 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000353756 Halichondria okadai Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- WRSBNZWBSCGDBK-RAGQUBRYSA-N O=C(Cl)CBr.[H][C@@]12C[C@@](O)(C[C@H]3OC(C)(C)OC31)C(=O)O2.[H][C@@]12C[C@@](OC(=O)CBr)(C[C@H]3OC(C)(C)OC31)C(=O)O2.[H][C@@]12C[C@@](OC(=O)CC=C)(C[C@H]3OC(C)(C)OC31)C(=O)O2.[H][C@@]12C[C@]3(C[C@H]4OC(C)(C)OC41)OC(=O)C=C3O2.[H][C@]12CC(=O)O[C@]13C[C@H]1OC(C)(C)OC1[C@@]([H])(C3)O2 Chemical compound O=C(Cl)CBr.[H][C@@]12C[C@@](O)(C[C@H]3OC(C)(C)OC31)C(=O)O2.[H][C@@]12C[C@@](OC(=O)CBr)(C[C@H]3OC(C)(C)OC31)C(=O)O2.[H][C@@]12C[C@@](OC(=O)CC=C)(C[C@H]3OC(C)(C)OC31)C(=O)O2.[H][C@@]12C[C@]3(C[C@H]4OC(C)(C)OC41)OC(=O)C=C3O2.[H][C@]12CC(=O)O[C@]13C[C@H]1OC(C)(C)OC1[C@@]([H])(C3)O2 WRSBNZWBSCGDBK-RAGQUBRYSA-N 0.000 description 1
- UBUZAAQMJTUEGT-XGAOLPMKSA-N O=C=O.O=C=O.[H]C(=O)[C@]1([H])O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@H](O)CO)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21 Chemical compound O=C=O.O=C=O.[H]C(=O)[C@]1([H])O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@H](O)CO)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21 UBUZAAQMJTUEGT-XGAOLPMKSA-N 0.000 description 1
- GYTJEUDVTKXTJI-LDVPUIOGSA-N O=C=O.O=C=O.[H][C@@]1(C(O)/C=C/[Si](C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@@H](O)/C=C/[Si](C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O)C1O Chemical compound O=C=O.O=C=O.[H][C@@]1(C(O)/C=C/[Si](C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@@H](O)/C=C/[Si](C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O)C1O GYTJEUDVTKXTJI-LDVPUIOGSA-N 0.000 description 1
- YKSXSWVJKAMJPM-DFTLJGMASA-N O=C=O.O=C=O.[H][C@@]1([C@@H](COC(C)=O)OC(C)=O)O[C@@H](C/C=C/CC)[C@H](C)[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@H](O)CO)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21 Chemical compound O=C=O.O=C=O.[H][C@@]1([C@@H](COC(C)=O)OC(C)=O)O[C@@H](C/C=C/CC)[C@H](C)[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@H](O)CO)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@@H]2OC3(CCCCC3)OC21 YKSXSWVJKAMJPM-DFTLJGMASA-N 0.000 description 1
- SKDSOAIPKJQICH-GSDIOKRPSA-N O=C=O.O=C=O.[H][C@@]1([C@@H](O)/C=C/[Si](C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O)C1O.[H][C@@]1([C@H](/C=C/[Si](C)(C)C)O[Si](C)(C)C(C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C Chemical compound O=C=O.O=C=O.[H][C@@]1([C@@H](O)/C=C/[Si](C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O)C1O.[H][C@@]1([C@H](/C=C/[Si](C)(C)C)O[Si](C)(C)C(C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C SKDSOAIPKJQICH-GSDIOKRPSA-N 0.000 description 1
- SPNUQSYHIZCZQW-HBDKISSXSA-N O=C=O.O=C=O.[H][C@@]1([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C.[H][C@@]1([C@H](/C=C/[Si](C)(C)C)O[Si](C)(C)C(C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C Chemical compound O=C=O.O=C=O.[H][C@@]1([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C.[H][C@@]1([C@H](/C=C/[Si](C)(C)C)O[Si](C)(C)C(C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C SPNUQSYHIZCZQW-HBDKISSXSA-N 0.000 description 1
- KNXOSVYKEKXSBR-KJQKYERJSA-N O=C=O.[H][C@@]1([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C Chemical compound O=C=O.[H][C@@]1([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)O[C@@]2([H])CC[C@H](CC)O[C@]2([H])[C@H](O[Si](C)(C)C(C)(C)C)[C@@H]1O[Si](C)(C)C(C)(C)C KNXOSVYKEKXSBR-KJQKYERJSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 241001674052 Phakellia Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 229910006024 SO2Cl2 Inorganic materials 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 229910003074 TiCl4 Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- AROGUZCJMSZHKF-JVBGBIQNSA-N [C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C=C[C@H]3OC(C)=O)O1.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(COC3O)O1 Chemical compound [C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C=C[C@H]3OC(C)=O)O1.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(COC3O)O1 AROGUZCJMSZHKF-JVBGBIQNSA-N 0.000 description 1
- OPONKUBBRSXLDE-IOGCSGLTSA-N [C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](O)C3O)O1.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1 Chemical compound [C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@@H](O)C3O)O1.[C-]#[N+]CC[C@H]1CC[C@@H]2O[C@@H]3C[C@]2(C[C@H]2OC4(CCCCC4)OC32)O1 OPONKUBBRSXLDE-IOGCSGLTSA-N 0.000 description 1
- KODNTESRDQAWLG-DTFACARLSA-N [H]C(=O)CC[C@H]1CC(=C)C(CC[C@H]2C[C@@H](C)C(=C)C(C[C@@H]3O[C@H](C[C@H](C)CC)[C@H](C)[C@H]3CC(=O)CC3CC[C@]4([H])O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)[C@@]4([H])O3)O2)O1.[H][C@@]12CCC3CC(=O)C[C@H]4[C@H](CC5O[C@@H](CCC6O[C@@H](CCC(O)/C=C/[C@H](O[Si](C)(C)C(C)(C)C)[C@H](O1)[C@@H](C)[C@@H](C)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](C)CC)[C@@H]4C Chemical compound [H]C(=O)CC[C@H]1CC(=C)C(CC[C@H]2C[C@@H](C)C(=C)C(C[C@@H]3O[C@H](C[C@H](C)CC)[C@H](C)[C@H]3CC(=O)CC3CC[C@]4([H])O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)[C@@]4([H])O3)O2)O1.[H][C@@]12CCC3CC(=O)C[C@H]4[C@H](CC5O[C@@H](CCC6O[C@@H](CCC(O)/C=C/[C@H](O[Si](C)(C)C(C)(C)C)[C@H](O1)[C@@H](C)[C@@H](C)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](C)CC)[C@@H]4C KODNTESRDQAWLG-DTFACARLSA-N 0.000 description 1
- KTTAEPRJYPPNHU-IOCQUORNSA-N [H]C(=O)C[C@H]1CC[C@]2([H])O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@]2([H])O1.[H][C@]12CC[C@H](CC(C)=O)O[C@]1([H])[C@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)O2 Chemical compound [H]C(=O)C[C@H]1CC[C@]2([H])O[C@@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@]2([H])O1.[H][C@]12CC[C@H](CC(C)=O)O[C@]1([H])[C@H](O[Si](C)(C)C(C)(C)C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H]([C@H](/C=C/I)O[Si](C)(C)C(C)(C)C)O2 KTTAEPRJYPPNHU-IOCQUORNSA-N 0.000 description 1
- QGCCGMOPFLFLCW-LVPJFEFHSA-N [H][C@@]1([C@@H](COC(C)=O)OC(C)=O)O[C@@H](C)[C@H](C)[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@H]2COC3(CCCCC3)O2)O[C@@H](O)[C@H](O)[C@@H]2OC3(CCCCC3)OC21 Chemical compound [H][C@@]1([C@@H](COC(C)=O)OC(C)=O)O[C@@H](C)[C@H](C)[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@H]2COC3(CCCCC3)O2)O[C@@H](O)[C@H](O)[C@@H]2OC3(CCCCC3)OC21 QGCCGMOPFLFLCW-LVPJFEFHSA-N 0.000 description 1
- LPKUTISTKRJTIO-IMVGAQKTSA-N [H][C@@]1([C@H](O)CO)OC(=O)[C@H](O)[C@@H]1O.[H][C@@]1([C@H]2COC3(CCCCC3)O2)OC(=O)[C@@H]2OC3(CCCCC3)OC21 Chemical compound [H][C@@]1([C@H](O)CO)OC(=O)[C@H](O)[C@@H]1O.[H][C@@]1([C@H]2COC3(CCCCC3)O2)OC(=O)[C@@H]2OC3(CCCCC3)OC21 LPKUTISTKRJTIO-IMVGAQKTSA-N 0.000 description 1
- BSKUJGVPHROQNQ-PHTGJBLVSA-N [H][C@@]1([C@H]2COC3(CCCCC3)O2)OC(=O)[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@H]2COC3(CCCCC3)O2)OC(O)[C@@H]2OC3(CCCCC3)OC21 Chemical compound [H][C@@]1([C@H]2COC3(CCCCC3)O2)OC(=O)[C@@H]2OC3(CCCCC3)OC21.[H][C@@]1([C@H]2COC3(CCCCC3)O2)OC(O)[C@@H]2OC3(CCCCC3)OC21 BSKUJGVPHROQNQ-PHTGJBLVSA-N 0.000 description 1
- YLTNMPVXXRRDRB-KRZAHVQRSA-N [H][C@@]12CCC3CC(=O)C[C@H]4[C@H](CC5O[C@@H](CCC6O[C@@H](CCC(=O)/C=C/[C@H](O[Si](C)(C)C(C)(C)C)[C@H](O1)[C@@H](C)[C@@H](C)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](C)CC)[C@@H]4C.[H][C@@]12CCC3CC(=O)C[C@H]4[C@H](CC5O[C@@H](CCC6O[C@@H](CCC(=O)CC7O[C@H]([C@@H](O1)[C@H]7O)[C@@H](O)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](O)CO)[C@@H]4C Chemical compound [H][C@@]12CCC3CC(=O)C[C@H]4[C@H](CC5O[C@@H](CCC6O[C@@H](CCC(=O)/C=C/[C@H](O[Si](C)(C)C(C)(C)C)[C@H](O1)[C@@H](C)[C@@H](C)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](C)CC)[C@@H]4C.[H][C@@]12CCC3CC(=O)C[C@H]4[C@H](CC5O[C@@H](CCC6O[C@@H](CCC(=O)CC7O[C@H]([C@@H](O1)[C@H]7O)[C@@H](O)[C@@]2([H])O3)CC6=C)C[C@@H](C)C5=C)O[C@H](C[C@H](O)CO)[C@@H]4C YLTNMPVXXRRDRB-KRZAHVQRSA-N 0.000 description 1
- HAZSTLVXIVKVGV-UTFJLIRBSA-N [H][C@]12CC[C@H](CCC)O[C@@]1(CO)CC([C@H](O)CO)O2.[H][C@]12CC[C@H](CCC)O[C@]13C=C[C@@H](O)[C@@]([H])(C3)O2 Chemical compound [H][C@]12CC[C@H](CCC)O[C@@]1(CO)CC([C@H](O)CO)O2.[H][C@]12CC[C@H](CCC)O[C@]13C=C[C@@H](O)[C@@]([H])(C3)O2 HAZSTLVXIVKVGV-UTFJLIRBSA-N 0.000 description 1
- QPJICTWAAQFBQQ-NWBWTORXSA-N [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](/C=C/C(=O)OC)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCC(=O)OC)O2 Chemical compound [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](/C=C/C(=O)OC)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCC(=O)OC)O2 QPJICTWAAQFBQQ-NWBWTORXSA-N 0.000 description 1
- RONOTCDLXOKLQN-RMNOJRSUSA-N [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](/C=C/C(=O)OC)O2.[H][C@]12CC[C@H](CCC)O[C@]13COC(O)[C@@H](C3)O2 Chemical compound [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](/C=C/C(=O)OC)O2.[H][C@]12CC[C@H](CCC)O[C@]13COC(O)[C@@H](C3)O2 RONOTCDLXOKLQN-RMNOJRSUSA-N 0.000 description 1
- YXSSBGUZUGSQRK-YJPHJVCUSA-N [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCC(=O)OC)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCO)O2 Chemical compound [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCC(=O)OC)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCO)O2 YXSSBGUZUGSQRK-YJPHJVCUSA-N 0.000 description 1
- IAZXKOLLDHBRLA-BKPZCICPSA-N [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCC)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCO)O2 Chemical compound [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCC)O2.[H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCO)O2 IAZXKOLLDHBRLA-BKPZCICPSA-N 0.000 description 1
- XVZWKLQAHBWFKX-AKJDEPCMSA-N [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCC)O2.[H][C@]12CC[C@H](CCO)O[C@@]1(CO)C[C@H](CCCC)O2 Chemical compound [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCC)O2.[H][C@]12CC[C@H](CCO)O[C@@]1(CO)C[C@H](CCCC)O2 XVZWKLQAHBWFKX-AKJDEPCMSA-N 0.000 description 1
- MPOFFQBFUNRZEH-XDQVBPFNSA-N [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCO)O2 Chemical compound [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H](CCCO)O2 MPOFFQBFUNRZEH-XDQVBPFNSA-N 0.000 description 1
- XQPZCGOFICFYTQ-GVVZUSJYSA-N [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H]([C@H](O)CO)O2.[H][C@]12CC[C@H](CCC)O[C@]13COC(O)[C@@H](C3)O2 Chemical compound [H][C@]12CC[C@H](CCC)O[C@@]1(CO)C[C@H]([C@H](O)CO)O2.[H][C@]12CC[C@H](CCC)O[C@]13COC(O)[C@@H](C3)O2 XQPZCGOFICFYTQ-GVVZUSJYSA-N 0.000 description 1
- GKKYRVGKTXUZEG-ABVZQXBSSA-N [H][C@]12CC[C@H](CCC)O[C@]13C[C@H]1OC4(CCCCC4)OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CCO)O[C@]13C[C@H]1OC4(CCCCC4)OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@]13C[C@@H](O)C(O)[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@]13C[C@H]1OC4(CCCCC4)OC1[C@@]([H])(C3)O2 Chemical compound [H][C@]12CC[C@H](CCC)O[C@]13C[C@H]1OC4(CCCCC4)OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CCO)O[C@]13C[C@H]1OC4(CCCCC4)OC1[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@]13C[C@@H](O)C(O)[C@@]([H])(C3)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@]13C[C@H]1OC4(CCCCC4)OC1[C@@]([H])(C3)O2 GKKYRVGKTXUZEG-ABVZQXBSSA-N 0.000 description 1
- NXDBVWKAGWYNES-QONRVRNRSA-N [H][C@]12CC[C@H](CCI)O[C@@]1(CI)C[C@H](CCCC)O2.[H][C@]12CC[C@H](CCO)O[C@@]1(CO)C[C@H](CCCC)O2 Chemical compound [H][C@]12CC[C@H](CCI)O[C@@]1(CI)C[C@H](CCCC)O2.[H][C@]12CC[C@H](CCO)O[C@@]1(CO)C[C@H](CCCC)O2 NXDBVWKAGWYNES-QONRVRNRSA-N 0.000 description 1
- NUAFXZKGLOGKCD-WTGGKBSUSA-N [H][C@]12CC[C@H](CCI)O[C@@]1(CI)C[C@H](CCCC)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCCC)O2 Chemical compound [H][C@]12CC[C@H](CCI)O[C@@]1(CI)C[C@H](CCCC)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCCC)O2 NUAFXZKGLOGKCD-WTGGKBSUSA-N 0.000 description 1
- QBZLEVRGFICEOX-VPCQQBHUSA-N [H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCC(=O)OC)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCCO)O2 Chemical compound [H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCC(=O)OC)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CI)C[C@H](CCCO)O2 QBZLEVRGFICEOX-VPCQQBHUSA-N 0.000 description 1
- LLQRZUVSQASBFI-CFTFZMGYSA-N [H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CO)C[C@H](/C=C/C(=O)OC)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@]13CO[C@H](O)C(C3)O2 Chemical compound [H][C@]12CC[C@H](CC[N+]#[C-])O[C@@]1(CO)C[C@H](/C=C/C(=O)OC)O2.[H][C@]12CC[C@H](CC[N+]#[C-])O[C@]13CO[C@H](O)C(C3)O2 LLQRZUVSQASBFI-CFTFZMGYSA-N 0.000 description 1
- WGEWZTJGHWULLO-PMEXXGOBSA-N [H][C@]12C[C@@]34CC[C@H]5CC(=C)C(CC[C@H]6C[C@@H](C)C(=C)C(C[C@@H]7OC(C[C@H](O)CN)[C@H](C)[C@H]7CC(=O)CC7CC[C@]8([H])O[C@@H](C1O3)[C@@H](O2)[C@@H](O4)[C@@]8([H])O7)O6)O5 Chemical compound [H][C@]12C[C@@]34CC[C@H]5CC(=C)C(CC[C@H]6C[C@@H](C)C(=C)C(C[C@@H]7OC(C[C@H](O)CN)[C@H](C)[C@H]7CC(=O)CC7CC[C@]8([H])O[C@@H](C1O3)[C@@H](O2)[C@@H](O4)[C@@]8([H])O7)O6)O5 WGEWZTJGHWULLO-PMEXXGOBSA-N 0.000 description 1
- VLPVOBDBFUZGQI-MCMPZBMISA-N [H][C@]12C[C@@]34CC[C@H]5CC(=C)C(CC[C@H]6C[C@@H](C)C(=C)C(C[C@@H]7O[C@H](C[C@H](O)CN)[C@H](C)[C@H]7CC(=O)CC7CCC8O[C@@H](C1O3)[C@@H](O2)[C@@H](O4)C8O7)O6)O5.[H][C@]12C[C@@]34CC[C@H]5CC(=C)C(CC[C@H]6C[C@@H](C)C(=C)C(C[C@@H]7O[C@H](C[C@H](O)CN)[C@H](C)[C@H]7CC(=O)CC7CCC8O[C@@H](C1O3)[C@@H](O2)[C@@H](O4)C8O7)O6)O5.[H][C@]12C[C@@]34CC[C@H]5CC(=C)C(CC[C@H]6C[C@@H](C)C(=C)C(C[C@@H]7O[C@H](C[C@H](O)CO)[C@H](C)[C@H]7CC(=O)CC7CCC8O[C@@H](C1O3)[C@@H](O2)[C@@H](O4)C8O7)O6)O5.[H][C@]12C[C@@]34CC[C@H]5CC(=C)C(CC[C@H]6C[C@@H](C)C(=C)C(C[C@@H]7O[C@H](C[C@H](O)CO)[C@H](C)[C@H]7CC(=O)CC7CCC8O[C@@H](C1O3)[C@@H](O2)[C@@H](O4)C8O7)O6)O5 Chemical compound [H][C@]12C[C@@]34CC[C@H]5CC(=C)C(CC[C@H]6C[C@@H](C)C(=C)C(C[C@@H]7O[C@H](C[C@H](O)CN)[C@H](C)[C@H]7CC(=O)CC7CCC8O[C@@H](C1O3)[C@@H](O2)[C@@H](O4)C8O7)O6)O5.[H][C@]12C[C@@]34CC[C@H]5CC(=C)C(CC[C@H]6C[C@@H](C)C(=C)C(C[C@@H]7O[C@H](C[C@H](O)CN)[C@H](C)[C@H]7CC(=O)CC7CCC8O[C@@H](C1O3)[C@@H](O2)[C@@H](O4)C8O7)O6)O5.[H][C@]12C[C@@]34CC[C@H]5CC(=C)C(CC[C@H]6C[C@@H](C)C(=C)C(C[C@@H]7O[C@H](C[C@H](O)CO)[C@H](C)[C@H]7CC(=O)CC7CCC8O[C@@H](C1O3)[C@@H](O2)[C@@H](O4)C8O7)O6)O5.[H][C@]12C[C@@]34CC[C@H]5CC(=C)C(CC[C@H]6C[C@@H](C)C(=C)C(C[C@@H]7O[C@H](C[C@H](O)CO)[C@H](C)[C@H]7CC(=O)CC7CCC8O[C@@H](C1O3)[C@@H](O2)[C@@H](O4)C8O7)O6)O5 VLPVOBDBFUZGQI-MCMPZBMISA-N 0.000 description 1
- SSYZKFINQYOPRQ-DJTZDKCKSA-N [H][C@]12OC(=O)[C@@H](O)[C@@]1([H])CC(O)[C@@H]2O.[H][C@]12OC(=O)[C@@H](O)[C@@]1([H])O[C@@H]1OC(C)(C)OC12 Chemical compound [H][C@]12OC(=O)[C@@H](O)[C@@]1([H])CC(O)[C@@H]2O.[H][C@]12OC(=O)[C@@H](O)[C@@]1([H])O[C@@H]1OC(C)(C)OC12 SSYZKFINQYOPRQ-DJTZDKCKSA-N 0.000 description 1
- ZQOFJPQENSMWLQ-QPCRVVNGSA-N [H][C@]12OC(=O)[C@@H](O)[C@@]1([H])O[C@@H]1OC(C)(C)OC12.[H][C@]12O[C@@H]3OC(C)(C)OC3[C@H]1OC(=O)[C@@H]2Cl Chemical compound [H][C@]12OC(=O)[C@@H](O)[C@@]1([H])O[C@@H]1OC(C)(C)OC12.[H][C@]12O[C@@H]3OC(C)(C)OC3[C@H]1OC(=O)[C@@H]2Cl ZQOFJPQENSMWLQ-QPCRVVNGSA-N 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- DGODWNOPHMXOTR-UHFFFAOYSA-N dipotassium;dioxido(dioxo)osmium;dihydrate Chemical compound O.O.[K+].[K+].[O-][Os]([O-])(=O)=O DGODWNOPHMXOTR-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 239000000295 fuel oil Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- YCOZIPAWZNQLMR-UHFFFAOYSA-N heptane - octane Natural products CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 1
- CLUPOLFGIGLMIQ-UHFFFAOYSA-N heptane;propan-2-ol Chemical compound CC(C)O.CCCCCCC CLUPOLFGIGLMIQ-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- NWYYWIJOWOLJNR-RXMQYKEDSA-N l-valinol Chemical compound CC(C)[C@H](N)CO NWYYWIJOWOLJNR-RXMQYKEDSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000011981 lindlar catalyst Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- QDYVPYWKJOJPBF-UHFFFAOYSA-M lithium;hydroxide;dihydrate Chemical compound [Li+].O.O.[OH-] QDYVPYWKJOJPBF-UHFFFAOYSA-M 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- BXBLTKZWYAHPKM-UHFFFAOYSA-M magnesium;methanidyl(trimethyl)silane;chloride Chemical compound [Mg+2].[Cl-].C[Si](C)(C)[CH2-] BXBLTKZWYAHPKM-UHFFFAOYSA-M 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical group 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- HWWVAHCWJLGKLW-UHFFFAOYSA-N n,n-dimethylhydroxylamine;hydron;chloride Chemical compound Cl.CN(C)O HWWVAHCWJLGKLW-UHFFFAOYSA-N 0.000 description 1
- KCLDECJIUSCXOX-GFCCVEGCSA-N n-[2-methyl-6-[(4s)-4-propan-2-yl-4,5-dihydro-1,3-oxazol-2-yl]phenyl]methanesulfonamide Chemical compound CC(C)[C@H]1COC(C=2C(=C(C)C=CC=2)NS(C)(=O)=O)=N1 KCLDECJIUSCXOX-GFCCVEGCSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000011924 stereoselective hydrogenation Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/40—Halogenated unsaturated alcohols
- C07C33/42—Halogenated unsaturated alcohols acyclic
- C07C33/423—Halogenated unsaturated alcohols acyclic containing only double bonds as unsaturation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/28—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to compounds useful as intermediates in the synthesis of pharmaceutically active macrolide compounds.
- Halichondrin B is a potent anticancer agent originally isolated from the marine sponge Halichondria okadai, and subsequently found in Axinella sp., Phakellia carteri, and Lisson-dendryx sp. A total synthesis of Halichondrin B was published in 1992 (Aicher, T. D. et al., J. Am. Chem. Soc. 114: 3162-3164).
- Halichondrin B has demonstrated in vitro inhibition of tubulin polymerization, microtubule assembly, beta S -tubulin crosslinking, GTP and vinblastine binding to tubulin, and tubulin-dependent GTP hydrolysis and has shown in vitro and in vivo anti-cancer properties. Accordingly, there is a need to develop synthetic methods for preparing analogs of Halichondrin B useful as anti-cancer agents.
- the present invention provides methods for preparing analogs of Halichondrin B having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity.
- These compounds include a compound of formula B-1939:
- These compounds are useful for treating cancer and other proliferative disorders including, but not limited to, melanoma, fibrosarcoma, leukemia, colon carcinoma, ovarian carcinoma, breast carcinoma, osteosarcoma, prostate carcinoma, and lung carcinoma.
- the present invention also provides synthetic intermediates useful for preparing said analogs of Halichondrin B.
- Halichondrin B As described in, e.g. U.S. Pat. No. 6,365,759 and U.S. Pat. No. 6,469,182 the entirety of which are incorporated herein by reference.
- These Halichondrin B analogs are prepared generally by the assembly of three fragments F-1, F-2, and F-3, as shown by Scheme I below:
- the present invention provides a compound F-1:
- R 1 is OR. In other embodiments, R 1 is OR wherein R is hydrogen, methyl, or benzyl.
- PG 1 and PG 2 are hydrogen. In other embodiments, one of PG 1 and PG 2 is hydrogen.
- each of PG 1 and PG 2 taken with the oxygen atom to which it is bound, is independently selected from esters, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of such esters include formates, acetates, carbonates, and sulfonates.
- Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio) pentanoate, pivaloate (trimethylacetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, or carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl.
- silyl ethers examples include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers.
- Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxycarbonyl ethers or derivatives.
- Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers.
- arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl.
- one or both of the PG 1 and PG 2 moieties of F-1 are silyl ethers or arylalkyl ethers. In yet other embodiments, one or both of the PG 1 and PG 2 moieties of F-1 are t-butyldimethylsilyl or benzoyl. In still other embodiments, both of the PG 1 and PG 2 moieties of F-1 are t-butyldimethylsilyl.
- PG 1 and PG 2 are taken together to form an acetonide group.
- R 2 is CHO.
- R 2 is —CH ⁇ CH 2 .
- TBS refers to t-butyldimethylsilyl
- the present invention provides a compound F-2:
- a suitable leaving group is a chemical moiety that is readily displaced by a desired incoming chemical moiety.
- Suitable leaving groups are well known in the art, e.g., see, “Advanced Organic Chemistry,” Jerry March, 4 th Ed., pp. 351-357, John Wiley and Sons, N.Y. (1992).
- Such leaving groups include, but are not limited to, halogen, alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, and diazonium moieties.
- Suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonyloxy (mesyloxy), tosyloxy, triflate, nitro-phenylsulfonyloxy (nosyloxy), and bromo-phenylsulfonyloxy (brosyloxy).
- the LG 1 moiety of F-2 is sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, or optionally substituted arylsulfonyloxy.
- the LG 1 moiety of F-2 is optionally substituted alkylsulphonyloxy.
- the LG 1 moiety of F-2 is mesyloxy or tosyloxy.
- the X moiety of F-2 is halogen. In other embodiments, the X moiety of F-2 is sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, or optionally substituted arylsulfonyloxy. In still other embodiments, the X moiety of F-2 is triflate.
- the PG 3 moiety of F-2, taken with the oxygen atom to which it is bound is a silyl ether. In other embodiments, the PG 3 moiety of F-2, taken with the oxygen atom to which it is bound, is an ester group. According to one aspect of the present invention, the PG 3 moiety of F-2 is t-butyldimethylsilyl. According to another aspect of the present invention, the PG 3 moiety of F-2 is pivaloyl or benzoyl.
- the present invention provides a compound of formula F-2 having the stereochemistry depicted in formula F-2′:
- a compound F-2a or F-2b is provided:
- MsO mesylate
- TfO triflate
- OPv pivaloate
- OBz benzoate
- TsO tosylate
- the present invention provides a compound of formula F-2b wherein said compound is crystalline.
- a compound of formula F-2b is provided wherein said compound is crystallized from an alkane solvent.
- crystalline F-2b is provided wherein said compound is crystallized from pentane or heptane.
- crystalline F-2b is provided wherein said compound is crystallized at about 0° C.
- Suitable hydroxyl protecting group PG 5 is as described and defined for the PG 3 moiety of compound F-2, supra.
- PG 5 taken with the oxygen atom to which it is bound, is a silyl ether.
- PG 5 is t-butyldimethylsilyl.
- the Alk moiety of compound F-2d is methyl.
- R′′ moiety of compound F-2e may be transformed from OH to a protected hydroxyl group, OPG 3 , or, alternatively, directly to LG 4 . Such transformations are known to one skilled in the art and include, among others, those described herein.
- R′′ is OH or LG 4 .
- the LG 4 leaving group of formula F-2e is as described and defined for the LG 1 moiety of compound F-2, supra.
- LG 4 is tosyloxy or mesyloxy.
- PG 3 moiety of compound F-2e is as defined and described for the PG 3 moiety of compound F-2, supra.
- PG 3 taken with the oxygen atom to which it is bound, is a silyl ether.
- PG 3 is t-butyldiphenylsilyl.
- Still another aspect of the present invention provides a compound F-2f:
- Alk, PG 3 and PG 5 are as defined generally and in classes and subclasses described above and herein.
- Compounds of formula F-2f are used to prepare compounds of formula F-2 by methods described herein and those known in the art.
- compounds of formula F-2 are prepared from D-quinic acid as shown by Scheme II below. Details of the preparation of compounds of formula F-2 are set forth in the Examples infra.
- Scheme III above shows an alternate method for preparing intermediate 17 from intermediate 12 via Eschenmoser-Tanabe Fragmentation, wherein each Rx R x is independently OPG x or CN wherein PG x is a suitable hydroxyl protecting group as described herein.
- Intermediate 17 is then used to prepare compounds of formula F-2 according to Scheme II above.
- Still another method for preparing compounds of formula F-2 from D-quinic acid provides an alternative route from intermediate 9 to intermediate 17 as shown in Scheme IV below.
- PG y is a suitable carboxyl protecting group, as described herein, and each PG x is independently a suitable hydroxyl protecting group as described herein.
- each PG 5 and PG 6 is independently a suitable hydroxyl protecting group.
- PG 5 and PG 6 are taken together to form a cyclic diol protecting group.
- PG 5 and PG 6 are taken together to form a cyclohexylidene protecting group.
- LG 5 is a suitable leaving group. Such suitable leaving groups are well known in the art and include those described herein.
- LG 5 is mesyloxy or tosyloxy.
- the present invention provides a compound of formula A:
- the present invention provides a compound of formula A having the stereochemistry as depicted in formula A′:
- the present invention provides a compound of formula A′ wherein W is C(O) and said compound is of formula A′-1:
- each Q 1 group of formulae A and A′ is independently selected from cyano, halo, azido, oxo, OR, SR, SO 2 R, OSO 2 R, N(R) 2 , NR(CO)R, NR(CO) (CO)R, NR(CO)N(R) 2 , NR(CO)OR, (CO)OR, O(CO)R, (CO)N(R) 2 , O(CO)N(R) 2 , or OPG 1 , wherein PG 1 is a suitable hydroxyl protecting group.
- each Q 1 group of formulae A and A′ is independently selected from cyano, halo, azido, oxo, N(R) 2 , OR, SR, SO 2 R, or OSO 2 R. In other embodiments, each Q 1 group of formulae A and A′ is independently selected from cyano, halo, azido, oxo, OR, SR, SO 2 R, OSO 2 R, N(R) 2 , NR(CO)R, NR(CO)R, and O(CO)N(R) 2 .
- exemplary Q 1 groups include NH(CO) (CO)-(heterocyclic radical or heteroaryl), OSO 2 -(aryl or substituted aryl), O(CO)NH-(aryl or substituted aryl), aminoalkyl, hydroxyalkyl, NH(CO) (CO)-(aryl or substituted aryl), NH(CO) (alkyl) (heteroaryl or heterocyclic radical), O(substituted or unsubstituted alkyl) (substituted or unsubstituted aryl), and NH(CO) (alkyl) (aryl or substituted aryl).
- the A group of formulae A and A′ has one of the following characteristics:
- Exemplary A groups of formulae A and A′ include 2,3-dihydroxypropyl, 2-hydroxyethyl, 3-hydroxy-4-perfluorobutyl, 2,4,5-trihydroxypentyl, 3-amino-2-hydroxypropyl, 1,2-dihydroxyethyl, 2,3-dihyroxy-4-perflurobutyl 2,3-dihydroxy-4-perfluorobutyl, 3-cyano-2-hydroxypropyl, 2-amino-1-hydroxy ethyl, 3-azido-2-hydroxypropyl, 3,3-difluoro-2,4-dihydroxybutyl, 2,4-dihydroxybutyl, 2-hydroxy-2-(p-fluorophenyl)-ethyl, —CH 2 (CO) (substituted or unsubstituted aryl), —CH 2 (CO) (alkyl or substituted alkyl, such as haloalkyl or hydroxyalkyl) and 3,3-diflu
- the A group of either of formulae A and A′ is 3-amino-2-hydroxypropyl.
- Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl.
- silyl ethers examples include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers.
- Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxycarbonyl ethers or derivatives.
- Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers.
- arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl.
- two Q 1 on A are optionally taken together to form a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, two Q 1 on A are taken together to form an epoxide ring.
- the PG 5 and PG 6 groups of formula A and A′ are independently selected from those suitable protecting groups described above for the PG 1 group of formula A and A′. In other embodiments, the PG 5 and PG 6 groups of formula A and A′ are taken together to form a cyclic diol protecting group.
- diol protecting groups are well known in the art and include those described by Greene and include cyclohexylidene and benzylidene diol protecting groups.
- the present invention provides a method for preparing compounds of formula F-2 according to Schemes V-a, V-b, and V-c below:
- Scheme VI-a shows a general method for using this compound in the preparation of intermediates useful for preparing compounds of formula F-2.
- the bromo intermediate is treated with triphenylphosphine to form a Wittig reagent in situ in a manner substantially similar to that described by Murphy, et al, Tetrahedron Letters, 40, (1999) 3455-3456.
- This Wittig reagent then forms the lactone ER-812772.
- stereoselective hydrogenation of the double bond affords ER-812829.
- the present invention also provides a method for preparing intermediates useful for preparing compounds of formula F-2 from D-quinic acid, from intermediate ER-812829 depicted in Scheme VII above, as shown in Scheme VII-a below.
- the present invention provides a compound F-3:
- each PG 4 is an independently selected suitable hydroxyl protecting group
- R 3 is CHO or C(O)OR 4
- R 4 is a suitable carboxyl protecting group
- LG 2 is a suitable leaving group.
- R 4 group of F-3 is an optionally substituted C 1-6 aliphatic group or an optionally substituted aryl group.
- suitable R 4 groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl wherein each group is optionally substituted.
- suitable leaving groups are well known in the art, e.g., see “Advanced Organic Chemistry,” Jerry March, 4 th Ed., pp. 351-357, John Wiley and Sons, N.Y. (1992).
- Such leaving groups include, but are not limited to, halogen, alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, silyl, and diazonium moieties.
- Suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonyloxy (mesyloxy), tosyloxy, triflate, nitro-phenylsulfonyloxy (nosyloxy), and bromo-phenylsulfonyloxy (brosyloxy).
- the LG 2 moiety of F-3 is iodo.
- the suitable leaving group may be generated in situ within the reaction medium.
- LG 2 in a compound of formula F-3 may be generated in situ from a precursor of that compound of formula F-3 wherein said precursor contains a group readily replaced by LG 2 in situ.
- said precursor of a compound of formula F-3 contains a group (for example, a trimethylsilyl group) which is replaced in situ by LG 2 , such as an iodo group.
- the source of the iodo group maybe, e.g., N-iodosuccinimide.
- Such an in situ generation of a suitable leaving group is well known in the art, e.g., see Id.
- each PG 4 taken with the oxygen atom to which it is bound, is independently selected from esters, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of such esters include formates, acetates, carbonates, and sulfonates.
- Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl.
- silyl ethers examples include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers.
- Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxycarbonyl ethers or derivatives.
- Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers.
- arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl.
- one, two, or three of the PG 4 moieties of F-3, taken with the oxygen atom(s) to which they are bound, are silyl ethers or arylalkyl ethers.
- one, two, or three of the PG 4 moieties of F-3 are t-butyldimethylsilyl or benzyl.
- all three of the PG 4 moieties of F-3 are t-butyldimethylsilyl.
- a compound of formula F-3 wherein said compound has the stereochemistry as depicted in formula F-3′:
- a compound F-3a is provided:
- TBS refers to t-butyldimethylsilyl
- Scheme VIII above shows a general method for preparing intermediate F-5a from fragments F-1 and F-2.
- fragments F-1 and F-2 are coupled using methods substantially similar to that described by Kishi, et al., Org Lett 4:25 p 4431 (2002) to afford intermediate F-4.
- This coupling is performed in the presence of the chiral oxazole (ER-807363) or, alternatively, in the absence of ER-807363.
- the coupling reaction of F-1 and F-2 proceeds with higher selectivity when performed in the presence of ER-807363.
- Intramolecular Williamson ether formation of F-4 by treating F-4 with potassium hexamethyldisilazide, then furnishes tetrahydropyran F-5 as a mixture of stereoisomers. The stereoisomers are then separated to afford F-5a. The details of these steps are set forth in the Examples infra.
- the present invention provides a compound F-4:
- PG 1 , PG 2 , PG 3 , LG 1 , and R 1 are as defined in general and in subclasses above and herein.
- PG 3 is hydrogen or a suitable hydroxyl protecting group.
- the present invention provides a compound of formula F-4 wherein said compound has the stereochemistry depicted in formula F-4′:
- PG 1 , PG 2 , PG 3 , LG 1 , and R 1 are as defined in general and in subclasses above and herein.
- the present invention also provides a compound F-4a:
- MsO mesylate
- TSS t-butyldimethylsilyl
- OPv pivaloate
- the present invention provides a compound F-5:
- each PG 1 , PG 2 , PG 3 , and R 1 is as defined in general and in subclasses above and herein.
- the present invention provides a compound of formula F-5 having the stereochemistry as depicted in formula F-5′ or F-5a:
- each PG 1 , PG 2 , PG 3 , and R 1 is as defined in general and in subclasses above and herein.
- Scheme IX above shows a general method for preparing an intermediate-F-9 from F-3′and F-6.
- the sulfone intermediate F-6 is treated with n-butyl lithium then with the aldehyde F-3′.
- the resulting diol intermediate F-7 is then oxidized with Dess-Martin reagent to form the ketone-aldehyde intermediate F-8 which is then treated with SmI 2 to afford intermediate F-9.
- SmI 2 SmI 2
- Scheme X above sets forth a general method for preparing the Halichondrin B analogs of the present invention from F-9a (LG 2 is iodo).
- an intramolecular coupling is achieved, by conditions substantially similar to those described at Scheme V above, to form hydroxyl compound F-10.
- the intramolecular coupling is performed in the presence of the chiral oxazole ligand, described herein.
- the addition of the chiral oxazole ligand imparts a higher yield and greater efficiency for the reaction.
- the details of this reaction are set forth in the Examples below.
- Compound F-10 is then oxidized to form F-11.
- the hydroxyl protecting groups of F-11 are removed by appropriate means to afford F-12.
- Halichondrin B analog B-1939 Using the preparation of Halichondrin B analog B-1939 to exemplify, the following Examples describe the synthesis of Halichondrin B analogs using the methods and compounds of the present invention.
- Halichondrin B is prepared by the methods and from the compounds of the present invention including, but not limited to, those analogs of Halichondrin B described in U.S. Pat. Nos. 6,214,865 and 6,365,759, the entirety of which are herein incorporated by reference. Accordingly, it will be appreciated that the synthetic methods described below, by way of example, do not limit the scope of the invention which is defined by the appended claims.
- D-glucurono-6,3-lactone (1 wt., 1 eq.) was combined with ACN (3 vol.) and acetone (9 vol.).
- Catalytic conc. sulfuric acid was added and the system held at reflux for 3 hours.
- the system was checked for dissolution of D-glucurono-6,3-lactone.
- the reaction was cooled to 25° C. and stirred for 15 hours.
- Solid sodium bicarbonate (0.5 wts) was added and the reaction stirred for 3 additional hours. Solids were removed by filtration and the organics were partially concentrated and azeotroped with additional ACN (2 wts).
- ER-806045 was taken into the next reaction without isolation.
- the toluene solution (10.1 wt %, 9.9 wts) of ER-806051/52 (1 wt, 1 eq.) was further diluted with additional toluene (3 wts).
- N-Methylmorpholine (0.94 wts, 3.0 eq.) and DMAP (0.075 wts, 0.2 eq.) were added to the toluene solution and the resulting mixture was cooled below 15° C.
- Benzoyl chloride was added keeping the internal temperature below 25° C.
- the reaction was then stirred for 12 hours at 75° C.
- the reaction was cooled to 15° C. and the temperature kept below 25° C. during the 1N HCl (5 vol.) quench.
- Allyl TMS (1.03 wts, 4.8 eq.) was premixed with ER-806053/54 (1 wt, 1 eq.), available as a 22 wt % solution in toluene from the previous step (4.55 wts, 1 eq.), and added to the freshly generated Ti(OiPr)Cl 3 .
- the internal temperature during the addition was kept below 30° C.
- the reaction was stirred between 20-30° C. for 2 hours.
- the reaction was cooled to ⁇ 5° C. and quenched with 1N HCl (6 vol.), keeping the internal temperature below 30° C.
- the layers were separated and the organic layer sequentially washed with aqueous NaHCO 3 (5 wt.) and water (3 vol.).
- the organic layer was partially concentrated at reduced pressure (100% crude yield) and further azeotroped with additional toluene (4 vol.).
- the resulting ketone (ER-806058) was dissolved in a final 4 vol. of toluene, checked for water content and used as is in the next reaction.
- ER-806068 (1 wt., 1 eq.) was dissolved in 1 vol. of MeOH. Water (1.5 vol.) and 2 N HCl (1.25 vol., 1 eq.) were added and the reaction stirred at 25° C. The reaction was quenched by inverse addition to 2M NaOH (1.34 vol.) at 10° C. The reaction was diluted with isopropyl acetate (5 vol.), the layers were mixed well and separated. The aqueous layer was back extracted with 5 vol. of isopropyl acetate and the combined organic layers were dried over MgSO 4 (0.5 wt.), filtered, and concentrated at reduced pressure to afford crude diol ER-806063.
- ER-806065 (1 wt., 1 eq.) was dissolved in heptane, isooctane, or IPA (10 vol.) The solution was cooled below ⁇ 60° C. ( ⁇ 10° C.). Ozone was bubbled through the solution at low temperature until the solution retained a blue color. Nitrogen was purged through the solution for 15-30 minutes, and the reaction warmed to 5° C. while the nitrogen flush was continued. 7-15 wt. % Lindlar Catalyst (5% Pd on CaCO 3 poisoned with Pb, 0.1 wt.) was added. The reactor head was purged several times with nitrogen, evacuated, and placed under 1 atmosphere H 2 (g).
- a reactor was charged with pre-rinsed Amberlyst 15 (0.05 wt.) and water (4.63 vol.) and cooled to an internal temperature of 0-5° C.
- the reactor was charged with 2,3-dihydrofuran (1 wt., 1 eq.) and stirred for 1.5 hours maintaining internal temperature around 5° C.
- a second reactor was charged with water (4.63 vol.) and heated to an internal temperature of 35° C.
- the same reactor was charged with tin powder (2.2 wt., 1.3 eq.), distilled 2,3-dibromopropene (3.71 wt., 1.3 eq.), and 48% hydrobromic acid (0.002 vol.), respectively.
- the second reactor was charged with 2,3-dibromopropene portion-wise (9 ⁇ 0.37 wt.) while maintaining the internal temperature below 45° C. After complete addition, the contents of the second reactor were stirred at an internal temperature of 35° C. for an additional 60 minutes. The filtered contents of the first reactor were charged into the second reactor at a rate such that internal temperature did not exceed 45° C. After complete addition, the heat source was removed and the second reactor was charged with Celite® 545 (2.0 wt.) and the resulting mixture stirred for 30 minutes.
- the heterogeneous mixture was filtered through a Celite® 545 pad (2.0 wt.) and the cake washed with additional water (5 vol.). All filtrates were combined into a reactor and charged with concentrated hydrochloric acid (1.5 vol.) until the cloudy solution becomes clear. With vigorous stirring, the reactor was charged with sodium chloride (3.6 wt.) and the layers allowed to partition. The organic layer was separated and set aside. The aqueous layer was extracted with n-butanol (20 vol.). The aqueous layer was drained and the reactor charged with the organics from the first separation. The organics were washed with concentrated sodium bicarbonate (24 vol.), followed by a back extraction of the aqueous layer with n-butanol (20 vol.).
- a reactor was charged with imidazole (0.65 wt., 2 eq.), ER-806909 (1 wt., 1 eq.), and anhydrous DMF (4.04 vol.). With stirring, the reactor was cooled to an internal temperature of 0° C. and then with tert-butylchlorodiphenylsilane (1.25 wt., 0.95 eq.) at a rate such that internal temperature did not exceed 15° C. While maintaining the internal temperature ⁇ 15° C., the reaction was stirred for an additional 1 hour. The reactor was charged with water (3.2 vol.) and n-heptane (6.4 vol.). The mixture was stirred for 5-15 minutes and the layers allowed to separate.
- the enantiomers of ER-806545 were separated via Simulated Moving Bed (SMB) chromatography to yield ER-808373 (0.55 wt., 0.55 eq.) and ER-806721 (0.45 wt., 0.45 eq.) as yellow oils.
- SMB chromatography protocol used to separate the enantiomers of ER-806545 is as follows.
- the enantiomers of ER-806545 were separated using the above protocol in the following manner.
- 10 L of 36 g/L ER-806545 in mobile phase was pumped (Silog model Chemtech) through a 142 mm diameter 0.45 ⁇ m pore size nylon filter (Cole-Parmer # 2916-48) and into the Feed tank.
- the Eluant tank was filled with 36L mobile phase that has been filtered through an in-line 45 mm diameter 1 ⁇ m glass fiber filter (Whatman GFC), additional vol. were added throughout the run.
- the internal temperature of the SMB apparatus was adjusted to 27° C.
- the Feed and Eluant inlets were both connected to the Eluant tank.
- the Feed and Eluant pumps were primed and purged with mobile phase solvent.
- the SMB apparatus column switching was initiated, the pumps were turned on and the flow rates were gradually increased to full speed while maintaining absolute flow rate differences between each pump. Once fall speed was achieved the Raffinate and Extract flow rates were measured and adjustments to pump flow rates were made to correct for deviations in pump specifications.
- the Feed pump (Pump 1) was reduced to 0 mL/min, the inlet reconnected to the Feed tank, the pump primed with Feed solution and then the flow rate gradually increased back to full operating speed.
- the Raffinate and Extract outlets were collected into separate tanks and samples of each of each were acquired every 2 hours. The samples were monitored for chiral purity by analytical HPLC using the HPLC method set forth below. Adjustments to the flow rates of Pumps 2, 3 and 4 as well as to the tact time were made to afford the desired outlet purities.
- the Feed pump was once again reduced to zero flow rate and connected to the Eluant tank.
- the Feed pump was brought back to full speed and the system was allowed to wash for 20 minutes.
- the Raffinate and Extract outlets were maintained for 10 minutes (10 tacts) during the wash period and, for the remainder of the wash, the outlets were collected into a separate tank.
- the column wash was eventually concentrated and added to the Feed on subsequent runs.
- a reactor was charged with ER-806721 (1 wt., 1 eq.) and anhydrous dichloromethane (4.2 vol.). The reaction was cooled to an internal temperature of 0-5° C., then triethylamine (0.34 wt., 1.5 eq.), p-toluenesulfonyl chloride (0.51 wt., 1.2 eq.), and 4-(dimethylamino)-pyridine (0.001 wt., 0.25 eq.) were added. The resulting mixture was stirred at ambient temperature for 48 hours then water (1.8 vol.) and dichloromethane (1.8 vol.) were added. After sufficient mixing, the organics were separated and concentrated.
- the concentrate was dissolved in MTBE (1.8 vol.) and washed with brine (1.8 vol.). The organic layer was separated and set aside. The aqueous layer was back extracted with MTBE (1.8 vol.) then all organics were combined and concentrated in vacuo.
- the crude oil was filtered through a plug of SiO 2 (70-230 mesh, 1 wt.) eluting with MTBE (7 vol.) and the filtrates were concentrated in vacuo.
- the concentrate was dissolved in IPA (5 vol.) and water (0.25 vol.) was added. The resulting mixture was cooled to an internal temperature of 15° C. and then seeded with ER-807204. After seeding, the mixture was cooled to an internal temperature of 0° C.
- a reactor was charged with 21% sodium ethoxide in ethanol (2.97 wt., 0.9 eq.). The solution was heated to an internal temperature of 65° C. then diethyl malonate (3.24 wt., 2 eq.) was added at a rate such that the internal temperature did not exceed 70° C. The mixture was stirred for 30 minutes and then ER-806906 (1 wt., 1 eq.) was added over 3-5 hours. Upon complete addition, the reaction was stirred for 60 minutes and then cooled to an internal temperature of 50° C. Concentrated hydrochloric acid (0.84 wt., 1.05 eq.) was added at a rate such that internal temperature did not exceed 65° C.
- a reactor was charged with LHMDS 1.0 M in toluene (6.61 wt., 1.04 eq.) and cooled to an internal temperature of ⁇ 75° C.
- ER-805552 (1 wt., 1 eq.) was dissolved in anhydrous THF and added to the reactor at a rate such that internal temperature did not exceed ⁇ 70° C. Upon complete addition, the resulting mixture was stirred for 30 minutes.
- a second reactor was charged with anhydrous THF (2.5 vol.) and methyl iodide (1.27 wt., 1.25 eq.) and cooled to an internal temperature of ⁇ 75° C.
- a reactor was charged with N,O-dimethylhydroxylamine HCl (1.05 wt., 1.5 eq.) and anhydrous CH 2 Cl 2 (8.1 vol.) and cooled to an internal temperature of 0° C. 2 M trimethylaluminum in toluene (3.93 wt., 1.5 eq.) was added at a rate such that internal temperature did not exceed 5° C. The reaction was stirred for an additional 10 minutes and ER-806724 was added at a rate such that internal temperature did not exceed 5° C. The reaction was diluted with CH 2 Cl 2 (15 vol.) then inverse quenched into 1.3 M sodium tartrate (20 vol.) at an internal temperature of 0° C.
- a reactor was charged with ER-806753 (1 wt., 1 eq.), CH 2 Cl 2 (5 vol.) and NMO-50% in water (0.8 wt., 1.1 eq.). The mixture was cooled to an internal temperature of 10° C. and then 0.197 M OsO 4 in toluene (0.06 vol., 0.004 eq.) was added. Sodium sulfite (0.1 wt., 0.25 eq.) and water (0.85 vol.) were added and the reaction stirred for 1 hour. The mixture was diluted with brine (0.85 vol.) and the organics were concentrated in vacuo to approximately 1 ⁇ 3 vol.
- a second reactor was charged with sodium periodate (1.3 wt., 2 eq.) followed by THF (2.5 vol.).
- the concentrated diol was added at a rate such that the internal temperature did not exceed 30° C.
- the resulting mixture was stirred at room temperature.
- Water (1.25 vol.), MTBE (7 vol.) and brine solution (1.25 vol.) were added and the layers separated. The organics were washed a second time with a mixture of brine solution (1 vol.) and saturated sodium bicarbonate (1 vol.).
- a reactor was charged with ER-806629 (1.53 wt., 3.1 eq.) and THF (10.5 vol.) and the solution was degassed with nitrogen sparge for 60 minutes.
- a second inserted reactor was charged with ER-807204 (1 wt., 1.0 eq.), ER-806754 (0.66 wt., 1.2 eq.) and THF (2.7 vol.) and this solution was degassed with argon sparge for 45 minutes.
- the reactor containing ER-806629 was charged with CrCl 2 (0.63 wt., 3.1 eq.) and followed by Et 3 N (0.52 wt., 3.1 eq.). The dark green suspension was stirred at an internal temperature of 30 to 35° C.
- a reactor was charged with ER-807524 (1 wt., 1 eq.) and anhydrous THF (1.25 vol.). The mixture was cooled to an internal temperature of ⁇ 20° C. and 3 M methyl magnesium chloride (0.59 vol., 1.2 eq.) was added at a rate such that the internal temperature did not exceed 0° C. Upon complete addition, the mixture was warmed to an internal temperature of 0° C. over 2 hours. The reaction mixture was inverse quenched into semi-saturated ammonium chloride (2.62 vol.) and the resulting mixture diluted with TBME (2 vol.) with vigorous mixing. The aqueous layer was discarded and the organics washed with brine (2 vol.) then concentrated in vacuo. The crude product was purified via SiO 2 column chromatography to yield ER-807525 (0.79-0.82 wt., 0.85-0.88 eq.) as yellow oil.
- a reactor was charged with ER-807525 (1 wt., 1 eq.), N-phenylbistrifluoromethanesulfonamide (0.59 wt., 1.1 eq.), and anhydrous THF (4.1 vol.) and the mixture cooled to an internal temperature of ⁇ 75° C.
- 0.5 M KHMDS in toluene (2.75 wt., 1 eq.) was added at a rate such that internal temperature did not exceed ⁇ 60° C. then the reaction was warmed to ⁇ 20° C. over 2 hours.
- the reaction was quenched with semi-saturated NH 4 Cl (2.4 vol.) at a rate such that internal temperature did not exceed 0° C.
- ER-807527 was separated by preparative HPLC chromatography and the desired fractions concentrated to yield ER-806730 (0.56 wt., 0.56 eq.) as a clear yellow oil.
- the preparative HPLC chromatography protocol used to isolate ER-806730 is as follows.
- ER-807527 was first diluted to 0.1 g/ml in the mobile phase and filtered under vacuum through a 47 mm, 1 ⁇ m pore size, glass fiber filter (Whatman GFC). The filtrate was then concentrated under vacuum on a rotary evaporator. Flow on the SD-1 HPLC pump A (primed and purged with mobile phase) was initiated and the flow rate gradually increased to 140 mL/minute. The system was washed until the UV and RI detectors achieved a stable baseline. The RI detector reference flow cell was flushed with fresh mobile phase.
- Chromatography of 8 g injections of ER-807527 was accomplished by diluting the current lot of ER-807527 to a concentration of 0.8 g/mL in the mobile phase. Injecting 10 mL aliquots of the dissolved material and collecting the eluant corresponding to the ER-806730 peak approximately beginning at the peak apex approximately 24 minutes and continuing to 35 minutes. Subsequent injections and fraction collection were continued until the starting material is exhausted.
- a reactor was charged with ER-806730 (1 wt., 1 eq.) and anhydrous dichloromethane (4.8 vol.) and cooled to an internal temperature of 0° C. 2,4,6-Collidine (1.16 wt., 4 eq.) and DMAP (0.03 wt., 0.1 eq.) were added and the resulting mixture stirred for 15 minutes and then trimethylacetyl chloride (0.3 wt., 1.05 eq.) was added at a rate such that internal temperature did not exceed 10° C. Water (3 vol.) was added and the mixture stirred for 15 minutes. TBME (10 vol.) was added and the mixture stirred for an additional 10 minutes.
- AlMe 3 (2 M in toluene, 1.5 eq, 1.5 v) was added to a suspension of dimethylhydroxylamine hydrogen chloride (1 wt) in CH 2 Cl 2 (2.5 v) at 0° C.
- the reaction mixture was then added to aqueous sodium tartrate (1.3 M, 20 v) keeping the temperature below 10° C.
- the layers were allowed to partition, were separated, and the organic layer was dried with Na 2 SO 4 (5 wt).
- the resulting suspension was filtered and the filtrate concentrated.
- Methyl magnesium chloride (3.0 M, 59 wt, 1.2 eq) was added to a solution of 21 (1 wt) in anhydrous THF (1.11 wt, 1.25 v) at a rate that maintained the reaction temperature below 0° C. After stirring at 0° C., the reaction was reverse quenched into saturated ammonium chloride (2.5 v) and water (2.3 v). The resulting mixture was diluted with MTBE (10 v) and stirred vigorously. The aqueous layer was separated and the organic layer washed with brine (2.5 v) and concentrated to provide 22 (0.84 wt).
- Example 4a provides an alternate method of preparing compounds of formula A, an intermediate to F 2, using the general scheme set forth at Scheme V above. This method uses ER-812935 as an intermediate as prepared according to Example 3 (compound 4), above.
- ER-812935 (1 wt) was dissolved in THF (10 v) and cooled to 0° C. LAH (1.0 M in THF, 0.70 eq, 2.0 v) was added keeping the temperature below 5° C. While stirring vigorously, excess reagent was quenched with water (0.078 v) keeping the temperature below 5° C. While maintaining the vigorous stirring, NaOH (15% wt/wt in water (0.078 v)) was added followed by water (0.18 v). After adding Celite® (2 wt), the suspension was filtered and the cake rinsed with THF (5 v). The solution of ER-817633 (0.92 wt, calcd. based on 100% conversion) was concentrated to 5 v and used directly in the next stage.
- ER-818950 was dissolved in acetic acid (5 v) and hydrogen chloride (1.0 M, 1 eq, 3 v) was added and the reaction was stirred at ambient temperature. The reaction was cooled to 0° C. and NaOH (50% wt/wt, 30 eq, 7 wt) was added at a rate that maintained the temperature below 10° C. The solution was extracted with heptane (2 ⁇ 10 vol). The aqueous phase was saturated with NaCl and extracted with ACN (2 ⁇ 10 v). The combined ACN extracts were concentrated and solvent exchanged with EtOAc by atmospheric distillation to provide a solution of ER-817664 in EtOAc (3 v). Salts were filtered from the hot solution which was then cooled to 0° C. The suspension was filtered to provide ER-817664 as a white crystalline solid.
- Example 4b provides an alternate method of preparing compounds of formula F-2 using the general scheme set forth at Schemes Vb and Vc above. This method uses ER-817664 as an intermediate as prepared according to Example 4a, above.
- ER-817664 (1 wt) was dissolved in ACN (10 v), the suspension was cooled to 0° C. and 2-acetoxy-2-methylpropanyl bromide (4.0 eq, 2.4 v) was added followed by the addition of H 2 O (1.0 eq., 0.07 v). The resulting mixture was stirred at 0° C. for 2 hours. NaHCO 3 (sat. aqueous, 8.0 eq. 40 v) was added slowly at 0° C. The resulting mixture was stirred at room temperature for 30 minutes prior to extraction with MTBE (2 ⁇ 20 v). The organic layer was washed with brine (5 v) and concentrated to give the product as colorless oil.
- ER-818638 (1 wt) and LiCl (2.0 eq, 0.35 wt) was stirred in ACN (8.7 v). Hunig's base (1.5 eq) was added at 25° C. 1 N HCl (5 v) was added and the mixture was extracted with MTBE (10 v). The organics were concentrated to provide ER-818640 which was used as is in the next step.
- the starting lactone as depicted immediately above, was dissolved in DCM (50 v), Et 3 N (5.0 eq.), DMAP (0.3 eq.) and TBDPSCl (1.5 eq.) were added separately at ambient temperature under N 2 , and the resulting solution was stirred at ambient temperature for 2 ⁇ 3 hours.
- the mixture was diluted with TBME (100 v), washed with sat. aq. NaHCO 3 solution (10 v), H 2 O (10 v) and brine (10 v).
- the organic layer was concentrated and purified by flash chromatography to give the product as colorless oil.
- Example 4c provides another alternate method of preparing compounds of formula F-2 using the general scheme set forth at Scheme VII above. This method uses ER-811510 as an intermediate as prepared according to Example 3, above where acetone is used instead of cyclohexanone.
- ER-811510 (1 wt, 1 eq) was dissolved in methylene chloride (6.3 v) and cooled to ⁇ 5° C. Pyridine (0.41 vol, 1.1 eq) was added followed by bromoacetyl bromide (0.44 vol, 1.1 eq) while keeping the temperature below 0° C. The reaction was stirred at I 1 hour and warmed to room temperature. Water (8 vol) was added and the layers separated. The organic layer was washed sequentially with aqueous copper sulfate pentahydrate (1.0 M, 10 vol), water (8 vol), and brine (10 vol) then dried over magnesium sulfate, filtered and concentrated in vacuo to afford ER-812771 as a tan solid.
- ER-812771 (1 wt, 1 eq) was dissolved in acetonitrile (6 v) and triphenylphosphine was added and the reaction heated at 50° C. for 45 minutes. The reaction was cooled to ⁇ 10° C. then 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU, 0.35 vol, 0.8 eq) was added. The reaction was stirred for 15 minutes, heated to 80° C. for 45 minutes then cooled to ambient temperature. Ammonium chloride (saturated aqueous, 10 vol) was added and the aqueous layer extracted with ethyl acetate (3 ⁇ 10 v). The combined organic layers were dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by chromatography to afford ER-812772 as a white solid.
- DBU 1,8-diazabicyclo [5.4.0]undec-7-ene
- ER-812772 (1 wt, 1 eq) was dissolved in ethyl acetate (8 v). 10% Palladium on carbon (0.05 wt, 0.01 eq) was added, the reaction purged with nitrogen then stirred under hydrogen atmosphere for 2 hours. The catalyst was removed by filtration through Celite with ethyl acetate washed. The combined filtrates were concentrated in vacuo to afford ER-812829 as a white solid.
- the mixture was heated to reflux for at least 1 hour before it was cooled to and aged at 85° C. for 3 hours, at 80° C. for 3 hrs and then cooled to 40° C. in 12 hrs.
- the product was collected by filtration and the cake washed with heptane (2 vol).
- the filter cake was dried by airflow to afford ER-805715 (1.48 wt) in 78% of yield.
- ER 805814 (1 wt.) was dissolved in anhydrous THF (3.3 vol.) and treated with (methoxymethyl)triphenylphosphonium chloride (2.11 wt., 2.1 eq.). The reaction mixture was heated to 28-32° C. then a solution of KOtBu (0.66 wt., 2 eq.) in anhydrous THF (2.64 vol.) was added over 100-140 minutes, maintaining reaction temperature 30-35° C. After 5 hours, the reaction was cooled to 20-25° C., MTBE (5.11 vol.) was added and the mixture stirred. Brine (3 wt.) and water (3 wt.) were added (exothermic at start of addition, controlled by bath @20-25° C.).
- a solution of t-BuOK (0.989 wt, 3 eq) in THF (4 wt) was added to a suspension of (methoxymethyl)triphenylphosphonium chloride (3.12 wt, 3.1 eq) in THF (1.78 wt), maintaining the reaction temperature between 0-10° C.
- the addition vessel was rinsed with THF (2 ⁇ 0.7 wt).
- a solution of ER-805814 (1 wt, 1 eq) in THF (1.42 wt) was added to the reaction, maintaining 0-10° C.
- the addition vessel was rinsed with THF (2 ⁇ 0.7 wt). The mixture was stirred at 20-30° C. overnight and 30-35° C.
- ER-805815 In an alternative method for workup of ER-805815, the crude organic layer that is produced following brine wash and concentration is treated with MTBE (2.86 wt) and celite (0.5 wt). After stirring for 2.5 h, heptane (1.46 wt) was added over 2 hrs and the mixture stirred overnight. The precipitate was filtered. The filter cake was washed with MTBE/Heptane (1:1) (5 wt). The filtrate was concentrated in vacuo until the volume was decreased to about 3 volume. The residue was dissolved in MeOH (2 wts) and H 2 O (6 wts). The mixture was extracted with heptane/MTBE (5:1) (3*6 wts). The organic layer was separated and concentrated to provide ER-805815 which was used as is for the following step.
- ER-805815 (1 wt) was dissolved in acetone (2.4 vol) and water (0.4 vol). N-Methylmorpholine N-oxide (0.62 wt, 2 eq) was added and the mixture cooled to 0-5° C. OSO 4 (0.15M in water, 0.065 vol) was added and the reaction was maintained at 0-5° C. The reaction mixture was stirred at 0-5° C. for 12 hours. Water (0.2 vol) was added over 1 hour at 0-2° C. The mixture was stirred for one hour at 0-5° C. The product was filtered and the solids washed twice with pre-cooled (0-5° C.) acetone/water (1/1, v/v, 2 ⁇ 0.7 vol). The product was dried to afford ER-805816 (0.526 wt, 52% yield, residual Os ⁇ 17 ppm).
- ER-805816 In an alternate method for preparing ER-805816, a solution of ER-805815 (1 wt, 1 eq) in acetone (4 wt) was charged into a four-necked flask, then water (0.5 wt) was added at ambient temperature. To the mixture was added anhydrous N-methylmorpholine-N-oxide (0.38 wt, 1.2 eq). Potassium osmate dihydrate (0.003 wt, 0.003 eq) was added portion-wise at 25 to 35° C. while cooling with water. The mixture was kept at this temperature for 4 hours.
- the precipitate was filtered and washed with water (1.53 wt) to afford the crude wet cake (1.05 wt).
- the crude ER-805816 (1.05 wt) was added to water (2.81 wt) and stirred for 2 hours at about 25° C.
- the precipitate was filtered and washed with water (1.4 wt) and methanol (0.45 wt) to afford the crude ER-805816 (0.736 wt).
- ER-805816 (0.56 wt) was dissolved in acetone (1.76 wt) at 45 to 55° C. To the solution was added active carbon (0.027 wt) and stirred at same temperature for 0.5 hour. The mixture was filtered and the cake was washed with hot acetone (0.214 wt). The filtrate was kept at 45 to 50° C. and water (0.83 wt) was added over 10 minutes and temperature was kept at 40 to 50° C. during water addition. The mixture was cooled to 0 to 5° C. and stirred for 1.5 hours.
- ER-805816 (1 wt) was slurried in acetic acid (0.89 vol, 5.8 eq) and acetic anhydride (3.57 wt, 13 eq). Anhydrous ZnCl 2 (0.2 wt, 0.54 eq) was added. Reaction mixture was stirred for 24 hours 18-22° C. Reaction was quenched into ice (5 wt) and water (5 vol). EtOAc (10 vol) was added with stirring and the aqueous layer is separated. The aqueous layer was back extracted with EtOAc (10 vol). The combined organic layers were washed sequentially with brine (10 vol), 5% aqueous NaOAc (6 vol), and brine (6 vol). The organic layer was concentrated.
- ER-805819 In an alternate method for preparing ER-805819, zinc chloride (0.2 wt, 0.54 eq), acetic anhydride (2.75 wt, 10 eq), and acetic acid (1 wt, 6 eq) were combined. The mixture was cooled to 15-20° C. ER-805816 (1 wt, 1 eq) was added, maintaining the internal temperature at 15 to 30° C. The mixture was then stirred at 35-40° C. for 6 hours. The reaction mixture was cooled below 25° C. Methanol (3.2 wt, 4 vol) was added drop-wise maintaining reaction temperature below 25° C. Heptane (2.7 wt, 4 vol) was added. Water was added (4 wt, 4 vol) maintaining reaction temperature below 25° C.
- the mixture was stirred for 15 minutes, and then the phases were separated.
- the lower layer was washed twice with heptane (2.7 wt, 4 vol) and the heptane layers were discarded.
- the lower layer was extracted twice with toluene (6.1 wt, 8 vol).
- the combined toluene layers were washed twice with 17 wt % potassium bicarbonate aqueous solution (0.82 wt KHCO3 in 3.98 wt water, 4.36 vol), twice with water (4 wt), and concentrated.
- Methanol (3.95 wt, 5 vol) was added at 25-30° C. and the mixture stirred for 10 minutes. Water (0.3 wt) was added at 25-30° C. The mixture was cooled to 0° C.
- ER-805819 (1 wt) was dissolved in anhydrous acetonitrile (15 vol) and treated with methyl 3-trimethylsilylpent-4-eneoate (0.93 vol, 2 eq). The reaction mixture was cooled to 0-5° C. and BF 3 •OEt 2 (0.54 vol, 1.95 eq) was added over 5 minutes, maintaining reaction temperature between 0-5° C. Reaction mixture was stirred 0-5° C. for 12 hours. Reaction was quenched into saturated sodium bicarbonate (20 vol) with vigorous stirring. Extracted twice with EtOAc (2 ⁇ 8 vol). The combined organics were washed with brine (12 vol) and concentrated to give ER-805821 (1 wt, 88% yield, use as is).
- ER 805819 (1 wt, 1 eq) and ER methyl 3-trimethysilylpent-4-eneoate (0.93 vol, 2 eq) were dissolved in anhydrous acetonitrile (5.46 wt, 7 vol).
- the reaction mixture was cooled to 0-5° C. and BF 3 •OEt 2 (0.54 vol, 1.95 eq) was added over 5 minutes, while maintaining reaction temperature between 0-5° C.
- the reaction mixture was stirred at 0-5° C. for 20 hours then heptane (5.47 wt, 8 vol) was added at 0-5° C.
- ER-805821 (1 wt) was dissolved in anhydrous THF (8.4 vol) and anhydrous MeOAc (2 vol). Triton B(OH) (3.6 vol) was added over 2 minutes, reaction maintained 17-23° C. Reaction was stirred for 1.5 hour. Reaction mixture was filtered. The filtrate was concentrated and passed through a pad of SiO 2 (5 wt, EtOAc, 20 vol). The filtrate was washed with brine (2.2 vol) and evaporated to give ER-805822 (0.54 wt, 72% yield).
- ER-805821 (1 wt, 1 eq, 11.18 g, 21.81 mmol) was dissolved in anhydrous MTBE (4.4 wt, 6 vol.) and cooled to 0-5° C.
- NaOMe 28 wt % in MeOH, 0.564 wt, 1.5 eq
- the reaction was quenched by addition of acetic acid (0.188 wt, 1.6 eq.), maintaining 0-5° C. during addition.
- ER 805822 (1 wt) was dissolved in ethyl acetate or another appropriate solvent (5 vol) and water (5 vol).
- NaIO 4 (0.58 wt, 1.05 eq) is added portionwise over 30 min to 1 hour, maintaining reaction temperature 0-10° C. Reaction is stirred for up to 2 hours.
- the reaction mixture was treated with NaCl (1 wt) and stirred for 30 min at 0 to 10° C.
- the reaction mixture was filtered and the cake is rinsed with ethyl acetate (2 vol).
- the phases were separated and the lower layer extracted with EtOAc (5 vol) three times.
- the combined organic layer was washed with 20% aqueous NaCl (5 wt).
- the organic layer was concentrated to give ER 804697 (1 wt).
- the residue was dissolved in toluene (2 vol) and the solution concentrated.
- the residue was dissolved in acetonitrile (7 vol) and used for the next step.
- NiCl 2 (0.025 wt) and CrCl 2 (2.5 wt) were charged to reaction vessel under inert atmosphere.
- Anhydrous dichloromethane (5 vol) was charged. Stirring was initiated and the mixture was cooled to 0-3° C.
- Anhydrous DMSO (6.7 vol) was added with vigorous stirring over 45 minutes, maintaining temperature below 20° C.
- ER-804697 (1 wt) was dissolved in anhydrous dichloromethane (1 vol) and charged to the reaction vessel.
- the resulting mixture was warmed to 25° C. and 1-bromo-2-trimethylsilylethylene (2.58 wt) was added neat over 20 minutes. The reaction temperature was maintained below 45° C.
- this reaction was performed in the presence of the chiral ligand ER-807363 in a manner substantially similar to that described for the preparation of ER-118047, infra.
- DMSO (7 vol.) and MeCN (7 vol) were degassed and cooled to 0-10° C.
- the solution was treated portionwise with CrCl 2 (10 eq, 3.47 wt) and NiCl 2 (0.1 eq, 0.037 wt) such that the internal temperature did not exceed 20° C.
- a solution of ER-804697 (1 wt, 1 eq) in MeCN (7 vol) and 1-bromo-2-trimethylsilylethylene (5 eq, 2.5 wt) were added dropwise at 0-10° C., not allowing the internal temperature to exceed 15° C.
- the reaction mixture was stirred at 5-15° C. overnight.
- the reactor was charged with layer 1, methanol (2.8 wts), and MTBE (2.8 wts). The mixture was stirred overnight. The lower layer was separated and discarded. The upper layer was treated with layer 2. The mixture was stirred for 1 hour and the lower layer was separated and discarded. The upper layer was treated with layer 3 and heptane (4.8 wts). The mixture was stirred for 1 hour and the lower layer was separated and discarded. The upper layer was drained and saved (organic 2). The reactor was charged with layer 3, MTBE (0.8 wts), and heptane (2.7 wts). The mixture was stirred for 1 hour and the lower layers was separated and discarded. The upper layer was combined with organic 1 and organic 2.
- ER 804698 (1 wt, 1 eq) was treated with AcOH (4.2 wts) and water (4.2 wts). The mixture was heated to 90-97° C. for 100 min. The mixture was cooled to below 15° C. then washed with heptane (2 ⁇ 2.7 wts) twice below 15° C. After phase separation, a mixture of 20 wt % aqueous KHCO 3 solution (7.7 wts, 35 eq) and MTBE (5.95 wts) was added dropwise to the lower layer such that temperature does not exceed 15° C.
- ER-807023 (1 wt, 1 eq) and MTBE (7.43 wts) were charged to a reactor under a nitrogen atmosphere.
- 2,6-lutidine (2.15 wts, 7.5 eq).
- TBSOTf (2.47 wts, 3.5 eq) at 0° C.
- MeOH (0.21 wts, 2.5 eq.) and water (14.8 wts) were added dropwise sequentially to the reaction mixture, maintaining temperature below 30° C.
- a pre-dried glass lined reactor was charged with triphosgene (1 wt., 1 eq.) and anhydrous THF (2 vol.) and was cooled to an internal temperature of ⁇ 10° C.
- a second pre-dried glass lined reactor was charged with ER-807244 (1.27 wt., 2.5 eq.) and anhydrous THF (3 vol.) then cooled to an internal temperature of ⁇ 10° C.
- the contents of the first reactor were transferred into the second reactor at a rate such that internal temperature did not exceed 15° C.
- the reaction was stirred at an internal temperature of 0° C. for 1 hour and then gradually warmed to 25° C.
- MTBE (2.6 vol.), was added followed by process water (2 vol.) at a rate such that the internal temperature did not exceed 35° C.
- the phases were allowed to partition and the aqueous phase separated. All organics were combined with water (0.7 vol.) and the aqueous phase discarded.
- the MTBE was distilled to a level of ⁇ 2 vol. at atmosphere pressure to constant bp 55° C. and KF ⁇ 500 ppm.
- ER-806629 or ER-807363 (1.7 wt., 0.57 eq.) as a crystalline solid.
- Reactor 2 was charged with triethylamine (0.62 wt, 3.55 eq) at a rate such that internal temperature did not exceed 45° C. After complete addition, an internal temperature of 30° C. was maintained for 1 hour. After 1 hour, reactor 2 was cooled to 0° C. and charged in an inert fashion with NiCl 2 (0.02 wt, 0.1 eq), followed by the contents of reactor 1 and the reaction was warmed to rt. Reactor 2 was cooled to an internal temperature of 0° C. and then ethylenediamine (1.2 vol, 10 eq) was added at a rate such that the internal temperature did not exceed 10° C. Note: An exotherm was observed.
- the ER-808227/THF solution from the previous step was analyzed via KF analysis. If KF ⁇ 1000 ppm, then proceeded. If KF 1000 ppm KF>1000 ppm, azeotroped in vacuo with anhydrous THF (4.1 vol.). Repeated azeotrope until specification was met. The final solution meeting specifications contained the dissolved crude ER-808227 in anhydrous THF (4.1 vol.). Once the specification was met, an appropriately sized inerted reactor was charged with anhydrous THF (106 vol.) and the ER-808227/THF solution from the previous step.
- the reactor was cooled to an internal temperature of ⁇ 15 to ⁇ 20° C., then 0.5 M KHMDS in toluene (9.1 wt., 3.0 eq.) was added at a rate such that internal temperature did not exceed ⁇ 12° C. Approximately 4.5 eq. KHMDS was necessary to drive the reaction to completion.
- the reaction was reverse quenched into semi-saturated ammonium chloride (40 vol.) at an internal temperature of 0° C. n-Heptane (80 vol.) was added, stirred for 2-5 minutes, and then allowed to partition.
- the crude ER-806746 was purified via SiO 2 column chromatography to yield ER-804027 (1.16 wt., 0.55 eq.) as a clear yellowish oil.
- the chromatography was performed as follows: the column was first flushed with sufficient MTBE to remove water then flushed with heptane to remove the MTBE.
- the ER-806746 was loaded onto the column as a solution in heptane then eluted from the column with heptane/MTBE (5:1) then heptane/MTBE (4:1) with the fractions monitored at 230 nm by UV detector.
- a reactor was charged with ER-804027 (1 wt, 1 eq) and anhydrous dichloromethane (7.6 vol). The reactor was cooled to an internal temperature of ⁇ 78° C. and then 1 M DIBALH in dichloromethane (3.0 wt, 2.25 eq) was added at a rate such that internal temperature did not exceed ⁇ 60° C. Methanol (0.1 vol) was added at a rate such that internal temperature did not exceed ⁇ 60° C. Note: hydrogen gas evolved and was diluted with a stream of nitrogen. Upon complete addition, the mixture was warmed to ambient temperature and then 1 N hydrochloric acid (10.6 vol) and MTBE (25 vol) were added. The mixture was stirred for 20 minutes and the layers allowed to partition.
- the organic layer was separated and the aqueous layer was back extracted layer with MTBE (15.3 vol).
- the organic layers were combined and washed with water (3 vol), saturated sodium bicarbonate (3 vol), and saturated sodium chloride (3 vol), respectively, then concentrated in vacuo.
- the crude concentrate was purified via SiO 2 column chromatography to yield ER-804028 (0.84 wt, 0.93 eq) as a white foam.
- ER-803895 (F-3a) was dissolved in anhydrous toluene (14 wt.) and cooled to ⁇ 75° C ⁇ 75° C. under an argon atmosphere. DIBALH (1.5M in toluene, 0.95 wt., 1.3 eq.) was added at a rate to maintain the internal reaction temperature ⁇ 70° C ⁇ 70° C. The resulting mixture was stirred for 30 minutes then quenched with anhydrous methanol (0.13 wt., 3.2 eq.), maintaining the internal reaction temperature ⁇ 65° C ⁇ 65° C. The reaction mixture was allowed to warm to ⁇ 10° C.
- DIBALH 1.5M in toluene, 0.95 wt., 1.3 eq.
- a solution of azeotropically dried sulfone ER-804028 (1.0 wt., 1 eq.) in anhydrous tetrahydrofuran (5 vol., 4.45 wt.) was treated with n-butyl lithium (1.6M in hexanes, 1.02 wt., 1.5 vol., 2.05 eq.) such that the internal temperature did not exceed 5° C.
- the mixture was stirred at internal temperature 0 to 5° C. for 10 minutes then cooled to ⁇ 75° C ⁇ 75° C.
- Azeotropically dried aldehyde ER-803896 (1.07 wt., 1.23 eq.) was dissolved in anhydrous hexanes (3.53 wt., 5.35 vol.) then cooled to ⁇ 75° C ⁇ 75° C.
- the aldehyde solution was added to the ER-804028 anion by cannula such that internal temperature ⁇ 65° C.
- the mixture was stirred for 45 minutes at internal temperature ⁇ 78° C. then quenched by the addition of saturated ammonium chloride (5 vol.), methyl tert-butyl ether (10 vol.), and water (5 vol.).
- the aqueous layer was discarded and the organic layer concentrated under reduced pressure.
- the crude material was purified via C-18 reverse phase chromatography to afford ER-804029 (84%, 1.57 wt.).
- samarium diiodide solution (2.5 eq.) and the solution cooled to internal temperature ⁇ 70° C ⁇ 70° C.
- ER-804030 (1 wt.) was dissolved in anhydrous methanol (4.1 wt.) and anhydrous THF (2.3 wt.) and then cooled to ⁇ 70° C ⁇ 70° C.
- ER-804030 was added to the cold samarium solution at a rate such that the internal temperature did not exceed ⁇ 70° C.
- the reaction was quenched with potassium carbonate/Rochelle's Salts/water (1/10/100; w/w/v, 15 vol.) and MTBE (5 vol.) such that internal temperature did not exceed ⁇ 65° C.
- the reaction was warmed to room temperature and the mixture transferred to a separatory vessel using the workup solution (20 vol. rinse) and MTBE (20 vol. rinse).
- the aqueous layer was discarded, the organic layer evaporated, and the residue purified via silica gel chromatography to afford ER-118049 (0.77 wt., 85%).
- the product was stored at ⁇ 20° C. under inert atmosphere.
- the crude material was purified by flash chromatography (prepped with 3 CV (1:1 (V/V) DCM/heptane, the material was loaded with 1:1 DCM/heptane then eluted with 10/10/1 heptane/DCM/MTBE).
- the product-containing fractions were concentrated and stored under inert atmosphere at ⁇ 20° C.
- ER-118047/48 the oxidation of ER-118047/48 to form the di-ketone ER-118046 was accomplished as follows. A flask was charged with ER-118047/48 (1 wt, 1.0 eq) and toluene (10 vol) and DMSO (0.15 wts, 2.5 eq) were added at room temperature. Et 3 N (0.31 wts, 4.0 eq) was added and the solution was cooled to ⁇ 15° C. TCAA (0.33 wts, 1.4 eq) was added neat and the reaction warmed to 0° C. then stirred for 10 minutes at 0° C. The reaction was stirred for additional 10 minutes then was quenched with IPA (0.15 vol).
- reaction solution was loaded onto a column and purified by silica gel chromatography.
- the dried ER-118064 (F-12 wherein R 1 is MeO) residue was dissolved in anhydrous dichloromethane (28 vol) under a nitrogen atmosphere and treated with PPTS (1.0 wt, 5.2 eq) in one portion. After 30-90 minutes, the reaction mixture was directly loaded atop an appropriate column and purified by silica gel chromatography. The desired fractions of ER-076349 were concentrated in vacuo. The material resulting from the concentration of all pure fractions was azeotroped twice from toluene (20 vol), affording ER-076349 as a crunchy colorless solid/foam (0.44 wt, 0.79 eq after correction for residual toluene).
- ER-076349 (1 wt, 1 eq) was dissolved in anhydrous toluene (20 vol) and concentrated to dryness under reduced pressure.
- the substrate was re-dissolved in anhydrous toluene (20 vol) and concentrated to dryness.
- the substrate was dissolved in DCM (5 vol), and the solution placed under an argon atmosphere.
- Collidine (0.66 wts, 4.0 eq) was added as a single portion.
- Pyridine, as a solution in DCM (Flask B) was added as a single portion (5 mole %).
- the resulting mixture in flask C was cooled to an internal temperature of ⁇ 20 to ⁇ 25° C.
- a DCM solution of Ts 2 O was added drop-wise keeping the internal temperature below ⁇ 16° C. (1.02 eq).
- the reaction was stirred at ⁇ 20 to ⁇ 25° C. for 80 minutes then warmed to 0° C. over 20 minutes and stirred for an additional 20 minutes.
- the reaction was quenched with water (2 vol). The bath was removed, and the reaction allowed to warm to room temperature (15-20° C.) and stirred (20 minutes).
- the reaction was rinsed to a larger vessel using the IPA (100 vol) and aqueous ammonium hydroxide (100 vol) was added to the reaction.
- the reaction was stirred at room temperature for 15-36 hours, monitoring for the disappearance of the tosylate (ER-082892) and epoxide (ER-809681) which formed in situ.
- the reaction was concentrated to dryness or near dryness at reduced pressure.
- the resulting material was diluted with DCM (25-40 vol) and washed pH 10 buffer (NaHCO 3 /Na 2 CO 3 (aq), 10 vol).
- the aqueous phase was back extracted with 25 vol of DCM and the combined organic layers were concentrated to dryness.
- the resulting free amine was purified by silica gel chromatography using a buffered ACN/water mobile phase. The pooled fractions were concentrated at reduced pressure to remove ACN.
- the resulting aqueous layer was diluted with DCM (40 vol) and with 30 vol of a pH 10 buffered stock solution (NaHCO 3 /Na 2 CO 3 ). The layers were mixed well and separated. The aqueous phase was back extracted with 25 vol of DCM and the combined organic layers were concentrated to dryness. The resulting free amine was polish filtered as a solution in 3:1 DCM/pentane and concentrated to dryness (0.80 wts) to afford B-1939.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4).
Description
This application claims priority under 35 U.S.C. §371 from international application PCT/US05/019669, filed Jun. 3, 2005, which claims priority to U.S. Provisional Patent Applications 60/576,642, filed Jun. 3, 2004, 60/626,769, filed Nov. 10, 2004, and 60/663,300, filed Mar. 18, 2005, the entire contents of each of which are hereby incorporated herein by reference.
The present invention relates to compounds useful as intermediates in the synthesis of pharmaceutically active macrolide compounds.
The invention relates to pharmaceutically active macrolides, synthesis thereof and intermediates thereto. Halichondrin B is a potent anticancer agent originally isolated from the marine sponge Halichondria okadai, and subsequently found in Axinella sp., Phakellia carteri, and Lisson-dendryx sp. A total synthesis of Halichondrin B was published in 1992 (Aicher, T. D. et al., J. Am. Chem. Soc. 114: 3162-3164). Halichondrin B has demonstrated in vitro inhibition of tubulin polymerization, microtubule assembly, betaS-tubulin crosslinking, GTP and vinblastine binding to tubulin, and tubulin-dependent GTP hydrolysis and has shown in vitro and in vivo anti-cancer properties. Accordingly, there is a need to develop synthetic methods for preparing analogs of Halichondrin B useful as anti-cancer agents.
As described herein, the present invention provides methods for preparing analogs of Halichondrin B having pharmaceutical activity, such as anticancer or antimitotic (mitosis-blocking) activity. These compounds include a compound of formula B-1939:
These compounds are useful for treating cancer and other proliferative disorders including, but not limited to, melanoma, fibrosarcoma, leukemia, colon carcinoma, ovarian carcinoma, breast carcinoma, osteosarcoma, prostate carcinoma, and lung carcinoma. The present invention also provides synthetic intermediates useful for preparing said analogs of Halichondrin B.
The methods and intermediates of the present invention are useful for preparing various analogs of Halichondrin B as described in, e.g. U.S. Pat. No. 6,365,759 and U.S. Pat. No. 6,469,182 the entirety of which are incorporated herein by reference. These Halichondrin B analogs are prepared generally by the assembly of three fragments F-1, F-2, and F-3, as shown by Scheme I below:
According to one embodiment, the present invention provides a compound F-1:
- each of PG1 and PG2 is independently hydrogen or a suitable hydroxyl protecting group;
- R1 is R or OR;
- R2 is CHO or —CH═CH2; and
- each R is independently hydrogen, C1-4 haloaliphatic, benzyl, or C1-4 aliphatic, provided that when R1 is OMe then PG1 and PG2 do not form an acetonide group.
In certain embodiments, R1 is OR. In other embodiments, R1 is OR wherein R is hydrogen, methyl, or benzyl.
In certain embodiments, PG1 and PG2 are hydrogen. In other embodiments, one of PG1 and PG2 is hydrogen.
Suitable hydroxyl protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. In certain embodiments, each of PG1 and PG2, taken with the oxygen atom to which it is bound, is independently selected from esters, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of such esters include formates, acetates, carbonates, and sulfonates. Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio) pentanoate, pivaloate (trimethylacetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, or carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl. Examples of such silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers. Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxycarbonyl ethers or derivatives. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers. Examples of arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl.
In certain embodiments, one or both of the PG1 and PG2 moieties of F-1 are silyl ethers or arylalkyl ethers. In yet other embodiments, one or both of the PG1 and PG2 moieties of F-1 are t-butyldimethylsilyl or benzoyl. In still other embodiments, both of the PG1 and PG2 moieties of F-1 are t-butyldimethylsilyl.
According to an alternate embodiment, PG1 and PG2 are taken together, with the oxygen atoms to which they are bound, to form a diol protecting group, such as a cyclic acetal or ketal. Such groups include methylene, ethylidene, benzylidene, isopropylidene, cyclohexylidene, and cyclopentylidene, a silylene derivative such as di-t-butylsilylene and a 1,1,3,3-tetraisopropyldisiloxanylidene derivative, a cyclic carbonate, and a cyclic boronate. Methods of adding and removing such hydroxyl protecting groups, and additional protecting groups, are well-known in the art and available, for example, in P. J. Kocienski, Protecting Groups, Thieme, 1994, and in T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, 1999. According to another embodiment, PG1 and PG2 are taken together to form an acetonide group.
According to one embodiment, R2 is CHO.
According to another embodiment, R2 is —CH═CH2.
In certain embodiments, the present invention provides a compound of formula F-1 having the stereochemistry depicted in compound F-1′:
In certain embodiments, the following compounds F-1a and F-1b are provided:
Details of the syntheses of F-1a and F-1b are set forth in the Examples infra.
2. Fragment F-2
According to another embodiment, the present invention provides a compound F-2:
- each is independently a single or double bond, provided that both groups are not simultaneously a double bond;
- LG1 is a suitable leaving group;
- X is halogen or —OSO2(Ry);
- Ry is C1-6 aliphatic or a 5-7 membered saturated, partially unsaturated, or fully unsaturated ring, wherein Ry is optionally substituted with up to 3 groups selected from halogen, R, NO2, CN, OR, SR, or N(R)2;
- each R is independently hydrogen, C1-4 haloaliphatic, or C1-4 aliphatic; and
- PG3 is a suitable hydroxyl protecting group.
As used herein, a suitable leaving group is a chemical moiety that is readily displaced by a desired incoming chemical moiety. Suitable leaving groups are well known in the art, e.g., see, “Advanced Organic Chemistry,” Jerry March, 4th Ed., pp. 351-357, John Wiley and Sons, N.Y. (1992). Such leaving groups include, but are not limited to, halogen, alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, and diazonium moieties. Examples of suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonyloxy (mesyloxy), tosyloxy, triflate, nitro-phenylsulfonyloxy (nosyloxy), and bromo-phenylsulfonyloxy (brosyloxy). In certain embodiments, the LG1 moiety of F-2 is sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, or optionally substituted arylsulfonyloxy. In other embodiments, the LG1 moiety of F-2 is optionally substituted alkylsulphonyloxy. In yet other embodiments, the LG1 moiety of F-2 is mesyloxy or tosyloxy.
In certain embodiments, the X moiety of F-2 is halogen. In other embodiments, the X moiety of F-2 is sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, or optionally substituted arylsulfonyloxy. In still other embodiments, the X moiety of F-2 is triflate.
In certain embodiments, the PG3 moiety of F-2, taken with the oxygen atom to which it is bound, is a silyl ether. In other embodiments, the PG3 moiety of F-2, taken with the oxygen atom to which it is bound, is an ester group. According to one aspect of the present invention, the PG3 moiety of F-2 is t-butyldimethylsilyl. According to another aspect of the present invention, the PG3 moiety of F-2 is pivaloyl or benzoyl.
In certain embodiments, the present invention provides a compound of formula F-2 having the stereochemistry depicted in formula F-2′:
In certain embodiments, a compound F-2a or F-2b is provided:
wherein “MsO” refers to mesylate, “TfO” refers to triflate, “OPv” refers to pivaloate, “OBz” refers to benzoate, and “TsO” refers to tosylate.
In other embodiments, the present invention provides a compound of formula F-2b wherein said compound is crystalline. According to another embodiment, a compound of formula F-2b is provided wherein said compound is crystallized from an alkane solvent. In certain embodiments, crystalline F-2b is provided wherein said compound is crystallized from pentane or heptane. In other embodiments, crystalline F-2b is provided wherein said compound is crystallized at about 0° C.
Compounds of formula F-2 are prepared generally from intermediates F-2d and F-2e as shown in Scheme A below.
Accordingly, another aspect of the present invention provides a compound of formula F-2d:
- R′ is —CH═CH2 or —C(O)H;
- Alk is a C1-4 straight or branched aliphatic group; and
- PG5 is a suitable hydroxyl protecting group.
Suitable hydroxyl protecting group PG5 is as described and defined for the PG3 moiety of compound F-2, supra. In certain embodiments, PG5, taken with the oxygen atom to which it is bound, is a silyl ether. In other embodiments, PG5 is t-butyldimethylsilyl.
According to one embodiment, the Alk moiety of compound F-2d is methyl.
In certain embodiments, a compound of formula F-2d′ is provided:
Yet another aspect of the present invention provides a compound of formula F-2e:
- R″ is OH, OPG3, or LG4;
- LG4 is a suitable leaving group; and
- each PG3 is independently a suitable hydroxyl protecting group, provided that R″ is other than OMs when PG3 is t-butyldiphenylsilyl.
One of ordinary skill in the art would recognize that the R″ moiety of compound F-2e may be transformed from OH to a protected hydroxyl group, OPG3, or, alternatively, directly to LG4. Such transformations are known to one skilled in the art and include, among others, those described herein. In certain embodiments, R″ is OH or LG4. The LG4 leaving group of formula F-2e is as described and defined for the LG1 moiety of compound F-2, supra. In certain embodiments, LG4 is tosyloxy or mesyloxy.
The PG3 moiety of compound F-2e is as defined and described for the PG3 moiety of compound F-2, supra. In certain embodiments, PG3, taken with the oxygen atom to which it is bound, is a silyl ether. In other embodiments, PG3 is t-butyldiphenylsilyl.
Still another aspect of the present invention provides a compound F-2f:
wherein Alk, PG3 and PG5 are as defined generally and in classes and subclasses described above and herein. Compounds of formula F-2f are used to prepare compounds of formula F-2 by methods described herein and those known in the art.
Details of the synthesis of F-2a are set forth in the Examples infra.
Alternatively, compounds of formula F-2 are prepared from D-quinic acid as shown by Scheme II below. Details of the preparation of compounds of formula F-2 are set forth in the Examples infra.
Yet another method for preparing compounds of formula F-2 from D-quinic acid provides an alternative route from intermediate 12 to intermediate 17 as shown in Scheme III below.
Scheme III above shows an alternate method for preparing intermediate 17 from intermediate 12 via Eschenmoser-Tanabe Fragmentation, wherein each Rx Rx is independently OPGx or CN wherein PGx is a suitable hydroxyl protecting group as described herein. Intermediate 17 is then used to prepare compounds of formula F-2 according to Scheme II above.
Still another method for preparing compounds of formula F-2 from D-quinic acid provides an alternative route from intermediate 9 to intermediate 17 as shown in Scheme IV below.
wherein PGy is a suitable carboxyl protecting group, as described herein, and each PGx is independently a suitable hydroxyl protecting group as described herein.
Yet another method for preparing intermediates useful for preparing compounds of formula F-2 from D-quinic acid is shown in Scheme V below.
In Scheme V above, intermediate 7 (from Scheme II), wherein R is a methyl ester, is used to prepare ER-817664 as a crystalline intermediate. As depicted in Scheme V above, each PG5 and PG6 is independently a suitable hydroxyl protecting group. In certain embodiments, PG5 and PG6 are taken together to form a cyclic diol protecting group. In other embodiments, PG5 and PG6 are taken together to form a cyclohexylidene protecting group. As depicted in Scheme V above, LG5 is a suitable leaving group. Such suitable leaving groups are well known in the art and include those described herein. In certain embodiments, LG5 is mesyloxy or tosyloxy.
According to another embodiment, the present invention provides a compound of formula A:
- designates a single or double bond;
- n is 1, 2, or 3;
- each of PG5 and PG6 is independently a suitable hydroxyl protecting group;
- W is CH-A or C(O);
- A is a C1-6 aliphatic group, wherein A is optionally substituted with one or more Q1 groups;
- each Q1 is independently selected from cyano, halo, azido, oxo, OR, SR, SO2R, OSO2R, N(R)2, NR(CO)R, NR(CO)(CO)R, NR(CO)N(R)2, NR(CO)OR, (CO)OR, O(CO)R, (CO)N(R)2, O(CO)N(R)2, or OPG1, wherein PG1 is a suitable hydroxyl protecting group, and wherein:
- two Q1 on A are optionally taken together to form a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and
- each R is independently selected from hydrogen or an optionally substituted group selected from C1-6 aliphatic, a 5-10 membered saturated, partially unsaturated or aryl carbocyclic ring, or a 4-10 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
- two R groups on the same nitrogen atom are optionally taken together with said nitrogen atom to form a 3-8 membered saturated, partially unsaturated, or aryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
In certain embodiments, the present invention provides a compound of formula A having the stereochemistry as depicted in formula A′:
In certain embodiments, the present invention provides a compound of formula A′ wherein W is C(O) and said compound is of formula A′-1:
As defined generally above, the A group of formulae A and A′ is a C1-6 aliphatic group, wherein A is optionally substituted with Q1. In certain embodiments, the A group of formulae A and A′ is a C2-5 aliphatic group, wherein A is substituted with one or more Q1 groups.
As defined generally above, each Q1 group of formulae A and A′ is independently selected from cyano, halo, azido, oxo, OR, SR, SO2R, OSO2R, N(R)2, NR(CO)R, NR(CO) (CO)R, NR(CO)N(R)2, NR(CO)OR, (CO)OR, O(CO)R, (CO)N(R)2, O(CO)N(R)2, or OPG1, wherein PG1 is a suitable hydroxyl protecting group. In certain embodiments, each Q1 group of formulae A and A′ is independently selected from cyano, halo, azido, oxo, N(R)2, OR, SR, SO2R, or OSO2R. In other embodiments, each Q1 group of formulae A and A′ is independently selected from cyano, halo, azido, oxo, OR, SR, SO2R, OSO2R, N(R)2, NR(CO)R, NR(CO)R, and O(CO)N(R)2. In still other embodiments, exemplary Q1 groups include NH(CO) (CO)-(heterocyclic radical or heteroaryl), OSO2-(aryl or substituted aryl), O(CO)NH-(aryl or substituted aryl), aminoalkyl, hydroxyalkyl, NH(CO) (CO)-(aryl or substituted aryl), NH(CO) (alkyl) (heteroaryl or heterocyclic radical), O(substituted or unsubstituted alkyl) (substituted or unsubstituted aryl), and NH(CO) (alkyl) (aryl or substituted aryl).
In certain embodiments, the A group of formulae A and A′ has one of the following characteristics:
-
- (1) A has at least one substituent selected from hydroxyl, amino, azido, halo, and oxo;
- (2) A is a C1-6 alkyl group having at least one substituent selected from hydroxyl, amino, and azido;
- (3) A has at least two substituents independently selected from hydroxyl, amino, and azido;
- (4) A has at least two substituents independently selected from hydroxyl and amino;
- (5) A has at least one hydroxyl substituent and at least one amino substituent;
- (6) A has at least two hydroxyl substituents;
- (7) A is a C2-4 aliphatic group that is substituted;
- (8) A is a C3 aliphatic group that is substituted;
- (9) A has an (S)-hydroxyl alpha to the carbon atom linking A to the ring containing G or an (R)-hydroxyl; and
- (10) A is a C1-6 saturated aliphatic group having at least one substituent selected from hydroxyl and cyano.
The term “(S)-hydroxyl” means that the configuration of the carbon atom having the hydroxyl group is (S). Embodiments of the invention also include compounds wherein A is substituted at least once on each carbon atom: (1) alpha and gamma, (2) beta and gamma, or (3) alpha and beta to the carbon atom to which A is attached. Each of the alpha, beta, and gamma carbon atoms are independently in the (R) or (S) configuration. In certain embodiments, the invention provides said compound wherein A is substituted at least once on each carbon atom alpha and beta to the carbon atom to which A is attached.
Exemplary A groups of formulae A and A′ include 2,3-dihydroxypropyl, 2-hydroxyethyl, 3-hydroxy-4-perfluorobutyl, 2,4,5-trihydroxypentyl, 3-amino-2-hydroxypropyl, 1,2-dihydroxyethyl, 2,3-dihyroxy-4-perflurobutyl 2,3-dihydroxy-4-perfluorobutyl, 3-cyano-2-hydroxypropyl, 2-amino-1-hydroxy ethyl, 3-azido-2-hydroxypropyl, 3,3-difluoro-2,4-dihydroxybutyl, 2,4-dihydroxybutyl, 2-hydroxy-2-(p-fluorophenyl)-ethyl, —CH2(CO) (substituted or unsubstituted aryl), —CH2(CO) (alkyl or substituted alkyl, such as haloalkyl or hydroxyalkyl) and 3,3-difluoro-2-hydroxypent-4-enyl.
In certain embodiments, the A group of either of formulae A and A′ is 3-amino-2-hydroxypropyl.
According to one aspect, the present invention provides a compound of either of formulae A and A′, wherein Q1 is OPG1, wherein PG1 is a suitable hydroxyl protecting group. Suitable hydroxyl protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. In certain embodiments, the PG1 moiety of either of formulae A and A′, taken with the oxygen atom to which it is bound, is selected from esters, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of such esters include formates, acetates, carbonates, and sulfonates. Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl. Examples of such silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers. Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxycarbonyl ethers or derivatives. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers. Examples of arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl.
In certain embodiments, the PG1 moiety of either of formulae A and A′, taken with the oxygen atom to which it is bound, is a silyl ether or arylalkyl ether. In yet other embodiments, the PG1 moiety of either of formulae A and A′ is t-butyldimethylsilyl or benzoyl. In still other embodiments, the PG1 moiety of either of formulae A and A′ is t-butyldimethylsilyl (“TBS”).
As defined generally above, two Q1 on A are optionally taken together to form a 3-8 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, two Q1 on A are taken together to form an epoxide ring.
In certain embodiments, the PG5 and PG6 groups of formula A and A′ are independently selected from those suitable protecting groups described above for the PG1 group of formula A and A′. In other embodiments, the PG5 and PG6 groups of formula A and A′ are taken together to form a cyclic diol protecting group. Such diol protecting groups are well known in the art and include those described by Greene and include cyclohexylidene and benzylidene diol protecting groups.
In certain embodiments, the present invention provides a method for preparing compounds of formula F-2 according to Schemes V-a, V-b, and V-c below:
In other embodiments, the present invention provides crystalline ER-817664.
Using ER-817664 as a crystalline intermediate, Scheme VI-a shows a general method for using this compound in the preparation of intermediates useful for preparing compounds of formula F-2.
The triol intermediate depicted in Scheme VI-a above is used in an alternate method for preparing intermediates useful for preparing compounds of formula F-2, as shown in Scheme VI-b below.
In Scheme VI-b, shown above, the triol intermediate is treated with periodate to form the aldehyde. This compound is homologated with methyl Wittig reagent, and the resulting olefin reduced, to form the ester compound. The remaining free hydroxyl group is treated with N-iodosuccinimide to form the iodo intermediate and the ester reduced with sodium borohydride to form the hydroxyl compound depicted above. One of ordinary skill in the art will recognize that the resulting iodo compound corresponds to compound 21 depicted in Scheme II, supra, wherein compound 21 has a protecting group at the hydroxyl position. The final treatment with zinc affords the lactone depicted above. One of ordinary skill in the art will recognize that the resulting lactone compound corresponds to compound 22 depicted in Scheme II, supra, wherein compound 22 has a protecting group at the hydroxyl position.
Yet another alternate method for preparing intermediates useful for preparing compounds of formula F-2 from D-quinic acid provides an alternative route from intermediate 2, of Scheme II as shown in Scheme VII below.
In Scheme VII above, intermediate 2 (from Scheme II) is used to prepare ER-812829 in a stereoselective manner. It will be appreciated that other protecting groups are useful for protecting the diol of ER-812829. Such groups are known to one of ordinary skill in the art and include cyclohexylidene and benzylidene diol protecting groups. First, at step (a), the hydroxyl group of ER-811510 is treated with 2-bromo acetylchloride to form ER-812771. The bromo intermediate is treated with triphenylphosphine to form a Wittig reagent in situ in a manner substantially similar to that described by Murphy, et al, Tetrahedron Letters, 40, (1999) 3455-3456. This Wittig reagent then forms the lactone ER-812772. At step (d), stereoselective hydrogenation of the double bond affords ER-812829.
The present invention also provides a method for preparing intermediates useful for preparing compounds of formula F-2 from D-quinic acid, from intermediate ER-812829 depicted in Scheme VII above, as shown in Scheme VII-a below.
According to yet another embodiment, the present invention provides a compound F-3:
wherein:
each PG4 is an independently selected suitable hydroxyl protecting group;
R3 is CHO or C(O)OR4;
R4 is a suitable carboxyl protecting group; and
LG2 is a suitable leaving group.
Suitable carboxylate protecting groups are well known in the art and are described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999. In certain embodiments, the R4 group of F-3 is an optionally substituted C1-6 aliphatic group or an optionally substituted aryl group. Examples of suitable R4 groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl wherein each group is optionally substituted.
As described above, suitable leaving groups are well known in the art, e.g., see “Advanced Organic Chemistry,” Jerry March, 4th Ed., pp. 351-357, John Wiley and Sons, N.Y. (1992). Such leaving groups include, but are not limited to, halogen, alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, silyl, and diazonium moieties. Examples of suitable leaving groups include chloro, iodo, bromo, fluoro, methanesulfonyloxy (mesyloxy), tosyloxy, triflate, nitro-phenylsulfonyloxy (nosyloxy), and bromo-phenylsulfonyloxy (brosyloxy). In certain embodiments, the LG2 moiety of F-3 is iodo.
According to an alternate embodiment, the suitable leaving group may be generated in situ within the reaction medium. For example, LG2 in a compound of formula F-3 may be generated in situ from a precursor of that compound of formula F-3 wherein said precursor contains a group readily replaced by LG2 in situ. In a specific illustration of such a replacement, said precursor of a compound of formula F-3 contains a group (for example, a trimethylsilyl group) which is replaced in situ by LG2, such as an iodo group. The source of the iodo group maybe, e.g., N-iodosuccinimide. Such an in situ generation of a suitable leaving group is well known in the art, e.g., see Id.
As described above, suitable hydroxyl protecting groups are well known in the art and include those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rd edition, John Wiley & Sons, 1999 the entirety of which is incorporated herein by reference. In certain embodiments, each PG4, taken with the oxygen atom to which it is bound, is independently selected from esters, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of such esters include formates, acetates, carbonates, and sulfonates. Specific examples include formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, carbonates such as methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl, and p-nitrobenzyl. Examples of such silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl, and other trialkylsilyl ethers. Alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, allyl, and allyloxycarbonyl ethers or derivatives. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers. Examples of arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- and 4-picolyl.
In certain embodiments, one, two, or three of the PG4 moieties of F-3, taken with the oxygen atom(s) to which they are bound, are silyl ethers or arylalkyl ethers. In yet other embodiments, one, two, or three of the PG4 moieties of F-3 are t-butyldimethylsilyl or benzyl. In still other embodiments, all three of the PG4 moieties of F-3 are t-butyldimethylsilyl.
According to another embodiment, a compound of formula F-3 is provided wherein said compound has the stereochemistry as depicted in formula F-3′:
In certain embodiments, a compound F-3a is provided:
Details of the synthesis of F-3a are set forth in the Examples infra.
4. Assembly of F-1, F-2, and F-3 to Prepare Compound I
Coupling of the fragments F-1 and F-2 is accomplished, in general, as set forth in Scheme VIII below.
Scheme VIII above shows a general method for preparing intermediate F-5a from fragments F-1 and F-2. First, fragments F-1 and F-2 are coupled using methods substantially similar to that described by Kishi, et al., Org Lett 4:25 p 4431 (2002) to afford intermediate F-4. This coupling is performed in the presence of the chiral oxazole (ER-807363) or, alternatively, in the absence of ER-807363. However, the coupling reaction of F-1 and F-2 proceeds with higher selectivity when performed in the presence of ER-807363. Intramolecular Williamson ether formation of F-4, by treating F-4 with potassium hexamethyldisilazide, then furnishes tetrahydropyran F-5 as a mixture of stereoisomers. The stereoisomers are then separated to afford F-5a. The details of these steps are set forth in the Examples infra.
According to another embodiment, the present invention provides a compound F-4:
wherein PG1, PG2, PG3, LG1, and R1 are as defined in general and in subclasses above and herein. PG3 is hydrogen or a suitable hydroxyl protecting group.
In certain embodiments, the present invention provides a compound of formula F-4 wherein said compound has the stereochemistry depicted in formula F-4′:
The present invention also provides a compound F-4a:
wherein “MsO” refers to mesylate, “TBS” refers to t-butyldimethylsilyl, and “OPv” refers to pivaloate.
Details of the synthesis of F-4a are set forth in the Examples infra.
According to yet another embodiment, the present invention provides a compound F-5:
In certain embodiments, the present invention provides a compound of formula F-5 having the stereochemistry as depicted in formula F-5′ or F-5a:
The PG3 group of intermediate F-5a is removed and the resulting hydroxyl compound F-6 is then coupled with a compound F-3′, wherein R3 is CHO, to form F-7 as depicted in Scheme IX below.
Scheme IX above shows a general method for preparing an intermediate-F-9 from F-3′and F-6. First, the sulfone intermediate F-6 is treated with n-butyl lithium then with the aldehyde F-3′. The resulting diol intermediate F-7 is then oxidized with Dess-Martin reagent to form the ketone-aldehyde intermediate F-8 which is then treated with SmI2 to afford intermediate F-9. The details of these steps are set forth in the Examples infra.
Scheme X above sets forth a general method for preparing the Halichondrin B analogs of the present invention from F-9a (LG2 is iodo). First, an intramolecular coupling is achieved, by conditions substantially similar to those described at Scheme V above, to form hydroxyl compound F-10. In an alternate method, the intramolecular coupling is performed in the presence of the chiral oxazole ligand, described herein. The addition of the chiral oxazole ligand imparts a higher yield and greater efficiency for the reaction. The details of this reaction are set forth in the Examples below. Compound F-10 is then oxidized to form F-11. The hydroxyl protecting groups of F-11 are removed by appropriate means to afford F-12. One of ordinary skill in the art would recognize that the methods appropriate to achieve removal of the protecting groups of compound F-11 depend upon the actual protecting groups used and include those described by Greene. For example, when each of the hydroxyl protecting groups of F-11 is a TBS group, such removal may be achieved by treatment with optionally buffered tetrabutylammonium fluoride. The details of these steps are set forth in the Examples infra.
Intermediate F-12 is useful for preparing various analogs of Halichondrin B as described in, e.g. U.S. Pat. Nos. 6,365,759 and 6,469,182 the entirety of which are incorporated herein by reference.
Using the preparation of Halichondrin B analog B-1939 to exemplify, the following Examples describe the synthesis of Halichondrin B analogs using the methods and compounds of the present invention.
One of ordinary skill in the art would recognize that many analogs of Halichondrin B are prepared by the methods and from the compounds of the present invention including, but not limited to, those analogs of Halichondrin B described in U.S. Pat. Nos. 6,214,865 and 6,365,759, the entirety of which are herein incorporated by reference. Accordingly, it will be appreciated that the synthetic methods described below, by way of example, do not limit the scope of the invention which is defined by the appended claims.
In an appropriately sized vessel, D-glucurono-6,3-lactone (1 wt., 1 eq.) was combined with ACN (3 vol.) and acetone (9 vol.). Catalytic conc. sulfuric acid was added and the system held at reflux for 3 hours. The system was checked for dissolution of D-glucurono-6,3-lactone. The reaction was cooled to 25° C. and stirred for 15 hours. Solid sodium bicarbonate (0.5 wts) was added and the reaction stirred for 3 additional hours. Solids were removed by filtration and the organics were partially concentrated and azeotroped with additional ACN (2 wts). ER-806045 was taken into the next reaction without isolation.
Crude ER-806045 (1 wt, 1 eq.) was dissolved in ACN (6.5 vol.) at −20° C. Pyridine (1.5 vol., 4.0 eq.) was added and SO2Cl2 (0.38 vol., 1.02 eq.) was added slowly, while keeping the internal temperature below 5° C. The reaction was quenched by inverse addition into cool water (28 vol.) with an ACN rinse (0.5 vol.), keeping the internal temperature below 10° C. The white solid, ER-806410 (0.87 wt., 79% of theoretical) was isolated by filtration with a heptane rinse (2 vol.) and drying.
An appropriately sized vessel was charged with ER-806410 (1 wt, 1 eq.) and THF (10 vol.) and then cooled to 10° C. Wet palladium on carbon (5%, 0.5 wts) was added and the heterogeneous solution stirred for ten minutes. The reaction was buffered with pyridine (0.44 wts, 1.3 eq.) and placed under a hydrogen atmosphere for 3 hours. The reaction was filtered and the solids rinsed with water (2 vol.) and EtOAc (10 vol.). The resulting solution was acidified with 1N HCl (2.1 vol.), mixed well and the resulting layers were separated. The organic layer was sequentially washed with aqueous sodium bicarbonate (5 vol.) and water (5 vol.). The organics were concentrated under reduced pressure and the resulting product recrystallized from IPA (3.4 vol.) and further cropped by the addition of heptane (3.4 vol.) at 15° C. ER-806047 was isolated as a white solid (67% yield).
An appropriately sized vessel was charged with ER-806047 (1 wt, 1 eq.) and toluene (8 vol.) and then cooled to −40° C. A 17 wt % solution of DIBAL in toluene (4.6 wts, 1.1 eq.) was added, keeping the internal temperature below −35° C. After assaying the reaction, excess reagent was quenched by the addition of acetone (0.15 wts, 0.5 eq.), keeping the temperature below 10° C. The reaction was diluted with EtOAc (7 vol.) and 15% aqueous citric acid (8 wts) below 10° C.; and stirred at 20° C. until a clear solution was obtained. The layers were separated and the aqueous layer back extracted twice with EtOAc (2×10 vol.). The combined organics were washed sequentially with aqueous sodium bicarbonate (5 vol.) and brine (5 vol.) and then dried with magnesium sulfate (0.2 wts). After filtration, the organic layers were partially concentrated at reduced pressure, and azeotroped with toluene (4 vol.). The products were stored as a THF solution for use in the next reaction.
An appropriately sized vessel was charged with a 20 wt % ether solution of TMSCH2MgCl (2.04 wts, 3.0 eq.) and chilled below 5° C. A THF (7 vol.) solution of ER-806048 (1 wt, 1 eq.) was added to the reaction vessel keeping the internal temperature below 15° C. The reaction was warmed to 35° C. for 1.5 hours. The reaction was cooled, diluted with toluene (7 vol.) and quenched with AcOH (3 vol.) below 20° C. The reaction was further diluted with 10% aqueous ammonium chloride (6 wts), mixed well, and the layers were separated. The organic layer was washed sequentially with aqueous sodium bicarbonate (5 vol.) and brine (5 vol.). After drying over magnesium sulfate (0.2 wts) and filtration, the solution was concentrated under reduced pressure and ER-807114 isolated as a concentrated solution in toluene (90% yield).
An appropriately sized vessel was charged sequentially with ER-807114 (1 wt, 1 eq.) and THF (20 vol.), and the solution was cooled below 5° C. A 15 wt % solution of KHMDS in toluene (9.16 wts, 2.0 eq.) was added. The reaction was quenched with 10% aqueous ammonium chloride (5 vol.). The layers were separated and the organic layer washed sequentially with ammonium chloride (5 vol.), 2N HCl (8.5 vol.), aqueous sodium bicarbonate (5 vol.), and water (5 vol.). The organics were transferred to concentration vessels using EtOAc, and concentrated to a viscous oil (90% yield). The material was recrystallized from toluene (4 vol.) and heptane (4 vol.) at 35° C. with additional cropping at lower temperatures and heptane (2×4 vol.) at 15 and 10° C. (94% yield).
An appropriately sized vessel was charged with KOtBu (0.67 wts, 1.2 eq.) and THF (7.7 vol.), and cooled to an internal temperature of −20° C. A solution of ER-806049 (1 wt, 1 eq.) in THF (2.3 vol.) was added keeping the internal temperature below −7° C. Neat BnBr was added, maintaining −7° C. as the maximum temperature. The reaction was stirred at −20° C. for 2 hours and 10 hours at 10° C. The reaction was quenched with 10% aqueous NH4Cl (4 wts), diluted with toluene (4 vol.), and mixed well. The layers were separated and the organic layer washed with 10% brine (4 wts) and dried over MgSO4 (0.15 wts). ER-806050 was isolated as a tBuOH solution (2.5 vol.) after concentration at reduced pressure (95% yield).
An appropriately sized vessel was charged sequentially with K3Fe(CN)6 (3.5 wt., 3.4 eq.), K2CO3 (1.5 wt., 3.4 eq.), (DHQ)2AQN (0.0134 wt., 0.005 eq.), water (18 vol.), t-BuOH (13 vol.), and ER-806050 in tBuOH (1 wt, 1 eq. in 5 vol.). The heterogeneous mixture was cooled to an internal temperature of 0° C., and K2OsO4.2H2O (0.0029 wt., 0.22 mole %) was added. After 36 hours at 0° C., the reaction was quenched with Na2S2O3 (3.5 eq., 1.7 wt.) and the flask allowed to warm to ambient temperature overnight. After 15 hours, the mixture was transferred to a workup vessel and diluted with toluene (15 vol.) and water (4 vol.). The biphasic mixture was vigorously stirred and separated. The organic layer was washed with brine (10 vol.), and concentrated and solvent exchanged to afford a crude mixture of diols ER-806051 and ER-806052 as a 10% toluene solution (92% yield).
The toluene solution (10.1 wt %, 9.9 wts) of ER-806051/52 (1 wt, 1 eq.) was further diluted with additional toluene (3 wts). N-Methylmorpholine (0.94 wts, 3.0 eq.) and DMAP (0.075 wts, 0.2 eq.) were added to the toluene solution and the resulting mixture was cooled below 15° C. Benzoyl chloride was added keeping the internal temperature below 25° C. The reaction was then stirred for 12 hours at 75° C. The reaction was cooled to 15° C. and the temperature kept below 25° C. during the 1N HCl (5 vol.) quench. Layers were mixed well and separated. The organic layer was sequentially washed with brine (3 wts), aqueous sodium bicarbonate (3 wts), and brine (3 wts). The organic layer was dried (MgSO4, 0.25 wts), treated with activated carbon (0.1 wts), and filtered (Celite®, 0.3 wts) with a toluene (1 wt). The products were partially concentrated under reduced pressure, azeotroped with toluene (3 wts). Bisbenzoate ER-806053/54 was isolated in 95% yield as a toluene solution (5 vol.).
Under an inert atmosphere, a 20 wt % solution of TiCl4 (6.42 wts, 3.6 eq.) in toluene was cooled to 15° C. Keeping the internal temperature below 30° C., Ti(OiPr)4 (0.64 wts, 1.2 eq.) was added, and the resulting solution stirred for 15 minutes. Allyl TMS (1.03 wts, 4.8 eq.) was premixed with ER-806053/54 (1 wt, 1 eq.), available as a 22 wt % solution in toluene from the previous step (4.55 wts, 1 eq.), and added to the freshly generated Ti(OiPr)Cl3. The internal temperature during the addition was kept below 30° C. The reaction was stirred between 20-30° C. for 2 hours. The reaction was cooled to −5° C. and quenched with 1N HCl (6 vol.), keeping the internal temperature below 30° C. After mixing well, the layers were separated and the organic layer sequentially washed with 1N HCl (3 vol.) and brine (2×3 vol.). The organic layer was stirred with MgSO4 (0.3 wts) and activated carbon (0.15 wts) and filtered through a Celite® plug (0.2 wts), rinsing with toluene (1 vol.). The product, as a 3:1 mixture at C-34 was isolated after concentration in 83% yield. Recrystallization from IPA/n-heptane afforded ER-806055 with 99.5% >99.5% d.e. at C-34 (71% yield).
At room temperature, an appropriately sized vessel was charged with alcohol ER-806055 (1 wt., 1.0 eq.), toluene (7 vol.), DMSO (0.31 wt., 2.0 eq.) and Et3N (0.78 wt., 4.0 eq.). The resulting solution was cooled to −19° C. TCAA (0.84 wt., 1.4 eq.) was added drop-wise, keeping the internal temperature below −10° C. The reaction was stirred for an additional 10 minutes. The reaction was diluted with IPA (0.5 vol.) and quenched with 1N HCl (5 vol.), keeping the internal temperature below 10° C. The layers were separated and the organic layer sequentially washed with aqueous NaHCO3 (5 wt.) and water (3 vol.). The organic layer was partially concentrated at reduced pressure (100% crude yield) and further azeotroped with additional toluene (4 vol.). The resulting ketone (ER-806058) was dissolved in a final 4 vol. of toluene, checked for water content and used as is in the next reaction.
A solution of ER-107446 (1 wt, 1.5 eq.) in THF (2.7 vol.) was cooled to 10° C. and treated with 25.5 wt % LHMDS in THF (5.2 wt., 1.4 eq.), keeping the internal temperature below 15° C. In a second vessel, the toluene solution of crude ER-806058 (21.9 wt %, 5.4 vol.) was cooled to 10° C. The contents of vessel one were transferred into the substrate containing solution, keeping the internal temperature below 20° C. The reaction was stirred for 30 minutes then quenched by adding 1M HCl (6.5 vol.), keeping the internal temperature below 20° C. The layers were separated and the organic layer washed four times with 1:1 MeOH/water (4×5 vol.) and then with aqueous bicarbonate (5 vol.), and brine solutions (2×5 vol.). The product was dried over MgSO4 (0.52 wt.), filtered (rinsing with 0.7 vol. of toluene), and concentrated to a heavy oil at reduced pressure.
ER-806059 was dissolved in 1:1 toluene/CH3CN (5 vol.) at room temperature. Filtered TMSI (1.23 wt., 4 eq.) was added, keeping the initial temperature below 40° C. The reaction was heated to 60° C. for 2 hours. The reaction was cooled to −15° and quenched with 25% aqueous ammonium hydroxide below 30° C. The reaction contents were stirred overnight and the layers separated. The organic layer was charged with additional toluene (5 vol.) and water (2 vol.). The layers were mixed well and separated. The organic layer was then washed sequentially with 10% aqueous sodium sulfite (5 vol.), 1N HCl (5 vol.), 5% aqueous sodium bicarbonate (5 vol.), and brine (5 vol.). The organic layer was dried over MgSO4 (0.2 wt.), filtered, partially concentrated and used in the next reaction as a 50% solution in toluene.
In an appropriately sized vessel, NaBH(OAc)3 (1.19 wt, 3.15 eq.), Bu4NCl (1.04. wt, 2.1 eq.), DME (8.2 vol.), and toluene (4 vol.) at 65° C., were combined and stirred at room temperature. The mixture was heated to 75° C. for one hour. ER-806060 (1 wt., 1 eq.) as a 50% wt solution in toluene was added at 75° C. and rinsed in with additional toluene (0.3 vol.). The reaction temperature was raised to 85° C. and the reaction stirred for 2-4 hours. The reaction was cooled to <10° C. and quenched with water (3.2 vol.) keeping the internal temperature below 20° C. The layers were mixed well and separated. The organic layer was sequentially washed with aqueous sodium bicarbonate (2×5 vol.) and water (2×5 vol.). The organic layer was concentrated and solvent exchanged to afford a 40 wt % solution of ER-806061 in MeOH.
A 40 wt % solution of ER-806061 (1 wt., 1.0 eq.) in MeOH was dissolved in additional methanol (1.6 vol.). Potassium carbonate (0.24 wts, 1.0 eq.) was added and the reaction temperature was raised to 50° C. for one hour. The reaction was cooled to 15° C., and quenched with 1N HCl (3.5 vol., 2 eq.) with the internal temperature below 30° C. The reaction was diluted with water (3.9 vol.) and toluene (3 vol.). The layers were separated and the aqueous layer back extracted with toluene (1.5 vol.). The aqueous phase was charged with sodium bicarbonate (0.3 wts) and sodium chloride (0.6 wts), and back extracted with nBuOH (3 vol.). The three organic phases were combined and concentrated to dryness to afford crude triol ER-806064 and inorganic salts. The product was dissolved in 7:1 toluene/nBuOH at 80° C., hot filtered, and recrystallized by cooling and stirring overnight. ER-806064 (F-1b) was isolated in a 57%, five step overall yield after filtration and a toluene rinse. FAB(+)-MS m/z 357 (M+H). Melting point 96.2° C.
Purified triol ER-806064 (1 wt., 1 eq.) was dispersed in acetone (2 vol.), diluted with 2,2-dimethoxypropane (1 vol.), and treated with conc. sulfuric acid (0.0086 wts, 0.03 eq.) at 25° C. The reaction was stirred until homogenous. The reaction was diluted with toluene (5 vol.) and quenched by the addition to 5% K2CO3 (2 vol.). The layers were mixed well and separated. The organic layer was washed with 10% brine, dried with Na2SO4 (0.5 wt.). The solution was filtered (toluene rinse) and concentrated at reduced pressure to afford ER-806126 as a yellow oil. The material was used as is in the next stage.
Solid NaOtBu (0.34 wt., 1.4 eq.) was dissolved in THF (2.7 vol.) and DMF (0.3 vol.), and then cooled below 10° C. A solution of ER-806126 (1 wt., 1 eq.) in THF (2.5 vol.) was added to the NaOtBu solution with a THF rinse (0.5 vol.), keeping the internal temperature below 15° C. After a 30 minute stir, methyl iodide (0.204 vol., 1.3 eq.) was added keeping the temperature below 15° C. (exothermic). The reaction was warmed to 25° C. and the reaction quenched with water (5 vol.) and diluted with toluene (7 vol.). The layers were mixed well and separated. The organic layer was washed twice with brine (2×5 vol.), dried over Na2SO4 (0.5 wt.), filtered, and concentrated under reduced pressure.
ER-806068 (1 wt., 1 eq.) was dissolved in 1 vol. of MeOH. Water (1.5 vol.) and 2 N HCl (1.25 vol., 1 eq.) were added and the reaction stirred at 25° C. The reaction was quenched by inverse addition to 2M NaOH (1.34 vol.) at 10° C. The reaction was diluted with isopropyl acetate (5 vol.), the layers were mixed well and separated. The aqueous layer was back extracted with 5 vol. of isopropyl acetate and the combined organic layers were dried over MgSO4 (0.5 wt.), filtered, and concentrated at reduced pressure to afford crude diol ER-806063.
To a 25° C. solution of crude ER-806063 (1 wt., 1.0 eq.) in DMF (4 vol.), was charged imidazole (0.62 wt., 3.4 eq.), followed by TBSCl (1.02 wt., 2.53 eq.) with the internal temperature below 30° C. The reaction was stirred at 25° C. The reaction was diluted with MTBE (10 vol.) and washed with H2O (4 vol.). The organic layer was washed sequentially with 1M HCl (3 vol.), water (3 vol.), aqueous sodium bicarbonate (3 vol.), and brine (3 vol.). The organic layer was dried over MgSO4 (0.5 wt.), filtered with one volume MTBE rinse, and concentrated at reduced pressure and solvent exchanged for heptane (4 vol.).
ER-806065 (1 wt., 1 eq.) was dissolved in heptane, isooctane, or IPA (10 vol.) The solution was cooled below −60° C. (±10° C.). Ozone was bubbled through the solution at low temperature until the solution retained a blue color. Nitrogen was purged through the solution for 15-30 minutes, and the reaction warmed to 5° C. while the nitrogen flush was continued. 7-15 wt. % Lindlar Catalyst (5% Pd on CaCO3 poisoned with Pb, 0.1 wt.) was added. The reactor head was purged several times with nitrogen, evacuated, and placed under 1 atmosphere H2 (g). The reaction was then warmed to room temperature (20-25° C.). The reaction was stirred for 2.5 hours. The resulting heterogeneous solution was filtered through Celite® (1.0 wt.) with an MTBE (2 vol.) rinse. The solution was concentrated to dryness, isolating 1.0 wt. of crude ER-806067. The crude isolate was recrystallized from heptane or isooctane to afford ER-806067 (F-1a) as a white crystalline solid in a 68% five step yield. FAB(+)-MS m/z 601 (M+H). Melting point 64.5° C.
A reactor was charged with pre-rinsed Amberlyst 15 (0.05 wt.) and water (4.63 vol.) and cooled to an internal temperature of 0-5° C. The reactor was charged with 2,3-dihydrofuran (1 wt., 1 eq.) and stirred for 1.5 hours maintaining internal temperature around 5° C. A second reactor was charged with water (4.63 vol.) and heated to an internal temperature of 35° C. The same reactor was charged with tin powder (2.2 wt., 1.3 eq.), distilled 2,3-dibromopropene (3.71 wt., 1.3 eq.), and 48% hydrobromic acid (0.002 vol.), respectively. After observation of reaction initiation indicated by a temperature spike to 36-38° C., the second reactor was charged with 2,3-dibromopropene portion-wise (9×0.37 wt.) while maintaining the internal temperature below 45° C. After complete addition, the contents of the second reactor were stirred at an internal temperature of 35° C. for an additional 60 minutes. The filtered contents of the first reactor were charged into the second reactor at a rate such that internal temperature did not exceed 45° C. After complete addition, the heat source was removed and the second reactor was charged with Celite® 545 (2.0 wt.) and the resulting mixture stirred for 30 minutes. The heterogeneous mixture was filtered through a Celite® 545 pad (2.0 wt.) and the cake washed with additional water (5 vol.). All filtrates were combined into a reactor and charged with concentrated hydrochloric acid (1.5 vol.) until the cloudy solution becomes clear. With vigorous stirring, the reactor was charged with sodium chloride (3.6 wt.) and the layers allowed to partition. The organic layer was separated and set aside. The aqueous layer was extracted with n-butanol (20 vol.). The aqueous layer was drained and the reactor charged with the organics from the first separation. The organics were washed with concentrated sodium bicarbonate (24 vol.), followed by a back extraction of the aqueous layer with n-butanol (20 vol.). All organics were combined and concentrated in vacuo. The concentrate was dissolved in MTBE (10 vol.), filtered and the filtrate was concentrated to two vol. With stirring, the concentrate was cooled to an internal temperature of 0° C. and then n-heptane (4 vol.) was added. The heterogenous mixture was stirred for 2 hours at an internal temperature of 0° C. and the desired product was isolated via filtration and dried under vacuum to yield ER-806909 (1.34 wt., 0.45 eq.) as a white powder.
A reactor was charged with imidazole (0.65 wt., 2 eq.), ER-806909 (1 wt., 1 eq.), and anhydrous DMF (4.04 vol.). With stirring, the reactor was cooled to an internal temperature of 0° C. and then with tert-butylchlorodiphenylsilane (1.25 wt., 0.95 eq.) at a rate such that internal temperature did not exceed 15° C. While maintaining the internal temperature <15° C., the reaction was stirred for an additional 1 hour. The reactor was charged with water (3.2 vol.) and n-heptane (6.4 vol.). The mixture was stirred for 5-15 minutes and the layers allowed to separate. The organic layer was separated and set aside. The aqueous layer was extracted with n-heptane (3.2 vol.). All organics were combined and washed with brine (3.2 vol.) and concentrated in vacuo to a constant weight to yield ER-806545 (2.13 wt., 0.95 eq.) as a yellow oil. The product was utilized in the next stage without further purification.
The enantiomers of ER-806545 were separated via Simulated Moving Bed (SMB) chromatography to yield ER-808373 (0.55 wt., 0.55 eq.) and ER-806721 (0.45 wt., 0.45 eq.) as yellow oils. The SMB chromatography protocol used to separate the enantiomers of ER-806545 is as follows.
Columns and media: | Chiracel OD 20 μm 30 mm × 150 mm (12 columns) |
Solvent system: | 96:4 (vol/vol) heptane:tert-butanol (mobile phase) |
Simulated Moving | Knauer SMB System CSEP C912 |
Bed Chromatography | |
apparatus: |
Isotherms (Langmurian, determined by frontal analysis): |
Undesired isomer: | Qi* = 2.8768 × Ci/(1 + 0.02327 × Ci) |
Desired isomer: | Qi = 4.5320 × Ci/(1 + 0.0034595 × Ci) |
*Where Qi = solid phase concentration (in g/L) and Ci = liquid phase concentration (g/L). |
Column porosity: | 0.658 | ||
Temperature: | 27° C. | ||
Flow rates, etc. calculated by simulation on EuroChrom 2000 for Windows, SMB Guide ver.1.2, Wissenschaftliche Geratebau Dr.-Ing. Herbert Knauer GmbH, D-14163 Berlin; authors, H. Kniep and A. Seidel-Morgenstern:
Feed concentration: | 36 g/L (ER-806545) |
Feed flow rate (Pump 1): | 15 mL/min |
Eluent flow rate (Pump 2): | 76.4 mL/min |
Zone IV (Pump 3) flow rate: | 107 mL/min |
Zone II (Pump 4) flow rate: | 134.3 mL/min (actual flow rate = |
143.5 mL/min) | |
Zone I flow rate: | 183.4 mL/min |
Zone III flow rate: | 149.3 mL/min |
Raffinate* flow rate: | 42.3 mL/min *Raffinate = weakly |
bound isomer | |
Extract flow rate: | 49.1 mL.min *Extract = strongly |
bound isomer | |
Tact time | 0.8864 min (53.18 sec, actual tact |
(port switching time): | time = 54 sec) |
The enantiomers of ER-806545 were separated using the above protocol in the following manner. For an 11 hour run, 10 L of 36 g/L ER-806545 in mobile phase was pumped (Silog model Chemtech) through a 142 mm diameter 0.45 μm pore size nylon filter (Cole-Parmer # 2916-48) and into the Feed tank. The Eluant tank was filled with 36L mobile phase that has been filtered through an in-line 45 mm diameter 1 μm glass fiber filter (Whatman GFC), additional vol. were added throughout the run. The internal temperature of the SMB apparatus was adjusted to 27° C.
For initial startup, the Feed and Eluant inlets were both connected to the Eluant tank. The Feed and Eluant pumps were primed and purged with mobile phase solvent. The SMB apparatus column switching was initiated, the pumps were turned on and the flow rates were gradually increased to full speed while maintaining absolute flow rate differences between each pump. Once fall speed was achieved the Raffinate and Extract flow rates were measured and adjustments to pump flow rates were made to correct for deviations in pump specifications. The Feed pump (Pump 1) was reduced to 0 mL/min, the inlet reconnected to the Feed tank, the pump primed with Feed solution and then the flow rate gradually increased back to full operating speed. The Raffinate and Extract outlets were collected into separate tanks and samples of each of each were acquired every 2 hours. The samples were monitored for chiral purity by analytical HPLC using the HPLC method set forth below. Adjustments to the flow rates of Pumps 2, 3 and 4 as well as to the tact time were made to afford the desired outlet purities.
At the end of the run, the Feed pump was once again reduced to zero flow rate and connected to the Eluant tank. The Feed pump was brought back to full speed and the system was allowed to wash for 20 minutes. The Raffinate and Extract outlets were maintained for 10 minutes (10 tacts) during the wash period and, for the remainder of the wash, the outlets were collected into a separate tank. The column wash was eventually concentrated and added to the Feed on subsequent runs.
The collected Extract (ER-806721) at the end of each run was pooled with material collected from the same starting material lot and the final pooled lot was analyzed again for chiral purity by the analytical HPLC method described in Table 1 below. The same procedure was applied to the collected Raffinate (ER-808373).
TABLE 1 |
HPLC Analysis of ER-806721 chiral purity: |
Column: | Chiracel OD 10 um 250 × 4.6 mm. |
DAICEL Chemical Industries. Ltd., cat no. 14025 | |
Flow rate: | 0.8 mL/min |
Temp. (° C.): | 27 preferred over 35 |
Inj. Vol.: | 10 uL usually, sample in Solvent A, 5 mg/mL |
Instrument: | Waters Alliance W2690 with UV W2487 (also |
with Advanced Laser Polarimeter) | |
Mobile Phase Constituents: | (PDR-Chiral, Inc.) | |
A | 99:1 Heptane:2-Propanol | |
B | ||
C | ||
D | ||
Gradient Table: | (%) | Gradient |
Time (min) | A | B | C | D | |
0 | 100 | 0 | 0 | 0 | isocratic |
Run time | 30 min |
Detection: Absorbance at 254 nm UV |
|
|
A reactor was charged with triphenylphosphine (0.7 wt., 1.2 eq.), p-nitrobenzoic acid (0.45 wt., 1.2 eq.), ER-808373 (1 wt., 1 eq.), and anhydrous toluene (8 vol.). The reaction was cooled to internal temperature of 0° C. and DEAD (1.17 wt., 1.2 eq.) was slowly added at a rate such that the internal temperature did not exceed 7° C. n-Heptane (3.3 vol.) was added and the mixture cooled to an internal temperature 10° C. then stirred for 30-40 minutes. The resulting precipitate was removed by filtration. The filter-cake was washed with n-heptane (3.3 vol.), TBME (0.55 vol.), n-heptane (1.1 vol.), and MTBE (0.55 vol.), respectively. All filtrates were combined and concentrated in vacuo. The crude concentrate was dissolved in THF (8 vol.) then water (0.8 vol.) and lithium hydroxide dihydrate (0.18 wt., 2 eq.) were added. The mixture was stirred at ambient temperature then n-heptane (3.3 vol.) was added and stirred for 5 minutes. Water (2.2 vol.) and n-heptane (3.3 vol.) were added, the biphasic mixture was stirred for 5 minutes, and the layers were allowed to partition. The aqueous layer was separated and back extracted with n-heptane as necessary. The organic layers were combined and concentrated in vacuo. The crude product was purified via SiO2 column chromatography to yield ER-806721 (0.74-0.85 wt., 0.74-0.85 eq.) as a light yellow oil.
A reactor was charged with ER-806721 (1 wt., 1 eq.) and anhydrous dichloromethane (4.2 vol.). The reaction was cooled to an internal temperature of 0-5° C., then triethylamine (0.34 wt., 1.5 eq.), p-toluenesulfonyl chloride (0.51 wt., 1.2 eq.), and 4-(dimethylamino)-pyridine (0.001 wt., 0.25 eq.) were added. The resulting mixture was stirred at ambient temperature for 48 hours then water (1.8 vol.) and dichloromethane (1.8 vol.) were added. After sufficient mixing, the organics were separated and concentrated. The concentrate was dissolved in MTBE (1.8 vol.) and washed with brine (1.8 vol.). The organic layer was separated and set aside. The aqueous layer was back extracted with MTBE (1.8 vol.) then all organics were combined and concentrated in vacuo. The crude oil was filtered through a plug of SiO2 (70-230 mesh, 1 wt.) eluting with MTBE (7 vol.) and the filtrates were concentrated in vacuo. The concentrate was dissolved in IPA (5 vol.) and water (0.25 vol.) was added. The resulting mixture was cooled to an internal temperature of 15° C. and then seeded with ER-807204. After seeding, the mixture was cooled to an internal temperature of 0° C. and stirred for 4-5 hours. The suspension filtered, the filter cake was washed with cold IPA (1 vol.), and the cake dried in vacuo to a constant weight to yield ER-807204 (1.05 wt., 0.78 eq.) as a white powder. IR (thin film, cm-1) λ 2597, 1633, 1363, 1177, 907, 729. LRMS m/z 602 (M+H).
A reactor was charged with 21% sodium ethoxide in ethanol (2.97 wt., 0.9 eq.). The solution was heated to an internal temperature of 65° C. then diethyl malonate (3.24 wt., 2 eq.) was added at a rate such that the internal temperature did not exceed 70° C. The mixture was stirred for 30 minutes and then ER-806906 (1 wt., 1 eq.) was added over 3-5 hours. Upon complete addition, the reaction was stirred for 60 minutes and then cooled to an internal temperature of 50° C. Concentrated hydrochloric acid (0.84 wt., 1.05 eq.) was added at a rate such that internal temperature did not exceed 65° C. The DMF (3 vol.) and ethanol were removed via distillation then a solution of magnesium chloride hexahydrate (0.21 wt., 0.1 eq.) in distilled water (0.25 vol., 1.4 eq.) was added. The resulting mixture was heated to an internal temperature of 135° C. while removing the distillate. The mixture was heated at reflux then cooled to room temperature and brine (12 vol.) and TBME (16 vol.) were added. The organic layer was separated and washed with water (1.3 vol.) and brine (1.2 vol.) then concentrated in vacuo. The product was purified via distillation to yield ER-805552 (0.95-1.09 wt., 0.71 eq.).
A reactor was charged with LHMDS 1.0 M in toluene (6.61 wt., 1.04 eq.) and cooled to an internal temperature of −75° C. ER-805552 (1 wt., 1 eq.) was dissolved in anhydrous THF and added to the reactor at a rate such that internal temperature did not exceed −70° C. Upon complete addition, the resulting mixture was stirred for 30 minutes. A second reactor was charged with anhydrous THF (2.5 vol.) and methyl iodide (1.27 wt., 1.25 eq.) and cooled to an internal temperature of −75° C. The solution of ER-805552 in THF was added into the methyl iodide solution at a rate such that internal temperature did not exceed −65° C. Upon complete addition, the reaction was stirred at an internal temperature of −78° C. for 30 minutes. The reaction was inverse quenched a solution of 1 N hydrochloric acid (10 vol.) and MTBE (8 vol.) with vigorous stirring. After complete addition, the aqueous layer was separated and discarded. The organic layer was washed with brine solution (3 vol.) and concentrated in vacuo and the product purified via distillation to afford ER-806724 (0.75 wt.) as a ˜6/1 mixture of diastereomers.
A reactor was charged with N,O-dimethylhydroxylamine HCl (1.05 wt., 1.5 eq.) and anhydrous CH2Cl2 (8.1 vol.) and cooled to an internal temperature of 0° C. 2 M trimethylaluminum in toluene (3.93 wt., 1.5 eq.) was added at a rate such that internal temperature did not exceed 5° C. The reaction was stirred for an additional 10 minutes and ER-806724 was added at a rate such that internal temperature did not exceed 5° C. The reaction was diluted with CH2Cl2 (15 vol.) then inverse quenched into 1.3 M sodium tartrate (20 vol.) at an internal temperature of 0° C. at a rate such that the internal temperature did not exceed 10° C. After complete addition, the layers were partitioned and the aqueous layer was separated and set aside. The organics were washed with water (1 vol.), dried over sodium sulfate (1 wt.), filtered and concentrated in vacuo until minimal methylene chloride was being removed. To the concentrate was added anhydrous DMF (6.3 vol.), imidazole (0.64 wt., 1.5 eq.) and t-butyldimethylsilyl chloride (0.94 wt., 0.97 eq.), respectively. Water (5 vol.) and MTBE (10 vol.) were added and the resulting mixture stirred then the layers were allowed to partition. The aqueous layer was separated and discarded. The organic layer was washed with water (5 vol.) and the layers separated. 1 N sodium hydroxide (2.5 vol.) and methanol (2.5 vol.) were added and the resulting mixture stirred. The aqueous layer was separated and the organic layer washed with brine (2.5 vol.) then concentrated in vacuo to afford ER-806753 (1.94 wt., 0.91 eq.) as a brown oil.
A reactor was charged with ER-806753 (1 wt., 1 eq.), CH2Cl2 (5 vol.) and NMO-50% in water (0.8 wt., 1.1 eq.). The mixture was cooled to an internal temperature of 10° C. and then 0.197 M OsO4 in toluene (0.06 vol., 0.004 eq.) was added. Sodium sulfite (0.1 wt., 0.25 eq.) and water (0.85 vol.) were added and the reaction stirred for 1 hour. The mixture was diluted with brine (0.85 vol.) and the organics were concentrated in vacuo to approximately ⅓ vol. A second reactor was charged with sodium periodate (1.3 wt., 2 eq.) followed by THF (2.5 vol.). The mixture was diluted with pH=7 phosphate buffer (3.0 vol.) and cooled to an internal temperature of 20° C. The concentrated diol was added at a rate such that the internal temperature did not exceed 30° C. After complete addition, the resulting mixture was stirred at room temperature. Water (1.25 vol.), MTBE (7 vol.) and brine solution (1.25 vol.) were added and the layers separated. The organics were washed a second time with a mixture of brine solution (1 vol.) and saturated sodium bicarbonate (1 vol.). Finally, the organics were stirred over a mixture of brine (1 vol.) and 10% (w/v) sodium thiosulfate solution (1 vol.) for 1 hour then concentrated in vacuo. The crude material was purified via SiO2 column chromatography to yield ER-806754 (0.93 wt., 0.93 eq.) as a yellow oil. IR (thin film, cm-1) λ 2953, 2856, 1725, 1664, 1463, 1254, 1092, 833. LRMS m/z 332 (M+H).
A reactor was charged with ER-806629 (1.53 wt., 3.1 eq.) and THF (10.5 vol.) and the solution was degassed with nitrogen sparge for 60 minutes. A second inserted reactor was charged with ER-807204 (1 wt., 1.0 eq.), ER-806754 (0.66 wt., 1.2 eq.) and THF (2.7 vol.) and this solution was degassed with argon sparge for 45 minutes. The reactor containing ER-806629 was charged with CrCl2 (0.63 wt., 3.1 eq.) and followed by Et3N (0.52 wt., 3.1 eq.). The dark green suspension was stirred at an internal temperature of 30 to 35° C. for 1 hour, cooled to 0 to 5° C. and then NiCl2 (0.1 eq.) was added. The first reactor was charged with the contents of the second reactor slowly over 0.5 hours and the reaction allowed to warm to rt. The reaction was cooled to an internal temperature of 0° C. then ethylenediamine (1.0 wt., 10 eq.) was added over 30 minutes and the reaction stirred at an internal temperature of 25° C. for at least 30 minutes. To the reaction was added water (4 vol.), TBME (10 vol.) and n-heptane (1 vol.) and the resulting mixture stirred for 15 minutes and the phases allowed to separate (˜30 min). The aqueous phase was separated and back extracted with TBME (˜7.5 vol.). The organic layers were combined and washed with water (5 vol.), brine (3 vol.), and concentrated in vacuo to minimum volume. To the crude mixture was added IPA (10 vol.) and SiO2 (1 wt.) and the resulting mixture stirred at an internal temperature of 25° C. for up to 4 days. The slurry was filtered and the filter cake washed with IPA (2×1 volume). To the filtrate was added n-heptane (6.6 vol.) and the mixture was concentrated in vacuo until a suspension formed. The mixture was filtered and the cake washed with n-heptane then the mixture was concentrated in vacuo. The crude product was purified via SiO2 column chromatography to yield ER-807524 (0.54 wt., 0.48 eq.), as a clear yellow oil. IR (thin film, cm-1) λ 2934, 1668, 1471, 1108, 833. LRMS m/z 704 (M+Na).
A reactor was charged with ER-807524 (1 wt., 1 eq.) and anhydrous THF (1.25 vol.). The mixture was cooled to an internal temperature of −20° C. and 3 M methyl magnesium chloride (0.59 vol., 1.2 eq.) was added at a rate such that the internal temperature did not exceed 0° C. Upon complete addition, the mixture was warmed to an internal temperature of 0° C. over 2 hours. The reaction mixture was inverse quenched into semi-saturated ammonium chloride (2.62 vol.) and the resulting mixture diluted with TBME (2 vol.) with vigorous mixing. The aqueous layer was discarded and the organics washed with brine (2 vol.) then concentrated in vacuo. The crude product was purified via SiO2 column chromatography to yield ER-807525 (0.79-0.82 wt., 0.85-0.88 eq.) as yellow oil.
A reactor was charged with ER-807525 (1 wt., 1 eq.), N-phenylbistrifluoromethanesulfonamide (0.59 wt., 1.1 eq.), and anhydrous THF (4.1 vol.) and the mixture cooled to an internal temperature of −75° C. 0.5 M KHMDS in toluene (2.75 wt., 1 eq.) was added at a rate such that internal temperature did not exceed −60° C. then the reaction was warmed to −20° C. over 2 hours. The reaction was quenched with semi-saturated NH4Cl (2.4 vol.) at a rate such that internal temperature did not exceed 0° C. The mixture was warmed to an internal temperature of 20° C. and n-heptane (2.4 vol.) was added. The mixture was stirred and the aqueous layer was separated and discarded. The organic layer was washed three times with saturated sodium bicarbonate (2.3 vol. each) then concentrated in vacuo to yield ER-807526 (1.2-1.4 wt., 1.0-1.2 eq.). The material was utilized in the next stage without further purification.
A reactor was charged with ER-807526 (1 wt., 1 eq.) and anhydrous methanol (3 vol.) at 20° C. 1.25M HCl in IPA (4 vol., 5 eq.) was added and the mixture stirred for 3 hours. Solid NaHCO3 (0.42 wt., 5 eq.) was added portion-wise with stirring until the pH of the reaction mixture reached 6-7. The reaction mixture was filtered with methanol (3×2 vol.) washes. All filtrates were concentrated in vacuo and then purified via SiO2 column chromatography to yield ER-807527 (0.43 wt., 0.79-0.85 eq.).
The diastereomeric mixture of ER-807527 was separated by preparative HPLC chromatography and the desired fractions concentrated to yield ER-806730 (0.56 wt., 0.56 eq.) as a clear yellow oil. The preparative HPLC chromatography protocol used to isolate ER-806730 is as follows.
Column and Media: | Kromasil spherical silica 60 Å, 10 μm particle |
size packed to 7.7 cm (diam.) × 30 cm | |
(length) in a 7.7 cm × 60 cm Varian | |
Dynamax Rampak column. | |
HPLC Packing Station: | Varian (Rainin) Dynamax Rampak 41/77 mm |
Column Packing Station | |
HPLC Pumps: | Varian (Rainin) SD-1 Titanium Pump Heads |
Primary HPLC Detector: | Waters R403 Refractive Index detector |
Secondary HPLC Detector: | Varian (Rainin) UV-1 detector with |
preparative flow cell | |
Chromatography Control | Varian (Rainin) Dynamax DA version 1.4.6 |
and Acquisition Software: | |
Chromatography Data | Varian (Rainin) Dynamax R version 1.4.3 |
Processing Software: | |
Mobile Phase: | 28.5:63.7:7.85 (vol/vol) n-heptane: methyl |
tert-butyl ether:2-propanol | |
Flow Rate: | 140 mL/min |
Column Temperature: | Ambient (25° C.) |
Detection: | Refractive Index, negative polarity at 16 X |
affenuation and UV at 215 nm. | |
Mobile Phase Gradient: | Isocratic |
Run Time: | 40 minutes |
Injection Volume: | 10 ml of 0.8 g/mL of ER-807527 |
The above protocol was used to separate the diastereomers of ER-807527 in the following manner. Each lot of ER-807527 was first diluted to 0.1 g/ml in the mobile phase and filtered under vacuum through a 47 mm, 1 μm pore size, glass fiber filter (Whatman GFC). The filtrate was then concentrated under vacuum on a rotary evaporator. Flow on the SD-1 HPLC pump A (primed and purged with mobile phase) was initiated and the flow rate gradually increased to 140 mL/minute. The system was washed until the UV and RI detectors achieved a stable baseline. The RI detector reference flow cell was flushed with fresh mobile phase.
Chromatography of 8 g injections of ER-807527 was accomplished by diluting the current lot of ER-807527 to a concentration of 0.8 g/mL in the mobile phase. Injecting 10 mL aliquots of the dissolved material and collecting the eluant corresponding to the ER-806730 peak approximately beginning at the peak apex approximately 24 minutes and continuing to 35 minutes. Subsequent injections and fraction collection were continued until the starting material is exhausted.
The fractions corresponding to ER-806730 were pooled and concentrated under vacuum on a rotary evaporator. The diastereomeric purity and area-% purity area were assessed using the HPLC analytical method described in Table 2.
TABLE 2 |
HPLC Analysis of Diastereomeric Purity of ER-806730: |
Column: | Kromasil SlicaSilica 250 × |
4,6 mm, 5 μm,MetaChem cat. no. | |
0475-250X046 | |
Flow rate: | 1 mL/min |
Temp. (° C.): | 27 |
Inj. Vol.: | 10 μL, sample in Solvent A, 2.5 mg/mL |
Instrument: | Waters Alliance W2690 with UV W2487 |
Mobile Phase Constituents: |
A | 30:67:3 n-Heptane:Methyl tert-Butyl |
Ether:2-Propanol | |
B | 2-Propanol |
C | |
D | |
Gradient Table: | (%) | Gradient |
Time (min) | A | B | C | D | |
0 | 100 | 0 | 0 | 0 | isocratic |
22 | 100 | 0 | 0 | 0 | isocratic |
26 | 90 | 10 | 0 | 0 | linear |
32 | 90 | 10 | 0 | 0 | isocratic |
Run time | 32 min with 18 min re-equilibration time at |
initial conditions |
Detection: Absorbance at 205 nm UV |
A reactor was charged with ER-806730 (1 wt., 1 eq.) and anhydrous dichloromethane (4.8 vol.) and cooled to an internal temperature of 0° C. 2,4,6-Collidine (1.16 wt., 4 eq.) and DMAP (0.03 wt., 0.1 eq.) were added and the resulting mixture stirred for 15 minutes and then trimethylacetyl chloride (0.3 wt., 1.05 eq.) was added at a rate such that internal temperature did not exceed 10° C. Water (3 vol.) was added and the mixture stirred for 15 minutes. TBME (10 vol.) was added and the mixture stirred for an additional 10 minutes. The organic layer was washed with 1N HCl (10 vol.) washing until a negative result for 2,4,6-collidine is obtained then with water (5 vol.), saturated sodium bicarbonate (5 vol.), and saturated brine (5 vol.), respectively. The organic layer was concentrated in vacuo and the concentrate purified via SiO2 column chromatography to yield ER-806732 (1.02 wt., 0.85 eq.) as a yellow oil.
A reactor was charged with ER-806732 (1 wt., 1 eq.) and anhydrous THF (2.35 vol.) and cooled to an internal temperature of 0° C. Triethylamine (0.22 wt., 1.1 eq.) was added followed by methanesulfonyl chloride (0.24 wt., 1.05 eq.) at a rate such that internal temperature did not exceed 10° C. The reaction was stirred at an internal temperature of 0° C. then n-heptane (3.4 vol.) was added with vigorous stirring and the layers were allowed to partition. The organics were washed with saturated brine (3.4 vol.), dried over saturated sodium sulfate (2 wt.), filtered and the cake washed with n-heptane until a negative result for ER-805973 (F-2a) was obtained. The filtrates were concentrated in vacuo to obtain ER-805973 (1.12 wt., 0.97 eq.). The crude ER-805973 (F-2a) was used in the next stage without further purification. IR (thin film, cm-1) λ 2961, 1725, 1413, 1208, 926. LRMS m/z 579 (M+H).
Quinic acid (1 wt), cyclohexanone (2.11 eq, 1.08 wt), and conc. sulfuric acid (0.011 eq, 0.0056 wt) were added to a reactor. The reaction mixture was heated to 160° C. and water was removed by azeotropic distillation (azeotrope begins at 100° C.). The reaction was cooled to 90° C. to 100° C. and sodium bicarbonate (0.0096 wt) and toluene (3.6 wt) were added. The reaction was cooled to ambient temperature over 4-6 hours and the resulting precipitate was filtered, washed with toluene (2×0.9 wt), and dried to provide 1 (0.97 wt) as a white powder.
Compound 1 (1 eq, 1 wt) and imidazole (2.5 eq, 0.80 wt) were combined, purged with N2, and suspended in anhydrous THF (10 v). TMSCl (1.2 eq, 0.61 wt) was added at a rate that maintained the temperature below 30° C. The reaction was cooled to ambient temperature, heptane (10 v) was added and the resulting suspension filtered. The filter cake was washed with 1:1 hpt/THF (10 v) the filtrate solvent was exchanged with toluene by atmospheric distillation to provide a solution of 2a (calcd. at 1.34 wt) in toluene (˜5 wt).
The solution of 2a was cooled to −78° C. and DIBAL-H (1.5 M in toluene, 1.2 eq, 2.1 wt) was added at a rate that maintained the temperature below −65° C. The excess DIBAL-H was quenched with MeOH (0.3 eq, 0.034 wt) and the solution warmed to 0° C. The solution was transferred to a solution of 30% wt/wt aqueous Rochelle salt (10 wt) and sodium bicarbonate (1 wt) at a rate that maintained the temperature below 25° C. The mixture was stirred vigorously to obtain a biphasic solution. The layers were separated and the aqueous layer was extracted with MTBE (5v). The combined organic layers were washed with water (2.5 wt) and then saturated brine (2.5 wt). The organics were concentrated and solvent exchanged with THF to provide a solution of 2b (calcd. at 0.98 wt) in THF (5 v).
The solution of 2b was cooled to 5° C. and acetic acid (2.9 eq, 0.51 v) was added. Water (1.0 eq, 0.055 v) was added and the solution stirred at 0° C. to 5° C. Up to two additional aliquots of acetic acid and one aliquot of water were added as needed to facilitate deprotection of the silyl group. Et3N (12 eq, 3.6 wt) and DMAP (0.05 eq., 0.02 wt) were added at a rate that maintained the temperature below 20° C. Acetic anhydride (6 eq, 2.0 wt) was added and the reaction stirred at rt. The reaction was cooled to 5° C. and added to saturated aqueous sodium bicarbonate (10 v) at a rate that maintained the temperature below 30° C. The resulting mixture was allowed to stir for 3-4 hours and the layers allowed to separate. The aqueous layer was extracted with MTBE (5 v) and the combined organics were washed with water (5 v). The extracts were solvent exchanged with IPA by distillation to provide a solution of 2c in IPA (3 v). The solution was cooled to 5° C. and the resulting crystals were filtered. The mother liquor was concentrated and a second crop obtained after recrystallization to provide 2c (0.87 wt) as a white crystalline solid.
2c (1 wt) was dissolved in acetonitrile (6 v) and methyl 3-trimethylsilylpent-4-eneoate (3.0 eq, 1.86 wt) was added followed by TFAA (0.2 eq, 0.083 v). BF3•OEt2 (1.0 eq, 0.42 v) was then added to the solution at a rate that maintained the temperature below 25° C. The reaction was added to saturated aqueous sodium bicarbonate (10 v) and the resulting mixture stirred for 15 minutes. The mixture was extracted with heptane (10 v), followed by MTBE (5 v) and the combined extracts were concentrated to provide 3 (calcd. at 0.72 wt) as an orange oil.
A solution of 3 (1 wt) in THF (9 v) was treated with sodium methoxide (25% wt/wt in methanol (1.5 eq, 2.2 wt)) at a rate that maintains the temperature below 25° C. The reaction was quenched by addition to 1 N HCl (10 v). The organic layer was separated and the aqueous was extracted with MTBE (10 v). The combined organics were washed with water (2.5 v), saturated sodium bicarbonate (2.5 v), and water (2.5 v). The solution was concentrated to provide a solution of 4 (calcd. at 0.88 wt) in THF (2.5 v). The solution was used directly in the next step.
Methanol (5 v) was added to the solution of 4 (1 wt) in tetrahydrofuran (2.5 v). 1N HCl (0.75 eq, 2 v) was added and the reaction was warmed to 60-80° C. The reaction was cooled to rt and added to saturated aqueous bicarbonate. The mixture was extracted with DCM (3×2.5 v) and the combined DCM extracts were solvent exchanged with EtOAc to provide a solution of 5 in EtOAc (3 v). Heptane (2 v) was added to induce crystallization and the resulting suspension cooled to 0° C. The solids were collected by filtration and the filter cake washed with cold EtOAc/heptane (1:1 v/v) and dried to provide 5 (0.55 wt) as a white powder.
Compound 5 (1 wt) was dissolved in ACN (10 v) then 2-acetoxy-2-methylpropanyl bromide (4.0 eq, 2.2 wt) and water (1 eq, 0.067 wt) were added consecutively. The resulting mixture was stirred at ambient temperature then cooled to 5-10° C. NaOMe (25% wt/wt in MeOH, 8 eq, 6.2 wt) was added and the reaction allowed to warn to ambient temperature. The reaction was quenched by the addition of saturated sodium bicarbonate (10 v) and extracted with MTBE (2×10 v). The solvent was exchanged with methanol by atmospheric distillation to provide a solution of 6 (calcd at 0.91 wt) in methanol (10 v).
A solution of 6 (1 wt) in methanol (10 v) was heated to 55° C. Sodium borohydride (5 eq, 0.68 wt) was added in 6 portions and the reaction cooled to 5° C. and quenched with 1 N HCl (10 v). Brine (5 v) was added and the reaction extracted with EtOAc (2×10 v). The extracts were combined and concentrated to provide 7 as a tan residue.
Compound 7 (1 wt) was dissolved in CH2Cl2 (10 v) then DMAP (0.1 eq, 0.054 wt), Et3N (3.0 eq, 1.85 v), and TBDP-SCl (1.2 eq, 1.38 v) were added at ambient temperature. Sodium bicarbonate (10 v) was added and the organic layer separated. The aqueous layer was extracted again with CH2Cl2 (10 v), the organic extracts combined and concentrated to provide 8 (calculated at 1.8 wt) as a colorless oil.
LDA (1.5 M in cyclohexane, 4 eq, 6 v) was added to a solution of 8 (1 wt) in THF (10 v) at ambient temperature. The solution was warmed to 50° C. then quenched with 1 N HCl (5 v) and extracted with MTBE (10 v). The extracts were concentrated to provide 9 (0.9 wt) as an oil.
A solution of 9 (1 wt) in CH2Cl2 (5 v) in MeOH (5 v) was cooled to −60° C. and treated with O3 keeping temperature below −50° C. The reaction was purged with N2, NaBH4 (0.5 eq, 0.04 wt) was added and the mixture warmed to 0° C. Additional NaBH4 (1 eq, 0.08 wt) was added in portions and the reaction allowed to warm to ambient temperature. After 3 hours, the mixture was quenched with 1N HCl, (10 v), CH2Cl2 (5 v) was added and the layers were allowed to partition. The aqueous layer was re-extracted with CH2Cl2 (10 v) and the organic extracts were combined and concentrated to provide 10 (0.97 wt) as a colorless oil.
Compound 10 was dissolved in THF (10 v) and phosphate buffer (pH=7, 5 v) was added. NaIO4 (2 eq, 0.854 wt) was added and the reaction warmed to ambient temperature. Water (5 v) and MTBE (10 v) were added and the resulting mixture was stirred vigorously for 10 minutes. The organic layer was separated and washed with 10% wt/v aqueous sodium thiosulfate (5 v), water (5 v), and brine (5 v) then dried by azeotropic distillation with THF (˜200 ppm water) to provide a solution of 11 (calcd. at 0.93 wt) in THF (10 v). This solution was used directly in next step.
(Carbomethoxymethylene)triphenylphosphorane (1 wt) was added to the solution of 11 (1 wt) in THF (10 v) and heated to 65° C. Heptane (40 v) was added and the resulting mixture stirred for 30 minutes. The resulting precipitate was filtered and the filtrate concentrated to a total 10 v. SiO2 (5 wt) was added and the suspension filtered over a pad of SiO2 eluting with MTBE (20-40 v). The solvent was exchanged with MeOH to provide a solution of 12 (calcd. at 0.95 wt) in MeOH (10 v) which was used directly in the next step.
A solution of 12 (1 wt) in MeOH (10 v) was added to 10% Wt/wt Pd(C) (0.23 eq, 0.37 wt) and treated with H2. The suspension was filtered while rinsing the filter cake with THF (10 v). The solvent was exchanged with THF to provide a solution of 13 (calcd. at 0.95 wt) in THF (10 v) which was used directly in the next step.
The solution of 13 (1 wt) in THF (10 v) was cooled to 0-5° C. and LAH (1 M (THF), 0.78 eq, 1.5 v) was added at a rate that maintained the temperature below 10° C. Water (1.7 eq, 0.06 v) was then added at a rate that maintained the temperature below 10° C. NaOH (10% wt/wt in water, 0.16 eq, 0.06 v) was added followed by water (4.98 eq, 0.17 v) at a rate that maintained the temperature below 10° C. and the resulting mixture stirred vigorously while warming to ambient temperature. The suspension was filtered and the filter cake rinsed with THF (5 v). The filtrate was partially concentrated to provide 14 (calcd. at 0.9 wt) in THF (10 v) which was used directly in next step.
The solution of 14 (1 wt) in THF (10 v) was cooled to 0° C. then imidazole and TrCl (1.5 eq, 0.59 wt) were added. Saturated aqueous NaHCO3 (5 v) was added and the mixture extracted with heptane (10 v). The extract was washed with brine (10 v) and concentrated to provide 15 (1.35 wt).
Compound 15 (1 wt) was dissolved in THF (10 v) and treated with TBAF (1M, 1.2 eq, 1.6 v). The reaction mixture was concentrated to 2 v then heptane (5 v) and Si2 (5 wt) were added. The resulting suspension was filtered and eluted with heptane (5 v) followed by THF (10 v). The THF eluent was collected to provide a solution of 16 (calcd at 0.61 wt) in THF (10 v) which was used directly in the next step.
PPh3 (5 eq, 2.3 wt), pyridine (10 eq 1 vol), and NIS (3.0 eq, 1.1 wt) were added to the solution of 16 (1 wt) in THF (10 v). 20% wt/wt aqueous citric acid (10 eq, 14 wt) was then added and the resulting mixture allowed to stir for 10 minutes. The reaction was diluted with heptane (10 v) and the aqueous layer separated. The organic layer was washed with water (5 v), 10% wt/v aqueous sodium thiosulfate (5 v), water (5 v) and brine (5 v). The solvent was exchanged with EtOH and concentrated to 5 v. Water (10 v) was added and the resulting precipitate was collected by filtration to obtain 17 (0.65 wt) as a white solid.
Compound 17 (1 wt) and KCN (6 eq, 0.54 wt) were suspended in EtOH (5 v) and water (10 v) and the resulting suspension heated to 80° C. The reaction was diluted with water (5 v) and EtOAc (10 v) and mixed for 10 minutes. The aqueous layer was removed and the organic layer washed with water (5 v) and brine (5 v). The solvent was exchanged with EtOH to provide 18 (0.75 wt) in EtOH (10 v) which was used directly in next step.
Zn (37 eq, 3.9 wt) was added to the solution of 18 (1 wt) in EtOH (10 v) and the mixture heated to 75-80° C. The reaction was partially concentrated to 2-3 v, cooled to ambient temperature, and partitioned between MTBE (10 v) and water 5 (v). The aqueous layer was removed and the organic layer washed with saturated bicarbonate (5 v), water (5 v), and brine (5 v), then dried by THF azeotropic distillation to ˜200 ppm water to provide 19 (0.81 wt) in THF (10 v). The resulting solution was used directly in next step.
LDA (1.0 M in THF, 1.2 eq, 2.4 v) was added to the solution of 19 (1 wt) in THF (10 v) at −78° C. The resulting mixture was stirred for 10 minutes then the enolate solution was added to a solution of MeI (1.5 eq, 0.19 v) in THF (5 v) at −78° C. The reaction was inverse quenched into saturated sodium bicarbonate (10 v) and extracted with MTBE (15 v). The extract was washed with brine (5 v), concentrated, then purified by chromatography to provide 20 (0.86 wt).
AlMe3 (2 M in toluene, 1.5 eq, 1.5 v) was added to a suspension of dimethylhydroxylamine hydrogen chloride (1 wt) in CH2Cl2 (2.5 v) at 0° C. A solution of 20 (1 wt) in CH2Cl2 (5 v) was added at a rate that maintained the reaction temperature below 5° C. The reaction mixture was then added to aqueous sodium tartrate (1.3 M, 20 v) keeping the temperature below 10° C. The layers were allowed to partition, were separated, and the organic layer was dried with Na2SO4 (5 wt). The resulting suspension was filtered and the filtrate concentrated. The residue was dissolved in DMF (2 v) then imidazole (0.19 wt) and TBSCl (0.29 wt) were added. The reaction was diluted with water (5 v) and MTBE (10 v) and allowed to stir for 10 minutes. The aqueous layer was removed and the organic layer washed with water (5 v). The extract was added to a solution of aqueous NaOH (1N, 0.78 v) and MeOH (0.7 v). The reaction was allowed to stir then the aqueous layer was removed and the organic washed with brine (2.5 v) then concentrated to provide 21 (1.2 wt).
Methyl magnesium chloride (3.0 M, 59 wt, 1.2 eq) was added to a solution of 21 (1 wt) in anhydrous THF (1.11 wt, 1.25 v) at a rate that maintained the reaction temperature below 0° C. After stirring at 0° C., the reaction was reverse quenched into saturated ammonium chloride (2.5 v) and water (2.3 v). The resulting mixture was diluted with MTBE (10 v) and stirred vigorously. The aqueous layer was separated and the organic layer washed with brine (2.5 v) and concentrated to provide 22 (0.84 wt).
Compound 22 (1 wt) was dissolved in THF (4 v) and cooled to −78° C. KHMDS (1.5 M in toluene, 1.01 eq, 2.78 wt,) was added while maintaining the temperature below −60° C. A solution of Tf2NPh (0.62 wt, 1.1 eq) in THF (1.5 v) was added and the reaction warmed to −20° C. Saturated ammonium chloride (2.5 v), water (2.5 v), and n-heptane (2.5 v) were added and the mixture warmed to ambient temperature. The layers were allowed to partition and the aqueous layer removed. The organic extract was washed with saturated aqueous sodium bicarbonate (3×2.5 v) and brine (2.5 v) then concentrated in vacuo to provide 23 (1.1 wt).
Compound 23 was dissolved in MeOH (2.5 v) and cooled to 15° C. HCl (5N in IPA, 1.30 eq, 1.18 wt) was added and the resulting solution allowed to warm to 25° C. The reaction was cooled to 0° C. and sodium bicarbonate (3 eq, 0.33 wt) was added. The reaction was stirred for 15 minutes and the resulting precipitate removed by filtration. The filter cake was washed with ACS grade methanol (1 v) and filtrates were combined and concentrated. The crude concentrate was purified by chromatography to provide ER-806730 (24) (0.5 wt).
Example 4a provides an alternate method of preparing compounds of formula A, an intermediate to F 2, using the general scheme set forth at Scheme V above. This method uses ER-812935 as an intermediate as prepared according to Example 3 (compound 4), above.
ER-812935 (1 wt) was dissolved in THF (10 v) and cooled to 0° C. LAH (1.0 M in THF, 0.70 eq, 2.0 v) was added keeping the temperature below 5° C. While stirring vigorously, excess reagent was quenched with water (0.078 v) keeping the temperature below 5° C. While maintaining the vigorous stirring, NaOH (15% wt/wt in water (0.078 v)) was added followed by water (0.18 v). After adding Celite® (2 wt), the suspension was filtered and the cake rinsed with THF (5 v). The solution of ER-817633 (0.92 wt, calcd. based on 100% conversion) was concentrated to 5 v and used directly in the next stage.
The previously prepared solution of ER-817633 (1 wt in 5 v THF) was diluted with THF (5 v), cooled to 5° C. and Et3N (3 eq., 0.94 wt) was added. MsCl (1.05 eq, 0.25 v) was added at a rate that maintained the temperature below 10° C. The reaction was quenched by addition of water (5 wt). Heptane (8 v) was added and the mixture allowed to partition. The aqueous phase was separated and extracted with MTBE (2 v). The combined organic extracts were washed with saturated sodium bicarbonate (5 v) and water (1.9 v) The organic layer was concentrated and solvent exchanged with EtOH to prepare a solution of ER-818937 (1.23 wt calcd. based on 100% conversion) in EtOH (1 v) which was used directly in the next stage.
The previously prepared solution of ER-818937 (1 wt in EtOH (0.8 v) is diluted with EtOH (190 proof, 9 v). KCN (3 eq., 0.41 wt) was added and the suspension was heated to 70-80° C. The reaction was cooled to ambient temperature and water (10 v) was added followed by MTBE (10 v). The layers were separated and the aqueous extracted with MTBE (5 v). The combined organics are washed with water (2 v) and saturated brine (4 wt). The extracts were concentrated and used directly in the next stage.
ER-818950 was dissolved in acetic acid (5 v) and hydrogen chloride (1.0 M, 1 eq, 3 v) was added and the reaction was stirred at ambient temperature. The reaction was cooled to 0° C. and NaOH (50% wt/wt, 30 eq, 7 wt) was added at a rate that maintained the temperature below 10° C. The solution was extracted with heptane (2×10 vol). The aqueous phase was saturated with NaCl and extracted with ACN (2×10 v). The combined ACN extracts were concentrated and solvent exchanged with EtOAc by atmospheric distillation to provide a solution of ER-817664 in EtOAc (3 v). Salts were filtered from the hot solution which was then cooled to 0° C. The suspension was filtered to provide ER-817664 as a white crystalline solid.
Example 4b provides an alternate method of preparing compounds of formula F-2 using the general scheme set forth at Schemes Vb and Vc above. This method uses ER-817664 as an intermediate as prepared according to Example 4a, above.
ER-817664 (1 wt) was dissolved in ACN (10 v), the suspension was cooled to 0° C. and 2-acetoxy-2-methylpropanyl bromide (4.0 eq, 2.4 v) was added followed by the addition of H2O (1.0 eq., 0.07 v). The resulting mixture was stirred at 0° C. for 2 hours. NaHCO3 (sat. aqueous, 8.0 eq. 40 v) was added slowly at 0° C. The resulting mixture was stirred at room temperature for 30 minutes prior to extraction with MTBE (2×20 v). The organic layer was washed with brine (5 v) and concentrated to give the product as colorless oil.
The starting bromide (1 wt), depicted immediately above, was dissolved in toluene (10 v). DBU (1.8 eq., 0.73 v) was added and the mixture was heated at 80° C. The mixture was cooled to room temperature, diluted with MTBE (20 v), and washed with water (5 v) and then brine (5 v). The organic layer was then concentrated to give the product as an off-white powder.
The starting olefin compound (1 wt), depicted immediately above, was dissolved in CH2Cl2 (5 v) and MeOH (5 v), and cooled to between −40° C. to −45° C. The solution was then treated with O3. Excess O3 was removed by N2 purge and the solution was warmed to −15° C. NaBH4 (1.0 eq, 0.18 wt) was added and the mixture was warm warmed to 0° C. K2CO3 (1.3 eq.) was added and the suspension stirred at rt. The reaction was neutralized with 1N HCl (˜4 eq, ˜20 v) at 0° C. and the solution was extracted with MTBE(10 v) to remove lypophilics. The aqueous layer was concentrated to remove CH2Cl2 and MeOH. THF (4 v) was added followed by NaIO4 (2 eq, 2 wt). The reaction was extracted with MTBE (10 v) and n-BuOH (10 v). The combined organic extracts were concentrated and the resulting powder was triturated with EtOAc. After filtration the lactol was isolated as a pale yellow powder.
ER-818638 (1 wt) and LiCl (2.0 eq, 0.35 wt) was stirred in ACN (8.7 v). Hunig's base (1.5 eq) was added at 25° C. 1 N HCl (5 v) was added and the mixture was extracted with MTBE (10 v). The organics were concentrated to provide ER-818640 which was used as is in the next step.
The starting α-olefin ester compound (1 wt), depicted immediately above, was dissolved in MeOH (10 v) and added to 10 wt % of Pd(C) (0.09 eq, ˜0.33 wt) under N2. The suspension was then stirred under H2. The suspension was filtered through a Celite® pad (20 wt), rinsing the filter cake with MeOH (20 v). The filtrate was concentrated and purified by flash chromatography to give product as colorless oil (94.3% yield).
Pyridine (10 eq.), Ph3P (7 eq.) and NIS (4 eq.) were added to the solution of the ester (1 wt) in THF (15 v) separately. The reaction mixture was stirred at ambient temperature. Aqueous citric acid (20 wt %, 10 eq) was added and the mixture diluted with TBME (30 v). The aqueous layer was separated and the organic layer washed with water (5 v), aqueous Na2S2O3 (10% wt/v, (5 v), water (5 v) and brine (5 v). The organic layer was concentrated and purified by flash chromatography to give product as colorless oil.
The starting iodide (1 wt) was dissolved in MeOH (30 v) and heated to 55° C. NaBH4 (47 eq.) was added in 6 portions at 55° C. over 80 minutes. The reaction was cooled to 0° C. and quenched with 1N HCl (30 v). After stirring 5 minutes, the mixture was diluted with brine (30 v) and extracted with DCM (50 v×2). The organic layer was dried over Na2SO4 and concentrated. The crude product was used directly in the next step.
The starting alcohol (1 wt), depicted immediately above, was dissolved in EtOH (70 v) and Zn (165 eq.) was added. The suspension was refluxed at 75-80° C. The reaction mixture was cooled to ambient temperature and 1N HCl (70 v) was added. The mixture was extracted with DCM (3×100 v), the organic layer washed with brine and concentrated.
The starting lactone, as depicted immediately above, was dissolved in DCM (50 v), Et3N (5.0 eq.), DMAP (0.3 eq.) and TBDPSCl (1.5 eq.) were added separately at ambient temperature under N2, and the resulting solution was stirred at ambient temperature for 2˜3 hours. Upon the completion of the reaction, the mixture was diluted with TBME (100 v), washed with sat. aq. NaHCO3 solution (10 v), H2O (10 v) and brine (10 v). The organic layer was concentrated and purified by flash chromatography to give the product as colorless oil.
Example 4c provides another alternate method of preparing compounds of formula F-2 using the general scheme set forth at Scheme VII above. This method uses ER-811510 as an intermediate as prepared according to Example 3, above where acetone is used instead of cyclohexanone.
ER-811510 (1 wt, 1 eq) was dissolved in methylene chloride (6.3 v) and cooled to −5° C. Pyridine (0.41 vol, 1.1 eq) was added followed by bromoacetyl bromide (0.44 vol, 1.1 eq) while keeping the temperature below 0° C. The reaction was stirred at I 1 hour and warmed to room temperature. Water (8 vol) was added and the layers separated. The organic layer was washed sequentially with aqueous copper sulfate pentahydrate (1.0 M, 10 vol), water (8 vol), and brine (10 vol) then dried over magnesium sulfate, filtered and concentrated in vacuo to afford ER-812771 as a tan solid.
ER-812771 (1 wt, 1 eq) was dissolved in acetonitrile (6 v) and triphenylphosphine was added and the reaction heated at 50° C. for 45 minutes. The reaction was cooled to −10° C. then 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU, 0.35 vol, 0.8 eq) was added. The reaction was stirred for 15 minutes, heated to 80° C. for 45 minutes then cooled to ambient temperature. Ammonium chloride (saturated aqueous, 10 vol) was added and the aqueous layer extracted with ethyl acetate (3×10 v). The combined organic layers were dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by chromatography to afford ER-812772 as a white solid.
ER-812772 (1 wt, 1 eq) was dissolved in ethyl acetate (8 v). 10% Palladium on carbon (0.05 wt, 0.01 eq) was added, the reaction purged with nitrogen then stirred under hydrogen atmosphere for 2 hours. The catalyst was removed by filtration through Celite with ethyl acetate washed. The combined filtrates were concentrated in vacuo to afford ER-812829 as a white solid.
D-Gulonolactone (1 wt., 1 eq.), cyclohexanone (2 to 3 eq.), toluene (6 vol.), and p-toluenesulfonic acid (0.021 wt., 0.02 eq.) were charged to the reaction vessel. Reaction mixture was heated to reflux with stirring. Upon azeotropic removal of water the reaction was complete. The reaction mixture was cooled to 85 to 90° C. and agitation was increased. Heptane (5.2 vol.) was added over 20-30 minutes with stirring. Cooled to 65-70° C. and stirred for 30 minutes at 65-70° C. The solid product was filtered at 65-70° C., maintaining mother liquor temp 35° C >35° C. Re-filtered at 35-40° C. and maintained the mother liquor at ambient temperature for 30 minutes. Re-filtered the mother liquor. The filter cake was washed two times with heptane (2×1.7 vol.) then dried to afford ER-805715. Yield 84% (1.6 wt.).
In an alternate method for preparing ER-805715, D-gulonolactone (1 wt), cyclohexanone (1.32 wt, 2.4 eq), p-TsOH-monohydrate (0.02 wt, 0.02 eq) and toluene (12 vol) were refluxed together for 19 hours, while azeotropically removing water. The mixture was washed with 5% aqueous NaHCO3 (4 vol) followed by saturated aqueous NaCl (2 vol×2, pH=7). The organic phase was concentrated by distillation (ca. 4.5 vol of toluene remaining) and cooled to 100° C. before heptane (10 vol) was added, maintaining internal temperature 80° C >80° C. The mixture was heated to reflux for at least 1 hour before it was cooled to and aged at 85° C. for 3 hours, at 80° C. for 3 hrs and then cooled to 40° C. in 12 hrs. The product was collected by filtration and the cake washed with heptane (2 vol). The filter cake was dried by airflow to afford ER-805715 (1.48 wt) in 78% of yield.
ER-805715 (1 wt., 1 eq.) was charged to reaction vessel and dissolved in anhydrous THF (3.34 vol.) and anhydrous toluene (2.5 vol.). The mixture was cooled to −15 to −10° C. DIBALH (1.5M in toluene, 2.4 vol., 1.2 eq.) was added over 1 hour and the mixture stirred for 15-30 minutes at −15 to −10° C. The reaction was inverse quenched into KNa-Tartrate solution (1 wt. KNa Tartrate in 2.9 wt. water) at 10° C. and the resulting mixture allowed to warm to room temperature and stir for 4 hours. The mixture was filtered then the layers separated and extracted with MTBE (2 vol.). The organic layers were combined and the solvents removed in vacuo to afford ER-805814. Yield 100%, (1.02 wt.).
ER 805814 (1 wt.) was dissolved in anhydrous THF (3.3 vol.) and treated with (methoxymethyl)triphenylphosphonium chloride (2.11 wt., 2.1 eq.). The reaction mixture was heated to 28-32° C. then a solution of KOtBu (0.66 wt., 2 eq.) in anhydrous THF (2.64 vol.) was added over 100-140 minutes, maintaining reaction temperature 30-35° C. After 5 hours, the reaction was cooled to 20-25° C., MTBE (5.11 vol.) was added and the mixture stirred. Brine (3 wt.) and water (3 wt.) were added (exothermic at start of addition, controlled by bath @20-25° C.). Organic layer was separated and treated with a solution of maleic anhydride (0.27 wt.) in MTBE/THF (1/1 v/v, 1.78 vol.). NaOH solution (0.088 wt. in 2.5 vol. water) was added slowly to the reaction mixture. The organic layer was concentrated to give crude ER 805815 (0.985 wt.). The residue was triturated three times with MTBE/heptane (1/4 v/v, 6.6 vol.). The extract was filtered through SiO2 (3 wt), eluting with MTBE/heptane (1/2 v/v, 45 vol.). The filtrate was concentrated to give ER-805815 (0.88 wt., 81% yield).
In an alternate method for preparing ER-805815, a solution of t-BuOK (0.989 wt, 3 eq) in THF (4 wt) was added to a suspension of (methoxymethyl)triphenylphosphonium chloride (3.12 wt, 3.1 eq) in THF (1.78 wt), maintaining the reaction temperature between 0-10° C. The addition vessel was rinsed with THF (2×0.7 wt). A solution of ER-805814 (1 wt, 1 eq) in THF (1.42 wt) was added to the reaction, maintaining 0-10° C. The addition vessel was rinsed with THF (2×0.7 wt). The mixture was stirred at 20-30° C. overnight and 30-35° C. for 3 hours. The reaction was cooled below 30° C. and diluted with MTBE (3.7 wt) followed by 10 wt aqueous NaCl (4 wt) solution. The mixture was stirred for 30 minutes and the layers were separated. Maleic anhydride (0.63 wt, 2.2 eq) was added and the mixture stirred at room temperature for 30 minutes. Water (6 wt) and a solution of NaOH (48 wt %, 0.64 wt, 2.6 eq) was added dropwise, maintaining the reaction below 15° C. After stirring below 15° C., the lower layer was separated. Water (6 wt) was added followed by a solution of NaOH (48 wt %, 0.64 wt, 2.6 eq), keeping the mixture below 15° C. during the addition. After stirring below 15° C., the lower layer was separated. The organic layer was washed three times with a 15 wt % aqueous NaCl solution (3×4 wt). The organic layer was concentrated in vacuo. The residue was diluted with MTBE (1 wt) and concentrated in vacuo. The residue was diluted dropwise with IPE (3 wt) at 40-50° C. over 30 minutes. The suspension was stirred for 1 hour at 40-50° C. and slowly cooled to 0-10° C. and stirred for 1 hour. The solids were filtered and the cake washed with IPE (2 wt). The filtrate and washings were concentrated in vacuo. The residue was treated with MeOH (2.37 wt) and water (0.4 wt) and extracted with heptane (2.74 wt). The lower layer was extracted 9 times with heptane (2.05 wt). The extracted solutions were combined and concentrated in vacuo to give ER-805815 (1.07 wt, 98.6%).
In an alternative method for workup of ER-805815, the crude organic layer that is produced following brine wash and concentration is treated with MTBE (2.86 wt) and celite (0.5 wt). After stirring for 2.5 h, heptane (1.46 wt) was added over 2 hrs and the mixture stirred overnight. The precipitate was filtered. The filter cake was washed with MTBE/Heptane (1:1) (5 wt). The filtrate was concentrated in vacuo until the volume was decreased to about 3 volume. The residue was dissolved in MeOH (2 wts) and H2O (6 wts). The mixture was extracted with heptane/MTBE (5:1) (3*6 wts). The organic layer was separated and concentrated to provide ER-805815 which was used as is for the following step.
ER-805815 (1 wt) was dissolved in acetone (2.4 vol) and water (0.4 vol). N-Methylmorpholine N-oxide (0.62 wt, 2 eq) was added and the mixture cooled to 0-5° C. OSO4 (0.15M in water, 0.065 vol) was added and the reaction was maintained at 0-5° C. The reaction mixture was stirred at 0-5° C. for 12 hours. Water (0.2 vol) was added over 1 hour at 0-2° C. The mixture was stirred for one hour at 0-5° C. The product was filtered and the solids washed twice with pre-cooled (0-5° C.) acetone/water (1/1, v/v, 2×0.7 vol). The product was dried to afford ER-805816 (0.526 wt, 52% yield, residual Os <17 ppm).
In an alternate method for preparing ER-805816, a solution of ER-805815 (1 wt, 1 eq) in acetone (4 wt) was charged into a four-necked flask, then water (0.5 wt) was added at ambient temperature. To the mixture was added anhydrous N-methylmorpholine-N-oxide (0.38 wt, 1.2 eq). Potassium osmate dihydrate (0.003 wt, 0.003 eq) was added portion-wise at 25 to 35° C. while cooling with water. The mixture was kept at this temperature for 4 hours. A solution of sodium thiosulfate 0.075 wt, 0.49 eq) in water (0.5 wt) was added at ambient temperature, then the mixture was stirred for 0.5 hour. The mixture was cooled to 0-5° C. and stirred for 2 hours. The resulting precipitate was collected and the wet cake was washed with methanol (0.6 wt) and water (1.5 wt) to obtain the crude product (1.25 wt). The crude product sample was dried (0.611 wt). The crude ER-805816 (1.25 wt) was added to water (3.05 wt) and stirred for 2 hours at about 25° C. The precipitate was filtered and washed with water (1.53 wt) to afford the crude wet cake (1.05 wt). The crude product sample was dried and sampled, ICP Os=37 ppm. The crude ER-805816 (1.05 wt) was added to water (2.81 wt) and stirred for 2 hours at about 25° C. The precipitate was filtered and washed with water (1.4 wt) and methanol (0.45 wt) to afford the crude ER-805816 (0.736 wt). The wet cake was dried crude product (0.56 wt, ICP (Os)=28 ppm). ER-805816 (0.56 wt) was dissolved in acetone (1.76 wt) at 45 to 55° C. To the solution was added active carbon (0.027 wt) and stirred at same temperature for 0.5 hour. The mixture was filtered and the cake was washed with hot acetone (0.214 wt). The filtrate was kept at 45 to 50° C. and water (0.83 wt) was added over 10 minutes and temperature was kept at 40 to 50° C. during water addition. The mixture was cooled to 0 to 5° C. and stirred for 1.5 hours. The white precipitate was filtered and washed with a solution of acetone (0.17 wt) and water (0.22 wt) then dried to give ER-805816 (0.508 wt, 0.49 eq, KF 5.0%, ICP (Os) 9.6 ppm).
ER-805816 (1 wt) was slurried in acetic acid (0.89 vol, 5.8 eq) and acetic anhydride (3.57 wt, 13 eq). Anhydrous ZnCl2 (0.2 wt, 0.54 eq) was added. Reaction mixture was stirred for 24 hours 18-22° C. Reaction was quenched into ice (5 wt) and water (5 vol). EtOAc (10 vol) was added with stirring and the aqueous layer is separated. The aqueous layer was back extracted with EtOAc (10 vol). The combined organic layers were washed sequentially with brine (10 vol), 5% aqueous NaOAc (6 vol), and brine (6 vol). The organic layer was concentrated. The crude concentrate was dissolved in 25% EtOAc/hex (4 vol) and filtered through SiO2. The pad was washed with 25% EtOAc/hex (2×12 vol) and further 25% EtOAc/hex (48 vol). The organic layer was concentrated to give ER-805819 (1 wt, 81%).
In an alternate method for preparing ER-805819, zinc chloride (0.2 wt, 0.54 eq), acetic anhydride (2.75 wt, 10 eq), and acetic acid (1 wt, 6 eq) were combined. The mixture was cooled to 15-20° C. ER-805816 (1 wt, 1 eq) was added, maintaining the internal temperature at 15 to 30° C. The mixture was then stirred at 35-40° C. for 6 hours. The reaction mixture was cooled below 25° C. Methanol (3.2 wt, 4 vol) was added drop-wise maintaining reaction temperature below 25° C. Heptane (2.7 wt, 4 vol) was added. Water was added (4 wt, 4 vol) maintaining reaction temperature below 25° C. The mixture was stirred for 15 minutes, and then the phases were separated. The lower layer was washed twice with heptane (2.7 wt, 4 vol) and the heptane layers were discarded. The lower layer was extracted twice with toluene (6.1 wt, 8 vol). The combined toluene layers were washed twice with 17 wt % potassium bicarbonate aqueous solution (0.82 wt KHCO3 in 3.98 wt water, 4.36 vol), twice with water (4 wt), and concentrated. Methanol (3.95 wt, 5 vol) was added at 25-30° C. and the mixture stirred for 10 minutes. Water (0.3 wt) was added at 25-30° C. The mixture was cooled to 0° C. and seeded. The mixture was stirred at 0° C. for 1 hour. Water (0.7 wt) was added drop-wise over 1 hour. Water (4 wt) was added drop-wise over 1 hour. The resulting precipitated solids were filtered, and the filter cake washed twice with a 0° C. methanol (1.03 wt) and water (0.7 wt) solution. The cake was dried to afford ER-805819 (0.99 wt, 0.84 eq).
ER-805819 (1 wt) was dissolved in anhydrous acetonitrile (15 vol) and treated with methyl 3-trimethylsilylpent-4-eneoate (0.93 vol, 2 eq). The reaction mixture was cooled to 0-5° C. and BF3•OEt2 (0.54 vol, 1.95 eq) was added over 5 minutes, maintaining reaction temperature between 0-5° C. Reaction mixture was stirred 0-5° C. for 12 hours. Reaction was quenched into saturated sodium bicarbonate (20 vol) with vigorous stirring. Extracted twice with EtOAc (2×8 vol). The combined organics were washed with brine (12 vol) and concentrated to give ER-805821 (1 wt, 88% yield, use as is).
In an alternate method for preparing ER-805821, ER 805819 (1 wt, 1 eq) and ER methyl 3-trimethysilylpent-4-eneoate (0.93 vol, 2 eq) were dissolved in anhydrous acetonitrile (5.46 wt, 7 vol). The reaction mixture was cooled to 0-5° C. and BF3•OEt2 (0.54 vol, 1.95 eq) was added over 5 minutes, while maintaining reaction temperature between 0-5° C. The reaction mixture was stirred at 0-5° C. for 20 hours then heptane (5.47 wt, 8 vol) was added at 0-5° C. The phases were separated and the lower layer treated with heptane (5.47 wt, 8 vol) at 0-5° C. The reaction was quenched by dropwise addition of 7.4% potassium bicarbonate aqueous solution (0.64 wt KHCO3 and 8 wt water), while maintaining the reaction temperature at 0-15° C. Toluene (8.65 wt, 10 vol) was added and the mixture stirred for 30 minutes. The lower layer was separated and the upper organic layer washed twice with water (10 vol) and concentrated to afford ER-805821 as a crude oil (1.05 wt, 0.935 eq).
ER-805821 (1 wt) was dissolved in anhydrous THF (8.4 vol) and anhydrous MeOAc (2 vol). Triton B(OH) (3.6 vol) was added over 2 minutes, reaction maintained 17-23° C. Reaction was stirred for 1.5 hour. Reaction mixture was filtered. The filtrate was concentrated and passed through a pad of SiO2 (5 wt, EtOAc, 20 vol). The filtrate was washed with brine (2.2 vol) and evaporated to give ER-805822 (0.54 wt, 72% yield).
In an alternate method for preparing ER-805822, ER-805821 (1 wt, 1 eq, 11.18 g, 21.81 mmol) was dissolved in anhydrous MTBE (4.4 wt, 6 vol.) and cooled to 0-5° C. NaOMe (28 wt % in MeOH, 0.564 wt, 1.5 eq) was added to the mixture over 1 hour at 0-5° C. and stirred for 3 hour at same temperature range. The reaction was quenched by addition of acetic acid (0.188 wt, 1.6 eq.), maintaining 0-5° C. during addition. The mixture was stirred overnight then treated with a 5 wt % aqueous solution of KHCO3 (3 wt) and ethyl acetate (3.6 wt, 4 vol) at 0-5° C., and then stirred for 15 minutes. After phase separation, the lower layer was extracted with ethyl acetate (3.6 wt, 4 vol) twice. The combined organic layer was concentrated. To the residue was added acetone (2 wt, 2.5 vol) and IPE (2 wt, 2.7 vol) and stirred overnight at 0-5° C. The mixture was filtered through Celite® (0.25 wt) and washed with acetone (2 wt). The filtrate was concentrated to afford the crude oil (0.55 wt). To the residue was added acetone (0.2 wt, 0.25 vol.) and IPE (0.54 wt, 0.75 vol.) and stirred for 1 hour at 40-50° C. The solution was seeded with ER-805822 at room temperature and stirred overnight at room temperature. To the suspension was added IPE (1.27 wt, 1.75 vol.) over 2 hours at room temperature. After stirring for 5 hours at room temperature, the precipitate was collected by filtration, and the cake washed with acetone/IPE (1/10) (2 vol.). The obtained cake was dried in a tray-type chamber at 30-40° C. overnight to afford the desired product ER-805822 (0.286 wt, 0.38 eq) in 38.0% yield from ER-805819.
In an alternative method for workup of crude ER-805822, the residue following concentration of the final EtOAc solution was dissolved in IPA (2 wt) and the solution was heated to 50° C. Heptane (5 wts) was added and the mixture was cooled to 20° C. and seeded. The mixture was stirred at 20° C. overnight. Heptane (10 wts) was added and the mixture was cooled to −5° C. in 30 min and stirred at −5° C. for 5 hrs. The mixture was filtered and the filter cake was washed with heptane (2 wts). The filter cake was dried with air flow under vacuum to provide ER-805822 (60%).
ER 805822 (1 wt) was dissolved in ethyl acetate or another appropriate solvent (5 vol) and water (5 vol). NaIO4 (0.58 wt, 1.05 eq) is added portionwise over 30 min to 1 hour, maintaining reaction temperature 0-10° C. Reaction is stirred for up to 2 hours. The reaction mixture was treated with NaCl (1 wt) and stirred for 30 min at 0 to 10° C. The reaction mixture was filtered and the cake is rinsed with ethyl acetate (2 vol). The phases were separated and the lower layer extracted with EtOAc (5 vol) three times. The combined organic layer was washed with 20% aqueous NaCl (5 wt). The organic layer was concentrated to give ER 804697 (1 wt). The residue was dissolved in toluene (2 vol) and the solution concentrated. The residue was dissolved in acetonitrile (7 vol) and used for the next step.
NiCl2 (0.025 wt) and CrCl2 (2.5 wt) were charged to reaction vessel under inert atmosphere. Anhydrous dichloromethane (5 vol) was charged. Stirring was initiated and the mixture was cooled to 0-3° C. Anhydrous DMSO (6.7 vol) was added with vigorous stirring over 45 minutes, maintaining temperature below 20° C. ER-804697 (1 wt) was dissolved in anhydrous dichloromethane (1 vol) and charged to the reaction vessel. The resulting mixture was warmed to 25° C. and 1-bromo-2-trimethylsilylethylene (2.58 wt) was added neat over 20 minutes. The reaction temperature was maintained below 45° C. The reaction was stirred for 30 minutes at 25-35° C. following complete addition. Methanol (5 vol) was added and the mixture was stirred for 10 minutes. MTBE (33 vol) was charged and the slurry transferred into 1N HCl (25 vol) and water (10 vol). The mixture was stirred for 5 minutes. The aqueous layer was back extracted with MTBE (10 vol) and the combined organics washed sequentially with 0.2N HCl (17 vol), twice with 1% NaCl solution (2×17 vol), and brine (13 vol). The organic layer was concentrated and purified (SiO2, 25 wt, 10 column vol EtOAc/Hex 1/3.5 v/v) to give ER-804698 (0.53 wt, 61%).
In an alternate method, this reaction was performed in the presence of the chiral ligand ER-807363 in a manner substantially similar to that described for the preparation of ER-118047, infra.
In an alternate method for preparing ER-804698, DMSO (7 vol.) and MeCN (7 vol) were degassed and cooled to 0-10° C. The solution was treated portionwise with CrCl2 (10 eq, 3.47 wt) and NiCl2 (0.1 eq, 0.037 wt) such that the internal temperature did not exceed 20° C. A solution of ER-804697 (1 wt, 1 eq) in MeCN (7 vol) and 1-bromo-2-trimethylsilylethylene (5 eq, 2.5 wt) were added dropwise at 0-10° C., not allowing the internal temperature to exceed 15° C. The reaction mixture was stirred at 5-15° C. overnight. To the mixture was added methanol (5.5 wt), water (7 wts), and MTBE (5.2 wts). The reaction was stirred for 1 hour and the lower layer was separated (layer 1). To the upper layer was added a premixed solution of NaCl (1.5 wts) and water (13.5 wts). The mixture was stirred for 1 hour and the lower layer was separated (layer 2). To the upper layer was added heptane (4.8 wts), methanol (2.8 wts), and a premixed solution of NaCl (1.5 wts) and water (13.5 wts). The mixture was stirred for 1 hour and the lower layer was separated (layer 3). The upper layer was drained and saved (organic 1). The reactor was charged with layer 1, methanol (2.8 wts), and MTBE (2.8 wts). The mixture was stirred overnight. The lower layer was separated and discarded. The upper layer was treated with layer 2. The mixture was stirred for 1 hour and the lower layer was separated and discarded. The upper layer was treated with layer 3 and heptane (4.8 wts). The mixture was stirred for 1 hour and the lower layer was separated and discarded. The upper layer was drained and saved (organic 2). The reactor was charged with layer 3, MTBE (0.8 wts), and heptane (2.7 wts). The mixture was stirred for 1 hour and the lower layers was separated and discarded. The upper layer was combined with organic 1 and organic 2. The combined organics were filtered and concentrated at reduced pressure to afford the crude ER-804698 which was purified by chromatography (SiO2, 25 wt, 10 column vol EtOAc/Hex 1/3.5 v/v) to give ER-804698 (0.67 wt, 57% yield).
In an alternate method of preparation of ER-804698, the crude material is taken directly to the next step without purification.
ER 804698 (1 wt, 1 eq) was treated with AcOH (4.2 wts) and water (4.2 wts). The mixture was heated to 90-97° C. for 100 min. The mixture was cooled to below 15° C. then washed with heptane (2×2.7 wts) twice below 15° C. After phase separation, a mixture of 20 wt % aqueous KHCO3 solution (7.7 wts, 35 eq) and MTBE (5.95 wts) was added dropwise to the lower layer such that temperature does not exceed 15° C. After phase separation the upper layer was washed successively with 5 wt % aqueous KHCO3 solution (0.2 wts), and twice with 5 wt % aqueous NaCl solution (2×0.2 wts). The organic layer was concentrated under reduced pressure and MTBE (1.49 wts) was added. The mixture was heated to 55° C. and stirred until dissolved. Heptane (1.00 wts) was added to the solution and the solution was cooled to 40-45° C. Additional heptane (4.47 wts) was added to the solution and the solution was cooled to 5-15° C. and then stirred overnight. The crystals were filtered and rinsed with heptane to provide ER-807023 (0.58 wts, 71% yield).
ER-807023 (1 wt, 1 eq) and MTBE (7.43 wts) were charged to a reactor under a nitrogen atmosphere. To the reaction was added 2,6-lutidine (2.15 wts, 7.5 eq). To the mixture was added dropwise TBSOTf (2.47 wts, 3.5 eq) at 0° C. The reaction mixture was stirred for 30 min at 0-10° C., then warmed to 23° C. over 1 hr and held at 23° C. for 16 hrs. MeOH (0.21 wts, 2.5 eq.) and water (14.8 wts) were added dropwise sequentially to the reaction mixture, maintaining temperature below 30° C. After phase separation, the upper layer was washed with 1N aqueous hydrochloric acid (16.2 wts), 5% NaClaq. (14.8 wts), 5% NaHCO3 aq. (14.8 wts), 5% NaCl aq. (14.8 wts), and 5% NaCl aq. (14.8 wts), respectively. The upper organic layer was concentrated by distillation under reduced pressure to afford the crude ER-804699. MeOH (7.91 wts) was added and the mixture was heated to 50° C. for 30 min. The mixture was cooled to 0° C. over 5 h, and then stirred overnight at 0° C. The solid was filtered, and the cake was washed with cold MeOH (4 wts) and dried to yield ER 804699 (1.42 wts, 74% yield).
Into a reactor under a nitrogen atmosphere was charged a solution of ER-804699 (1 wt, 1 eq) in toluene (2.60 wts). Acetonitrile (4.72 wts) was added. TBSCl (0.011 wts, 0.05 eq) was added. The reaction mixture was warmed to 30° C. and the NIS was added (1.25 wts, 4 eq). The reaction mixture was stirred at 22 hrs at 30° C. The reaction was cooled to 25° C. and the mixture of aqueous sodium thiosulfate and sodium bicarbonate (10.35 wts) were added over 10 minutes keeping the internal temperature below 30° C. The reaction was stirred for 30 minutes at 25° C. The aqueous layer was separated. The upper layer was washed twice with 10% NaCl (aq) (2×9.9 wts). The organic layer was concentrated under reduced pressure to give crude ER-803895 that was purified using silica gel chromatography to provide ER-803895 (0.96 wt, 89.5% yield).
A pre-dried glass lined reactor was charged with triphosgene (1 wt., 1 eq.) and anhydrous THF (2 vol.) and was cooled to an internal temperature of −10° C. A second pre-dried glass lined reactor was charged with ER-807244 (1.27 wt., 2.5 eq.) and anhydrous THF (3 vol.) then cooled to an internal temperature of −10° C. The contents of the first reactor were transferred into the second reactor at a rate such that internal temperature did not exceed 15° C. After complete addition, the reaction was stirred at an internal temperature of 0° C. for 1 hour and then gradually warmed to 25° C. A sparge of nitrogen was used for 18 hours to scrub away excess phosgene with trapping of the off-gases through a 2 N NaOH solution. MTBE (3 vol.) was added and the solvent removed by distillation under N2 purge at 40° to 46° C., adding more MTBE as needed. Upon complete removal of the phosgene, the mixture was cooled to an internal temperature of 5° to 10° C. and the solution filtered with MTBE (3 vol.) washes to yield ER-807245 (1.12 wt., 0.97 eq.) as a white crystalline solid.
Into a pre-dried and inerted reactor 1, was added ER-807245 (1 wt., 1 eq.) and anhydrous DMF (4 vol.). With stirring, the mixture was heated to an internal temperature of 95° C. D or L-Valinol (1.05 eq., 0.61 wt.) was dissolved in anhydrous (DMF 1.3 vol.) in reactor 2 with heating to an internal temperature of 90° C. The contents of reactor 2 were transferred into reactor 1 at internal temperature 90° C. CO2 evolution was be observed and the reaction was vented with a N2 bleed. The reaction solution was stirred at 90° C. for 3 hours and then cooled to an internal temperature of 65° C. Then, an aqueous slurry of lithium hydroxide (0.47 wt., 2 eq.) in water (2 vol.) was added to reactor 1 and the suspension stirred at an internal temperature of 65° C. for 1 hour. The reactor was charged with water (5 vol.) cooled to an internal temperature of ˜5° C. over 3 hours. The mixture was stirred for 8 hours at internal temperature ˜5° C. and the desired product collected by filtration with water (2×4 vol.) washes followed by n-heptane (2×3 vol.). The product was dried under vacuum and N2 flow at 35° C. for 24 hours or until KF≦250 ppm to yield ER-806628 or ER-808056 (0.80 wt., 0.60 eq.) as a crystalline solid.
A pre-dried and inerted reactor under nitrogen was charged with ER-806628 or ER-808056 (1 wt., 1 eq.), pyridine (3 wt., 11.4 eq.) and DMAP (0.03 wt., 0.05 eq.). The reaction was cooled to an internal temperature of −10° C. then methane-sulfonyl chloride (1.46 wt., 3 eq.) was added at a rate such that internal temperature was below 15° C. Upon complete addition, the reaction was stirred at an internal temperature of 0-15° C. for 1 hour and then slowly warmed to 25° C. over 2 hours. MTBE (2.6 vol.), was added followed by process water (2 vol.) at a rate such that the internal temperature did not exceed 35° C. The biphasic mixture was titrated with 6N hydrochloric acid, (˜1.9 vol.) portion-wise until the pH of the aqueous layer=˜3 to 5. If pH went under 3, 30% (w/w) aqueous solution of Na2CO3 was added to back titrate to the desired pH. The phases were allowed to partition and the aqueous phase separated. All organics were combined with water (0.7 vol.) and the aqueous phase discarded. The MTBE was distilled to a level of ˜2 vol. at atmosphere pressure to constant bp 55° C. and KF <500 ppm. Additional MTBE was added if necessary. The solution was cooled to an internal temperature of 5-10° C. with seeding when necessary to induce crystallization. n-Heptane (0.5 vol.) was added and the mixture stirred for 18 hours at 5° C. ER-806629 or ER-807363 was collected by filtration with n-heptane (2×3 vol.) washes. A second crop of crystals was obtained by concentration of the filtrates to ½ volume and cooling to 0° C. The filter cake was dried under N2 for 18 hours. The crude weighted ER-806629 was charged into a pre-dried reactor and MTBE (3 vol.) was added. The resulting mixture was heated to an internal temperature of 45-50° C. for 45 minutes and then slowly cooled to 5° C. over 3 hours, with seeding when necessary. n-Heptane (0.5 vol.) was added and the mixture stirred for 18 hours at an internal temperature of 5° C. The solid product was collected via filtration and n-heptane (2×3 vol.) washes then dried under vacuum at 35° C. for 24 hours to yield ER-806629 or ER-807363 (1.7 wt., 0.57 eq.) as a crystalline solid.
An appropriately sized reactor 1 was charged with ER-807363 (1.82 wt, 3.55 eq) and the atmosphere was exchanged for nitrogen. Anhydrous THF (15 vol) was added. In reactor 2, ER-806067 (F-1a, 1.14 wt, 1.1 eq) and ER-805973 (F-2a, 1 wt, 1 eq) were combined and dissolved in anhydrous THF (6.3 vol). With stirring, both reactors were sparged with nitrogen for 30-45 minutes. Under an inert atmosphere, reactor 2 was charged with CrCl2 (0.75 wt, 3.55 eq) and then heated to an internal temperature of 30° C. Reactor 2 was charged with triethylamine (0.62 wt, 3.55 eq) at a rate such that internal temperature did not exceed 45° C. After complete addition, an internal temperature of 30° C. was maintained for 1 hour. After 1 hour, reactor 2 was cooled to 0° C. and charged in an inert fashion with NiCl2 (0.02 wt, 0.1 eq), followed by the contents of reactor 1 and the reaction was warmed to rt. Reactor 2 was cooled to an internal temperature of 0° C. and then ethylenediamine (1.2 vol, 10 eq) was added at a rate such that the internal temperature did not exceed 10° C. Note: An exotherm was observed. The reaction was stirred for 1 hour, and then water (8 vol) and n-heptane (20 vol) were added and the biphasic mixture stirred for 4 minutes and the layers allowed to partition. The organic layer was separated and the aqueous layer back extracted with MTBE (20 vol). The combined organic layers were concentrated in vacuo to a crude oil followed by an azeotrope with anhydrous THF (2×10.5 vol). The crude product was dissolved in anhydrous THF (4.5 vol) and then stored at −20° C. until utilization in the next stage.
The ER-808227/THF solution from the previous step was analyzed via KF analysis. If KF <1000 ppm, then proceeded. If KF 1000 ppm KF>1000 ppm, azeotroped in vacuo with anhydrous THF (4.1 vol.). Repeated azeotrope until specification was met. The final solution meeting specifications contained the dissolved crude ER-808227 in anhydrous THF (4.1 vol.). Once the specification was met, an appropriately sized inerted reactor was charged with anhydrous THF (106 vol.) and the ER-808227/THF solution from the previous step. The reactor was cooled to an internal temperature of −15 to −20° C., then 0.5 M KHMDS in toluene (9.1 wt., 3.0 eq.) was added at a rate such that internal temperature did not exceed −12° C. Approximately 4.5 eq. KHMDS was necessary to drive the reaction to completion. The reaction was reverse quenched into semi-saturated ammonium chloride (40 vol.) at an internal temperature of 0° C. n-Heptane (80 vol.) was added, stirred for 2-5 minutes, and then allowed to partition. The organic layer was separated, the aqueous layer was back extracted with MTBE (70 vol.), then the organic layers were combined and washed with saturated sodium chloride solution (70 vol.). The organic layer was separated and concentrated in vacuo. To the crude concentrate was added n-heptane (60 vol.). Note: ER-807363 precipitated out of solution. The resulting suspension was filtered and the solids washed with n-heptane (20 vol.). The filtrate was concentrated in vacuo to afford crude ER-806746 (˜4 wt.) as a brown oil: Note: When additional ER-807363 precipitated out of solution, the filtration process was repeated. The crude ER-806746 was purified via SiO2 column chromatography to yield ER-804027 (1.16 wt., 0.55 eq.) as a clear yellowish oil. The chromatography was performed as follows: the column was first flushed with sufficient MTBE to remove water then flushed with heptane to remove the MTBE. The ER-806746 was loaded onto the column as a solution in heptane then eluted from the column with heptane/MTBE (5:1) then heptane/MTBE (4:1) with the fractions monitored at 230 nm by UV detector.
A reactor was charged with ER-804027 (1 wt, 1 eq) and anhydrous dichloromethane (7.6 vol). The reactor was cooled to an internal temperature of −78° C. and then 1 M DIBALH in dichloromethane (3.0 wt, 2.25 eq) was added at a rate such that internal temperature did not exceed −60° C. Methanol (0.1 vol) was added at a rate such that internal temperature did not exceed −60° C. Note: hydrogen gas evolved and was diluted with a stream of nitrogen. Upon complete addition, the mixture was warmed to ambient temperature and then 1 N hydrochloric acid (10.6 vol) and MTBE (25 vol) were added. The mixture was stirred for 20 minutes and the layers allowed to partition. The organic layer was separated and the aqueous layer was back extracted layer with MTBE (15.3 vol). The organic layers were combined and washed with water (3 vol), saturated sodium bicarbonate (3 vol), and saturated sodium chloride (3 vol), respectively, then concentrated in vacuo. The crude concentrate was purified via SiO2 column chromatography to yield ER-804028 (0.84 wt, 0.93 eq) as a white foam.
ER-803895 (F-3a) was dissolved in anhydrous toluene (14 wt.) and cooled to ←75° C <−75° C. under an argon atmosphere. DIBALH (1.5M in toluene, 0.95 wt., 1.3 eq.) was added at a rate to maintain the internal reaction temperature ←70° C <−70° C. The resulting mixture was stirred for 30 minutes then quenched with anhydrous methanol (0.13 wt., 3.2 eq.), maintaining the internal reaction temperature ←65° C <−65° C. The reaction mixture was allowed to warm to −10° C. and transferred with an MTBE rinse (3.74 wt.) to a workup vessel containing 1N HCl (10.2 wt.). The mixture was stirred for 30 minutes and the aqueous layer is was drained. The organic phase was washed sequentially with 1N HCl (10.2 wt.), water (10 wt.), saturated aqueous sodium bicarbonate (10 wt.), and brine (10 wt.) then concentrated under reduced pressure. The concentrate was purified via silica gel chromatography to afford ER-803896 (0.96 wt., 93% yield). The product is stored at −20° C. under argon.
At 0° C., a solution of azeotropically dried sulfone ER-804028 (1.0 wt., 1 eq.) in anhydrous tetrahydrofuran (5 vol., 4.45 wt.) was treated with n-butyl lithium (1.6M in hexanes, 1.02 wt., 1.5 vol., 2.05 eq.) such that the internal temperature did not exceed 5° C. The mixture was stirred at internal temperature 0 to 5° C. for 10 minutes then cooled to ←75° C <−75° C. Azeotropically dried aldehyde ER-803896 (1.07 wt., 1.23 eq.) was dissolved in anhydrous hexanes (3.53 wt., 5.35 vol.) then cooled to ←75° C <−75° C. The aldehyde solution was added to the ER-804028 anion by cannula such that internal temperature ≦−65° C. The mixture was stirred for 45 minutes at internal temperature −78° C. then quenched by the addition of saturated ammonium chloride (5 vol.), methyl tert-butyl ether (10 vol.), and water (5 vol.). The aqueous layer was discarded and the organic layer concentrated under reduced pressure. The crude material was purified via C-18 reverse phase chromatography to afford ER-804029 (84%, 1.57 wt.).
Sulfone-diol ER-804029 (1 wt., 1 eq.) was dissolved in wet dichloromethane (7.4 vol., 0.04 wt % water) and placed in a 20-25° C. water bath. Dess-Martin Reagent (0.67 wt., 2.5 eq.) was added in one portion. The reaction mixture was quenched with saturated sodium bicarbonate (10 vol) and 10 wt % aqueous sodium sulfite (10 vol.) and stirred for 30 minutes. The mixture was diluted with saturated sodium chloride (10 vol) and extracted with MTBE (25 vol). The aqueous layer was discarded and the organic layer concentrated and purified by silica gel chromatography to afford ER-804030 (0.9 wt., 90%). The material was stored under inert gas atmosphere at −20° C.
To a pre-dried reactor under inert atmosphere was charged samarium diiodide solution (2.5 eq.) and the solution cooled to internal temperature ←70° C <−70° C. ER-804030 (1 wt.) was dissolved in anhydrous methanol (4.1 wt.) and anhydrous THF (2.3 wt.) and then cooled to ←70° C <−70° C. ER-804030 was added to the cold samarium solution at a rate such that the internal temperature did not exceed −70° C. The reaction was quenched with potassium carbonate/Rochelle's Salts/water (1/10/100; w/w/v, 15 vol.) and MTBE (5 vol.) such that internal temperature did not exceed −65° C. Upon complete addition of the workup solution, the reaction was warmed to room temperature and the mixture transferred to a separatory vessel using the workup solution (20 vol. rinse) and MTBE (20 vol. rinse). The aqueous layer was discarded, the organic layer evaporated, and the residue purified via silica gel chromatography to afford ER-118049 (0.77 wt., 85%). The product was stored at −20° C. under inert atmosphere.
A pre-dried reactor was charged with (S)-ligand ER-807363 (2.05 wt) and the atmosphere was exchanged for nitrogen. The CrCl2 (0.85 wt, 10 eq) was added in one portion followed by anhydrous acetonitrile (21.5 wt) and the mixture was warmed and maintained between 30° C. to 35° C. Triethylamine (0.7 wt, 0.96 vol, 10 eq) was added in one portion and the mixture stirred for one hour. The NiCl2 (0.09 wt, 1 eq) was added in one portion, followed by the keto-aldehyde ER-118049 in anhydrous THF (2.43 wt, 2.73 vol) over 30 minutes. The heat was removed then heptane (20.5 wt, 30 vol) and Celite® (1.5 wt) were added. The mixture was stirred for 5 minutes and filtered over a pad of Celite® (15 wt) and the Celite® pad rinsed with heptane (7.3 vol) and acetonitrile (5 vol). The filtrate was transferred to a separatory funnel and the lower layer removed. The combined heptane layers were washed with acetonitrile (maximum 47.2 wt, maximum 60 vol) as necessary. The heptane layer was evaporated under reduced pressure and the product purified by silica gel chromatography to afford ER-118047/048 (0.64 wt, 70%).
Allyl alcohol ER-118047/048 was dissolved in dichloromethane (0.04 wt % water, 9 vol) and the reactor was placed in a water bath (20° C.) and the solution was treated with Dess-Martin Reagent (0.48 wt, 1.5 eq). The reaction mixture was treated with saturated aqueous sodium bicarbonate (9 vol) and 10 wt % aqueous sodium sulfite (9 vol) then stirred for 20 minutes and transferred to a separatory funnel with DCM (10 vol). The aqueous layer was discarded, and the organic layer evaporated to a residue. The crude material was purified by flash chromatography (prepped with 3 CV (1:1 (V/V) DCM/heptane, the material was loaded with 1:1 DCM/heptane then eluted with 10/10/1 heptane/DCM/MTBE). The product-containing fractions were concentrated and stored under inert atmosphere at −20° C.
Alternatively, the oxidation of ER-118047/48 to form the di-ketone ER-118046 was accomplished as follows. A flask was charged with ER-118047/48 (1 wt, 1.0 eq) and toluene (10 vol) and DMSO (0.15 wts, 2.5 eq) were added at room temperature. Et3N (0.31 wts, 4.0 eq) was added and the solution was cooled to −15° C. TCAA (0.33 wts, 1.4 eq) was added neat and the reaction warmed to 0° C. then stirred for 10 minutes at 0° C. The reaction was stirred for additional 10 minutes then was quenched with IPA (0.15 vol). The reaction was stirred at 0° C. for 10 minutes. 1N HCl (5 vol) was added over 2 minutes, and the reaction was warmed to room temperature and diluted with MTBE (5 vol). Two clear layers formed and the aqueous layer was removed and discarded. The organic layer was washed with 5 vol of 5% bicarbonate (aqueous), concentrated to a heavy yellow oil on a rotary evaporator and purified by silica gel chromatography (91% isolated yield).
Into an appropriately sized reaction vessel (vessel A) was charged imidazole hydrochloride (0.39 wt, 5 eq) followed by 1 M TBAF in THF (7.6 vol, 10 eq) at ambient temperature. The resulting mixture was stirred until it is homogenous (15-30 minutes). Into a second reaction vessel (vessel B) was charged ER-118046 (1 wt, 1 eq) and THF (33 vol). The contents of vessel B were placed under an inert atmosphere and stirred until ER-118046 was fully dissolved. The contents of flask A (TBAF/Imidazole) were charged as a single portion into flask B (ER-118046/THF). After 3-4 days, the reaction solution was loaded onto a column and purified by silica gel chromatography.
The dried ER-118064 (F-12 wherein R1 is MeO) residue was dissolved in anhydrous dichloromethane (28 vol) under a nitrogen atmosphere and treated with PPTS (1.0 wt, 5.2 eq) in one portion. After 30-90 minutes, the reaction mixture was directly loaded atop an appropriate column and purified by silica gel chromatography. The desired fractions of ER-076349 were concentrated in vacuo. The material resulting from the concentration of all pure fractions was azeotroped twice from toluene (20 vol), affording ER-076349 as a crunchy colorless solid/foam (0.44 wt, 0.79 eq after correction for residual toluene).
In a clean dry reaction vessel (flask C) ER-076349 (1 wt, 1 eq) was dissolved in anhydrous toluene (20 vol) and concentrated to dryness under reduced pressure. The substrate was re-dissolved in anhydrous toluene (20 vol) and concentrated to dryness. The substrate was dissolved in DCM (5 vol), and the solution placed under an argon atmosphere. Collidine (0.66 wts, 4.0 eq) was added as a single portion. Pyridine, as a solution in DCM (Flask B), was added as a single portion (5 mole %). The resulting mixture in flask C was cooled to an internal temperature of −20 to −25° C. A DCM solution of Ts2O was added drop-wise keeping the internal temperature below −16° C. (1.02 eq). The reaction was stirred at −20 to −25° C. for 80 minutes then warmed to 0° C. over 20 minutes and stirred for an additional 20 minutes. The reaction was quenched with water (2 vol). The bath was removed, and the reaction allowed to warm to room temperature (15-20° C.) and stirred (20 minutes). The reaction was rinsed to a larger vessel using the IPA (100 vol) and aqueous ammonium hydroxide (100 vol) was added to the reaction. The reaction was stirred at room temperature for 15-36 hours, monitoring for the disappearance of the tosylate (ER-082892) and epoxide (ER-809681) which formed in situ. The reaction was concentrated to dryness or near dryness at reduced pressure. The resulting material was diluted with DCM (25-40 vol) and washed pH 10 buffer (NaHCO3/Na2CO3 (aq), 10 vol). The aqueous phase was back extracted with 25 vol of DCM and the combined organic layers were concentrated to dryness. The resulting free amine was purified by silica gel chromatography using a buffered ACN/water mobile phase. The pooled fractions were concentrated at reduced pressure to remove ACN. The resulting aqueous layer was diluted with DCM (40 vol) and with 30 vol of a pH 10 buffered stock solution (NaHCO3/Na2CO3). The layers were mixed well and separated. The aqueous phase was back extracted with 25 vol of DCM and the combined organic layers were concentrated to dryness. The resulting free amine was polish filtered as a solution in 3:1 DCM/pentane and concentrated to dryness (0.80 wts) to afford B-1939.
While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example.
Claims (25)
1. A compound of formula F-4:
wherein:
each of PG1, PG2, and PG3 PG1 and PG2 is independently hydrogen or a suitable hydroxyl protecting group which taken with the oxygen atom to which it is bound, is selected from an ester, an ether, a silyl ether, an alkyl ether, an arylalkyl ether, and an alkoxyalkyl ether, or PG1 and PG2 are taken together, with the oxygen atoms to which they are bound, to form a diol protecting group selected from a cyclic acetal, a silylene, a cyclic carbonate, and a cyclic boronate;
PG3 is a suitable hydroxyl protecting group which taken with the oxygen atom to which it is bound, is selected from an ester, an ether, a silyl ether, an alkyl ether, an arylalkyl ether, and an alkoxyalkyl ether;
R1 is R or —OR;
each R is independently hydrogen, C1-4 haloaliphatic, benzyl, or C1-4 aliphatic; and
LG1 is a suitable leaving group chosen from alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, and halogen.
3. The compound according to claim 2 , wherein R1 is OR wherein R is hydrogen, methyl, or benzyl.
4. The compound according to claim 2 , wherein PG1 and PG2 are both hydrogen.
5. The compound according to claim 2 , wherein each of PG1 and PG2 is independently a suitable hydroxyl protecting group.
6. The compound according to claim 5 , wherein one or both of PG1 and PG2, taken together with the oxygen atom to which each is bound, is a silyl ether or an arylalkyl ether.
7. The compound according to claim 6 , wherein PG1 and PG2 are both t-butyldimethylsilyl.
8. The compound according to claim 5 , wherein PG1 and PG2 are taken together, with the oxygen atoms to which they are bound, to form a diol protecting group.
9. The compound according to claim 8 5, wherein said diol protecting group is a cyclic acetal or ketal, a silylene derivative, a cyclic carbonate, or a cyclic boronate one or both of PG1 and PG2, taken together with the oxygen atom to which each is bound, is selected from a carbonate, a sulfonate, a trialkylsilyl ether, and an acetal.
10. The compound according to claim 2 , wherein LG1 is sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, or halogen.
11. The compound according to claim 10 1, wherein LG1 is mesyloxy, tosyloxy, chloro, iodo, bromo, or triflate.
13. The compound according to claim 1 , wherein said suitable hydroxyl protecting group, taken with the oxygen atom to which it is bound, is selected from an ester, an ether, a silyl ether, an alkyl ether, an arylalkyl ether, and an alkoxyalkyl ether.
14. The compound according to claim 13 1, wherein
said ester is a formate, acetate, carbonate, or sulfonate;
said silyl ether is a trialkylsilyl ether; or
said alkoxyalkyl ether is an acetal.
15. The compound according to claim 13 1, wherein
said ester is formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, methyl carbonate, 9-fluorenylmethyl carbonate, ethyl carbonate, 2,2,2-trichloroethyl carbonate, 2-(trimethylsilyl)ethyl carbonate, 2-(phenylsulfonyl)ethyl carbonate, vinyl carbonate, ally! allyl carbonate, or p-nitrobenzyl carbonate;
said silyl ether is trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, or triisopropylsilyl ether;
said alkyl ether is methyl, trityl, t-butyl, allyl, or allyloxycarbonyl ether;
said alkoxyalkyl ether is methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and or tetrahydropyranyl ethers ether; or
said arylalkyl ether is benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- picolyl, or 4-picolyl.
16. The compound according to claim 1 , wherein LG1 is mesyloxy or tosyloxy.
17. The compound according to claim 9 8, wherein said cyclic acetal or ketal is diol protecting group is selected from methylene, ethylidene, benzylidene, isopropylidene, cyclohexylidene, or cyclopentylidene; or said silylene derivative is, di-t-butylsilylene or a, and 1,1,3,3-tetraisopropyldisiloxanylidene derivative.
18. The compound according to claim 1 , wherein LG1 is sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, or halogen.
19. A compound of formula F-4:
wherein:
each of PG1, PG2, and PG3 is independently hydrogen or a suitable hydroxyl protecting group;
PG1 and PG2, taken together with the oxygen atom to which each is bound, form a diol protecting group which is not a cyclic ketal;
R1 is R or —OR;
each R is independently hydrogen, C1-4 haloaliphatic, benzyl, or C1-4 aliphatic; and
LG1 is a suitable leaving group chosen from alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, and halogen.
20. A compound of formula F-4:
wherein:
each of PG1, PG2, and PG3 is independently hydrogen or a suitable hydroxyl protecting group;
PG1 and PG2, taken together with the oxygen atom to which each is bound, do not form a diol protecting group;
R1 is R or —OR;
each R is independently hydrogen, C1-4 haloaliphatic, benzyl, or C1-4 aliphatic; and
LG1 is a suitable leaving group chosen from alkoxy, sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, and halogen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/495,909 USRE45324E1 (en) | 2004-06-03 | 2005-06-03 | Intermediates for the preparation of analogs of halichondrin B |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57664204P | 2004-06-03 | 2004-06-03 | |
US62676904P | 2004-11-10 | 2004-11-10 | |
US66330005P | 2005-03-18 | 2005-03-18 | |
PCT/US2005/019669 WO2005118565A1 (en) | 2004-06-03 | 2005-06-03 | Intermediates for the preparation of halichondrin b |
US11/628,396 US7982060B2 (en) | 2004-06-03 | 2005-06-03 | Intermediates for the preparation of analogs of Halichondrin B |
US13/495,909 USRE45324E1 (en) | 2004-06-03 | 2005-06-03 | Intermediates for the preparation of analogs of halichondrin B |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE45324E1 true USRE45324E1 (en) | 2015-01-06 |
Family
ID=34972515
Family Applications (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/924,892 Active 2027-01-08 USRE46965E1 (en) | 2004-06-03 | 2005-06-03 | Intermediates for the preparation of analogs of Halichondrin B |
US13/495,909 Active 2027-01-08 USRE45324E1 (en) | 2004-06-03 | 2005-06-03 | Intermediates for the preparation of analogs of halichondrin B |
US11/628,396 Ceased US7982060B2 (en) | 2004-06-03 | 2005-06-03 | Intermediates for the preparation of analogs of Halichondrin B |
US13/171,971 Abandoned US20120029213A1 (en) | 2004-06-03 | 2011-06-29 | Intermediates for the preparation of analogs of halichondrin b |
US13/476,276 Active US8445701B2 (en) | 2004-06-03 | 2012-05-21 | Intermediates for the preparation of analogs of halichondrin B |
US13/868,641 Active US8618313B2 (en) | 2004-06-03 | 2013-04-23 | Intermediates for the preparation of analogs of Halichondrin B |
US14/096,549 Active US8884031B2 (en) | 2004-06-03 | 2013-12-04 | Intermediates for the preparation of analogs of halichondrin B |
US14/250,086 Active US8975422B2 (en) | 2004-06-03 | 2014-04-10 | Intermediates for the preparation of analogs of halichondrin B |
US14/624,171 Ceased US9303050B2 (en) | 2004-06-03 | 2015-02-17 | Intermediates for the preparation of analogs of Halichondrin B |
US15/944,480 Active USRE47797E1 (en) | 2004-06-03 | 2018-04-03 | Intermediates for the preparation of analogs of halichondrin B |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/924,892 Active 2027-01-08 USRE46965E1 (en) | 2004-06-03 | 2005-06-03 | Intermediates for the preparation of analogs of Halichondrin B |
Family Applications After (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/628,396 Ceased US7982060B2 (en) | 2004-06-03 | 2005-06-03 | Intermediates for the preparation of analogs of Halichondrin B |
US13/171,971 Abandoned US20120029213A1 (en) | 2004-06-03 | 2011-06-29 | Intermediates for the preparation of analogs of halichondrin b |
US13/476,276 Active US8445701B2 (en) | 2004-06-03 | 2012-05-21 | Intermediates for the preparation of analogs of halichondrin B |
US13/868,641 Active US8618313B2 (en) | 2004-06-03 | 2013-04-23 | Intermediates for the preparation of analogs of Halichondrin B |
US14/096,549 Active US8884031B2 (en) | 2004-06-03 | 2013-12-04 | Intermediates for the preparation of analogs of halichondrin B |
US14/250,086 Active US8975422B2 (en) | 2004-06-03 | 2014-04-10 | Intermediates for the preparation of analogs of halichondrin B |
US14/624,171 Ceased US9303050B2 (en) | 2004-06-03 | 2015-02-17 | Intermediates for the preparation of analogs of Halichondrin B |
US15/944,480 Active USRE47797E1 (en) | 2004-06-03 | 2018-04-03 | Intermediates for the preparation of analogs of halichondrin B |
Country Status (15)
Country | Link |
---|---|
US (10) | USRE46965E1 (en) |
EP (4) | EP3587408A1 (en) |
JP (5) | JP5226304B2 (en) |
KR (1) | KR101434673B1 (en) |
CN (2) | CN104876896A (en) |
AU (1) | AU2005250487B2 (en) |
CA (3) | CA2935786C (en) |
ES (1) | ES2748200T3 (en) |
HR (1) | HRP20150543T1 (en) |
HU (1) | HUE046436T2 (en) |
IL (5) | IL180252A (en) |
PL (1) | PL2522663T3 (en) |
RS (1) | RS54054B1 (en) |
SI (1) | SI2522663T1 (en) |
WO (1) | WO2005118565A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9303050B2 (en) | 2004-06-03 | 2016-04-05 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
US9303039B2 (en) | 2013-12-06 | 2016-04-05 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin B analogs |
US9382262B2 (en) | 2010-01-26 | 2016-07-05 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
US9469651B2 (en) | 2008-04-04 | 2016-10-18 | Eisai R&D Management Co., Ltd. | Halichondrin B analogs |
US9604993B2 (en) | 2007-10-03 | 2017-03-28 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US9783549B2 (en) | 2013-11-04 | 2017-10-10 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B |
US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
WO2018187331A1 (en) | 2017-04-05 | 2018-10-11 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
WO2019099646A1 (en) | 2017-11-15 | 2019-05-23 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
US10308661B2 (en) | 2015-05-07 | 2019-06-04 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides |
US10344038B2 (en) | 2015-04-30 | 2019-07-09 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
US10392400B2 (en) | 2016-11-11 | 2019-08-27 | President And Fellows Of Harvard College | Palladium-mediated ketolization |
US10556910B2 (en) | 2014-06-30 | 2020-02-11 | President And Fellows Of Harvard College | Synthesis of halichondrin analogs and uses thereof |
US10676481B2 (en) | 2016-02-12 | 2020-06-09 | Eisai R&D Management Co., Ltd. | Intermediates in the synthesis of eribulin and related methods of synthesis |
US11136335B2 (en) | 2016-06-30 | 2021-10-05 | Eisai R&D Management Co., Ltd. | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof |
US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
US11542269B2 (en) | 2018-01-03 | 2023-01-03 | Eisai R&D Management Co., Ltd. | Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof |
US11548898B2 (en) | 2017-07-06 | 2023-01-10 | President And Fellows Of Harvard College | Synthesis of halichondrins |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4454151B2 (en) | 1998-06-17 | 2010-04-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Macrocyclic analogs and their use and methods of preparation |
BRPI0820519A2 (en) * | 2007-11-16 | 2017-05-23 | Eisai R&D Man Co Ltd | intermediate for the synthesis of the halicondrin b analogue and desulfonylation reaction used for the intermediate |
SI2415470T1 (en) | 2009-03-30 | 2016-12-30 | Eisai R&D Management Co., Ltd. | Liposome composition |
US8765974B2 (en) | 2009-04-14 | 2014-07-01 | Nissan Chemical Industries, Ltd. | Method for producing tetrahydropyran compound and intermediate thereof |
WO2012147900A1 (en) | 2011-04-28 | 2012-11-01 | Eisai R&D Management Co., Ltd. | Microreactor process for halichondrin b analog synthesis |
WO2013053102A1 (en) * | 2011-10-11 | 2013-04-18 | Givaudan Sa | Improvements in or relating to organic compounds |
EP2785687B1 (en) | 2011-11-30 | 2019-02-20 | Sandoz AG | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
US9174956B2 (en) | 2011-12-16 | 2015-11-03 | Alphora Research Inc. | Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof |
WO2013097042A1 (en) * | 2011-12-29 | 2013-07-04 | Alphora Research Inc. | 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation |
EP2831082B1 (en) | 2012-03-30 | 2019-02-20 | Sandoz AG | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein |
JP6466339B2 (en) | 2012-12-04 | 2019-02-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Use of eribulin in the treatment of breast cancer |
BR112015029386B1 (en) | 2013-06-26 | 2023-11-14 | Eisai R&D Management Co., Ltd. | USE OF ERIBULIN AND LENVATINIB AS COMBINATION THERAPY AND KIT |
EP3016957A4 (en) | 2013-07-03 | 2016-11-30 | Alphora Res Inc | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups |
TW201617326A (en) | 2014-03-06 | 2016-05-16 | Alphora研發股份有限公司 | Crystalline derivatives of (S)-1-((2R,3R,4S,5S)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol |
EP3148526B1 (en) | 2014-05-28 | 2021-01-06 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of cancer |
WO2016038624A1 (en) * | 2014-09-09 | 2016-03-17 | Cipla Limited | "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof" |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
EP3265122B1 (en) | 2015-03-04 | 2022-05-04 | Merck Sharp & Dohme Corp. | Combination of pembrolizumab and eribulin for treating triple-negative breast cancer |
KR101777634B1 (en) * | 2016-01-18 | 2017-09-12 | 연성정밀화학(주) | Process for preparing 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivative and intermediate therefor |
TWI825834B (en) | 2016-03-02 | 2023-12-11 | 日商衛材R&D企管股份有限公司 | Eribulin-based antibody-drug conjugates and methods of use |
WO2017188350A1 (en) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Method for inhibiting tumor growth |
US11059799B2 (en) * | 2016-05-26 | 2021-07-13 | Dr. Reddy's Laboratories Limited. | Process for preparation of eribulin and intermediates thereof |
CN110072552A (en) | 2016-10-14 | 2019-07-30 | 默沙东公司 | For treating PD-1 antagonist and the combination of Ai Libulin of bladder transitional cell carcinoma |
EP3544596A4 (en) * | 2016-11-23 | 2020-10-07 | Dr. Reddy S Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
US10865212B2 (en) | 2017-01-02 | 2020-12-15 | Yonsung Fine Chemical Co.. Ltd. | Intermediate for preparing eribulin mesylate and process for preparing the same |
KR101880939B1 (en) * | 2017-01-02 | 2018-08-17 | 연성정밀화학(주) | Intermediate for Preparing Eribulin Mesylate and Process for Preapring the Same |
CN108948064B (en) | 2017-05-17 | 2021-02-02 | 上海时莱生物技术有限公司 | Eribulin intermediate and preparation method thereof |
US20190046513A1 (en) | 2017-08-10 | 2019-02-14 | Huya Bioscience International, Llc | Combination therapies of hdac inhibitors and tubulin inhibitors |
WO2019093776A1 (en) | 2017-11-09 | 2019-05-16 | 연성정밀화학(주) | Intermediate for preparing eribulin mesylate and method for preparing same |
US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
WO2019102490A1 (en) | 2017-11-21 | 2019-05-31 | Natco Pharma Limited | Intermediates for the preparation of eribulin thereof |
CN107973804B (en) * | 2017-11-29 | 2020-07-03 | 戊言医药科技(上海)有限公司 | Synthetic method of eribulin intermediate |
JP7063487B2 (en) * | 2018-03-02 | 2022-05-09 | 北京天一緑甫医葯科技有限公司 | Pyran condensed ring system compound, its production method and use |
WO2019211877A1 (en) | 2018-05-03 | 2019-11-07 | Cipla Limited | Process for the preparation of macrocyclic ketone analogs of halichondrin b |
WO2020008382A1 (en) * | 2018-07-04 | 2020-01-09 | Dr. Reddy’S Laboratories Limited | Process for preparation of eribulin and intermediates thereof |
CN111285894B (en) * | 2018-12-10 | 2021-03-05 | 北京天一绿甫医药科技有限公司 | Intermediate for preparing halichondrin compound and preparation method thereof |
CN111454277A (en) * | 2019-01-21 | 2020-07-28 | 上海茂晟康慧科技有限公司 | Synthetic method of eribulin intermediate ER806047 |
CN111689982B (en) * | 2019-03-15 | 2023-04-07 | 博瑞生物医药(苏州)股份有限公司 | Eribulin intermediate and preparation method thereof |
US11447499B2 (en) | 2019-06-14 | 2022-09-20 | Rk Pharma Inc. | Process for the preparation of eribulin mesylate intermediate |
US20220333139A1 (en) | 2019-06-21 | 2022-10-20 | Council Of Scientific And Industrial Research | A Chemo-Enzymatic Process for the Preparation of Homopropargylic Alcohol |
US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
CN112409302A (en) * | 2019-08-22 | 2021-02-26 | 上海茂晟康慧科技有限公司 | Synthetic method of eribulin intermediate ER806060 |
CN113024576B (en) * | 2019-12-09 | 2024-03-29 | 南通诺泰生物医药技术有限公司 | Preparation method of eribulin and intermediate thereof |
CN113024589A (en) * | 2019-12-09 | 2021-06-25 | 南通诺泰生物医药技术有限公司 | Preparation method of eribulin and intermediate thereof |
CN113135876B (en) * | 2020-01-16 | 2024-05-17 | 南通诺泰生物医药技术有限公司 | Preparation method of eribulin and intermediate thereof |
CN113121555B (en) * | 2020-01-16 | 2024-03-08 | 南通诺泰生物医药技术有限公司 | Method for preparing eribulin intermediate through microchannel reactor |
CN113549101A (en) * | 2020-04-26 | 2021-10-26 | 博瑞生物医药(苏州)股份有限公司 | Preparation method of eribulin and intermediate thereof |
CA3098164A1 (en) * | 2020-11-05 | 2022-05-05 | Eurofins Cdmo Alphora Inc. | Process for preparation of advanced intermediate for eribulin synthesys |
IL279168B (en) * | 2020-12-02 | 2022-04-01 | Finetech Pharmaceutical Ltd | Process for the preparation of eribulin |
CN114409617A (en) * | 2021-12-28 | 2022-04-29 | 南京格亚医药科技有限公司 | Preparation method of eribulin mesylate key intermediate isomer |
CN114213449A (en) * | 2021-12-28 | 2022-03-22 | 南京格亚医药科技有限公司 | Preparation method of eribulin mesylate key intermediate isomer |
WO2023157015A1 (en) * | 2022-02-17 | 2023-08-24 | Natco Pharma Limited | An improved process for the preparation of eribulin intermediates |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993017690A1 (en) | 1992-03-12 | 1993-09-16 | President And Fellows Of Harvard College | Halichondrins and related compounds |
EP0572109A1 (en) | 1992-03-23 | 1993-12-01 | Pharma Mar, S.A. | Halichondrins: Cytotoxic polyether macrolides |
US5436238A (en) | 1992-03-12 | 1995-07-25 | President And Fellows Of Harvard College | Halichondrins and related compounds |
WO1999065894A1 (en) | 1998-06-17 | 1999-12-23 | Eisai Co., Ltd. | Macrocyclic analogs and methods of their use and preparation |
US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
WO2005118565A1 (en) | 2004-06-03 | 2005-12-15 | Eisai Co., Ltd. | Intermediates for the preparation of halichondrin b |
WO2009046308A1 (en) | 2007-10-03 | 2009-04-09 | Eisai R & D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin b analogs |
WO2009064029A1 (en) | 2007-11-16 | 2009-05-22 | Eisai R & D Management Co., Ltd. | Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate |
WO2009124237A1 (en) | 2008-04-04 | 2009-10-08 | Eisai R&D Management Co., Ltd. | Halichondrin b analogs |
US20110184190A1 (en) | 2010-01-26 | 2011-07-28 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin b analogs |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW255880B (en) | 1992-09-09 | 1995-09-01 | Hoechst Ag | |
US6194586B1 (en) | 1996-09-06 | 2001-02-27 | Eli Lilly And Company | Selective sulphonation of the primary alcohol of a diol containing both primary and secondary alcohols |
US6870058B2 (en) * | 1996-12-03 | 2005-03-22 | The Trustees Of The University Of Pennsylvania | Compounds which mimic the chemical and biological properties of discodermolide |
US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
DE10106647A1 (en) * | 2001-02-12 | 2002-08-22 | Univ Hannover | Ratjadon derivatives to inhibit cell growth |
US20060045846A1 (en) | 2004-08-30 | 2006-03-02 | Horstmann Thomas E | Reagents and methods for labeling terminal olefins |
WO2006076100A2 (en) | 2004-12-09 | 2006-07-20 | Eisai Co. Ltd. | Tubulin isotype screening in cancer therapy using halichondrin b analogs |
WO2008010776A1 (en) | 2006-07-21 | 2008-01-24 | Agency For Science, Technology And Research | Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection |
WO2012147900A1 (en) | 2011-04-28 | 2012-11-01 | Eisai R&D Management Co., Ltd. | Microreactor process for halichondrin b analog synthesis |
EP2785687B1 (en) | 2011-11-30 | 2019-02-20 | Sandoz AG | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene |
EP2831082B1 (en) | 2012-03-30 | 2019-02-20 | Sandoz AG | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein |
JP6466339B2 (en) | 2012-12-04 | 2019-02-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Use of eribulin in the treatment of breast cancer |
EP3016957A4 (en) | 2013-07-03 | 2016-11-30 | Alphora Res Inc | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups |
BR112016009452B1 (en) | 2013-11-04 | 2022-06-07 | Eisai R&D Management Co., Ltd | Methods of preparing intermediates in the synthesis of eribulin, methods of preparing eribulin and eribulin mesylate, and intermediate compounds |
EP3505520A1 (en) | 2013-12-06 | 2019-07-03 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin b analogs |
US20170071903A1 (en) | 2014-03-03 | 2017-03-16 | Eisai R&D Management Co., Ltd. | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer |
EP3148526B1 (en) | 2014-05-28 | 2021-01-06 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of cancer |
WO2015184145A1 (en) | 2014-05-28 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
EP3265122B1 (en) | 2015-03-04 | 2022-05-04 | Merck Sharp & Dohme Corp. | Combination of pembrolizumab and eribulin for treating triple-negative breast cancer |
RU2739034C2 (en) | 2015-05-07 | 2020-12-21 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Macrocyclisation reaction and intermediate compound and other fragments, useful in synthesis of macrolides of halichondrins |
KR20180107243A (en) | 2016-02-12 | 2018-10-01 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Intermediates and related synthetic methods in the synthesis of eribulin |
CN109641917B (en) | 2016-06-30 | 2022-06-14 | 卫材R&D管理有限公司 | Prins reactions and intermediates useful for the synthesis of halichondrin macrolides and analogs thereof |
-
2005
- 2005-06-03 US US13/924,892 patent/USRE46965E1/en active Active
- 2005-06-03 CN CN201410850876.5A patent/CN104876896A/en active Pending
- 2005-06-03 WO PCT/US2005/019669 patent/WO2005118565A1/en active Application Filing
- 2005-06-03 EP EP19172746.0A patent/EP3587408A1/en not_active Withdrawn
- 2005-06-03 PL PL12178696T patent/PL2522663T3/en unknown
- 2005-06-03 EP EP05760356A patent/EP1771431A1/en not_active Ceased
- 2005-06-03 ES ES15159875T patent/ES2748200T3/en active Active
- 2005-06-03 CN CN201010236637.2A patent/CN101899026B/en active Active
- 2005-06-03 JP JP2007515643A patent/JP5226304B2/en active Active
- 2005-06-03 CA CA2935786A patent/CA2935786C/en active Active
- 2005-06-03 US US13/495,909 patent/USRE45324E1/en active Active
- 2005-06-03 CA CA3028453A patent/CA3028453C/en active Active
- 2005-06-03 EP EP12178696.6A patent/EP2522663B1/en active Active
- 2005-06-03 SI SI200531971T patent/SI2522663T1/en unknown
- 2005-06-03 CA CA2567984A patent/CA2567984C/en active Active
- 2005-06-03 EP EP15159875.2A patent/EP2949652B1/en active Active
- 2005-06-03 KR KR1020077000085A patent/KR101434673B1/en active IP Right Review Request
- 2005-06-03 HU HUE15159875A patent/HUE046436T2/en unknown
- 2005-06-03 RS RS20150371A patent/RS54054B1/en unknown
- 2005-06-03 AU AU2005250487A patent/AU2005250487B2/en active Active
- 2005-06-03 US US11/628,396 patent/US7982060B2/en not_active Ceased
-
2006
- 2006-12-21 IL IL180252A patent/IL180252A/en active IP Right Grant
-
2011
- 2011-06-29 US US13/171,971 patent/US20120029213A1/en not_active Abandoned
-
2012
- 2012-05-21 US US13/476,276 patent/US8445701B2/en active Active
- 2012-11-21 JP JP2012255149A patent/JP5705814B2/en active Active
-
2013
- 2013-04-23 US US13/868,641 patent/US8618313B2/en active Active
- 2013-07-09 IL IL227402A patent/IL227402A/en active IP Right Grant
- 2013-07-14 IL IL227474A patent/IL227474A/en active IP Right Grant
- 2013-12-04 US US14/096,549 patent/US8884031B2/en active Active
-
2014
- 2014-04-10 US US14/250,086 patent/US8975422B2/en active Active
- 2014-11-04 JP JP2014224099A patent/JP5964926B2/en active Active
-
2015
- 2015-02-17 US US14/624,171 patent/US9303050B2/en not_active Ceased
- 2015-05-20 HR HRP20150543TT patent/HRP20150543T1/en unknown
-
2016
- 2016-05-09 JP JP2016093633A patent/JP6138316B2/en active Active
- 2016-09-04 IL IL247620A patent/IL247620B/en not_active IP Right Cessation
-
2017
- 2017-03-07 JP JP2017042492A patent/JP6306235B2/en active Active
-
2018
- 2018-04-03 US US15/944,480 patent/USRE47797E1/en active Active
-
2019
- 2019-06-24 IL IL267606A patent/IL267606B/en active IP Right Grant
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5338865A (en) | 1992-03-12 | 1994-08-16 | President And Fellows Of Harvard College | Synthesis of halichondrin B and norhalichondrin B |
US5436238A (en) | 1992-03-12 | 1995-07-25 | President And Fellows Of Harvard College | Halichondrins and related compounds |
WO1993017690A1 (en) | 1992-03-12 | 1993-09-16 | President And Fellows Of Harvard College | Halichondrins and related compounds |
EP0572109A1 (en) | 1992-03-23 | 1993-12-01 | Pharma Mar, S.A. | Halichondrins: Cytotoxic polyether macrolides |
US7470720B2 (en) | 1998-06-17 | 2008-12-30 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
WO1999065894A1 (en) | 1998-06-17 | 1999-12-23 | Eisai Co., Ltd. | Macrocyclic analogs and methods of their use and preparation |
US6214865B1 (en) | 1998-06-17 | 2001-04-10 | Eisai Co., Ltd. | Macrocyclic analogs and methods of their use and preparation |
US6365759B1 (en) | 1998-06-17 | 2002-04-02 | Eisai Co., Ltd. | Intermediate compounds for preparing macrocylcic analogs |
JP2002518384A (en) | 1998-06-17 | 2002-06-25 | エーザイ株式会社 | Macrocyclic analogs and their use and methods of preparation |
US6469182B1 (en) | 1998-06-17 | 2002-10-22 | Eisai Co., Ltd. | Intermediates in the preparation of macrocyclic analogs |
US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
US20110172446A1 (en) | 1998-06-17 | 2011-07-14 | Littlefield Bruce A | Methods and compositions for use in treating cancer |
WO2005118565A1 (en) | 2004-06-03 | 2005-12-15 | Eisai Co., Ltd. | Intermediates for the preparation of halichondrin b |
US20070244187A1 (en) | 2004-06-03 | 2007-10-18 | Eisai Co., Ltd | Intermediates for the Preparation of Halichondrin B |
WO2009046308A1 (en) | 2007-10-03 | 2009-04-09 | Eisai R & D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin b analogs |
US20090198074A1 (en) | 2007-10-03 | 2009-08-06 | Eisai Co., Ltd. | Intermediates and methods for the synthesis of halichondrin b analogs |
WO2009064029A1 (en) | 2007-11-16 | 2009-05-22 | Eisai R & D Management Co., Ltd. | Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate |
US20090203771A1 (en) | 2007-11-16 | 2009-08-13 | Eisai R&D Management Co., Ltd. | Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate |
WO2009124237A1 (en) | 2008-04-04 | 2009-10-08 | Eisai R&D Management Co., Ltd. | Halichondrin b analogs |
US20110054194A1 (en) | 2008-04-04 | 2011-03-03 | Eisai R&D Management Co., Ltd. | Halichondrin B Analogs |
US20110184190A1 (en) | 2010-01-26 | 2011-07-28 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin b analogs |
WO2011094339A1 (en) | 2010-01-26 | 2011-08-04 | Eisai R&D Management Co., Ltd. | Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs |
Non-Patent Citations (87)
Title |
---|
Aicher et al., "Total Synthesis of Halichondrin B and Norhalichondrin B," J. Am. Chem. Soc. 114(8): 3162-3164 (1992). |
Aicher, T.D., et al., "Synthetic Studies Towards Halichondrins: Synthesis of the C.27-C.38 Segment," Tetrahedron Lett. 33(12): 1549-1552 (1992). |
Alley et al. "Comparison of the Relative Efficacies and Toxicities of Halichondrin B Analogues" Proceedings of the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, Nov. 14-18, 2005, C230, p. 257. |
Anderson, "Developing Processes for Crystallization-Induced Asymmetric Transformation," Org. Process. Res. Dev. 9: 800-813 (2005). |
Bai et al., "Halichondrin B and Homohalichondrin B, Marine Natural Products Binding in the Vinca Domain of Tubulin. Discovery of Tubulin-based Mechanism of Action by Analysis of Differential Cytotoxicity Data," J. Biol. Chem. 266(24): 15882-15889 (1991). |
Bernet et al., "Carbocyclische Verbindungen aus Monosacchariden, Umsetzungen in der Glucosereihe," Helv. Chim. Acta. 62: 1990-2016 (1979). |
Blanchette et al., "Horner-Wadsworth-Emmons Reaction: Use of Lithium Chloride and an Amine for Base-Sensitive Compounds," Tetrahedron Lett. 25(21): 2183-2186 (1984). |
Burke, S.D., et al., "Enantioselective Synthesis of a Halichondrin B C(20)->C(36) Precursor," Tetrahedron Lett., 36(39): 7023-7026 (1995). |
Burke, S.D., et al., "Synthesis of a C(22)->C(34) Halichondrin Precursor via a Double Dioxanone-to-Dihydropyran Rearrangement," Tetrahedron Lett., 32(32): 3961-3964 (1991). |
Burke, S.D., et al., "Synthesis of a C(22)-C(34) Halichondrin B Precursor via Ring Opening-Double Ring Closing Metathesis," J. Org. Chem., 63: 8626-8627 (1998). |
Burke, S.D., et al., "Synthetic Studies Toward Complex Polyether Macrolides of Marine Origin," Spec. Publ. R. Soc. Chem., 198: (Anti-Infectives), 73-85 (1997). |
Burke, S.D., et al., "Enantioselective Synthesis of a Halichondrin B C(20)→C(36) Precursor," Tetrahedron Lett., 36(39): 7023-7026 (1995). |
Burke, S.D., et al., "Synthesis of a C(22)→C(34) Halichondrin Precursor via a Double Dioxanone-to-Dihydropyran Rearrangement," Tetrahedron Lett., 32(32): 3961-3964 (1991). |
Chen C., et al., "Ni(II)/Cr(II)-Mediated Coupling Reaction: An Asymmetric Process," J. Org. Chem., 60: 5386-5387 (1995). |
Choi et al., "Assymmetric Ni(II)/Cr(II)-Mediated Coupling Reaction: Catalytic Process," Org. Lett. 4(25): 4435-4438 (2002). |
Choi et al., "Synthetic Studies on the Marine Natural Product Halichondrins," Pure Appl. Chem. 75(1): 1-17 (2003). |
Choi et al., "Synthetic Studies on the Marine Natural Product Halichondrins," Pure Appl. Chem. 75:1-17, 2003. |
Communication pursuant to Article 94(3) EPC from counterpart European Application EP 05760356.5, dated Jul. 4, 2012. |
Communication pursuant to Rule 114(2) EPC from counterpart European Application EP 05760356.5, dated Apr. 3, 2012. |
Cooper, A.J., et al., "Total Synthesis of Halichondrin B from Common Sugars: An F-Ring Intermediate from D-Glucose and Efficient Construction of the C1 to C21 Segment," Tetrahedron Lett., 34(51): 8193-8196 (1993). |
Dabybeen et al. "Comparison of the Activities of the Truncated Halichondrin B Analog NSC 707389 (E7389) with Those of the Parent Compound and a Proposed Binding Site on Tubulin" Molecular Pharmacology 2006, 70: 1866. |
Dong, C. et al. "New Syntheses of E7389 C14-C35 and Halichondrin C14-C38 Building Blocks: Reductive Cyclization and Oxy-Michael Cyclization Approaches"J. Am. Chem. Soc. 131: 15642-15646 (2009). |
Duan and Kishi, "Synthetic Studies on Halichondrins: A New Practical Synthesis of the C.1-C.12 Segment," Tetrahedron Lett. 34(47), pp. 7541-7544 (1993). |
English translation of the Office Action from the Chinese Patent Office for the counterpart Chinese Application No. 201010236637.2, dated Sep. 16, 2011. |
English translation of the Office Action from the Japanese Patent Office for the counterpart Japanese Application No. 2007-515,643, dated Apr. 24, 2012. |
English translation of the Office Action from the Japanese Patent Office for the counterpart Japanese Application No. 2007-515,643, dated Aug. 16, 2012. |
English translation of the Office Action from the Japanese Patent Office for the counterpart Japanese Application No. 2007-515,643, dated Sep. 13, 2011. |
Flemming et al., "Nitrile Anion Cyclizations," Tetrahedron 58:1-23 (2002). |
Hirata et al., "Halichondrins-Antitumor Polyether Macrolides from a Marine Sponge," Pure Appl. Chem. 58(5): 701-710 (1986). |
Hirata et al., "Halichondrins-Antitumor Polyether Macrolides from a Marine Sponge," Pure Appl. Chem. 58:701-710, 1986. |
Hori et al., "Efficient Synthesis of 2,3-trans-Tetrahedropyrans and Oxepanes: Rearrangement-Ring Expansion of Cyclic Ethers Having a Chloromethanesulfonate," Tetrahedron Lett. 40: 2145-2148 (1999). |
Horita et al., "Synthetic Studies of Halichondrin B, an Antitumor Polyether Macrolide Isolated from a Marine Sponge. 8. Synthesis of the Lactone Part (C1-C36) via Horner-Emmons Coupling Between C1-C15 and C16-C36 Fragments and Yamaguchi Lactonization," Tetrahedron Lett. 38(52): 8965-8968 (1997). |
Horita et al., "Synthetic Studies of Halichondrin B, an Antitumor Polyether Macrolide Isolated from a Marine Sponge. 8. Synthesis of the Lactone Part (C1-C36) via Horner-Emmons Coupling Between C1-C15 and C16-C36 Fragments and Yamaguchi Lactonization," Tetrahedron Lett. 38:8965-8968, 1997. |
Horita, K., et al., "Research on Anti-Tumor Active Site of Marine Source Natural Product, Halichondrin B.," International Congress Series, 1157 (Towards Natural Medicine Research in the 21st Century), 327-336 (1998). |
Horita, K., et al., "Synthetic Studies of Halichondrin B, an Antitumor Polyether Macrolide Isolated From a Marine Sponge. 2. Efficient Synthesis of C16-C26 Fragments via Construction of the D Ring by a Highly Stereocontrolled lodoetherification," Synlett, 40-43 (1994). |
Horita, K., et al., "Synthetic Studies of Halichondrin B, an Antitumor Polyether Macrolide Isolated from a Marine Sponge. 3. Synthesis of C27-C36 Subunit via Completely Stereoselective C-Glycosylation to the F ring," Synlett, 43-45 (1994). |
Horita, K., et al., "Synthetic Studies of Halichondrin B, an Antitumor Polyether Macrolide Isolated from a Sponge. 7. Synthesis of Two C27-C36 Units via Construction of the F ring and Completely Stereoselective C-Glycosylation Using Mixed Lewis Acids," Chem. Pharm. Bull., 45(10): 1558-1572 (1997). |
Horita, K., et al., "Synthetic Studies on Halichondrin B, an Antitumor Polyether Macrolide Isolated from a Marine Sponge. 9. Synthesis of the C16-C36 unit via Stereoselective Construction of the D and E Rings," Chem. Pharm. Bull., 46(8): 1199-1216 (1998). |
Horita, K., et al., "Synthetic Study of a Highly Antitumorigenic Marine Phytochemical, Halichondrin B," Phytochemicals and Phytopharmaceuticals, Shahihi, F. and Ho, C.-T., Eds., AOCS Press, Champaign, IL, 2000, 382-397. |
International Preliminary Report on Patentability from International Application No. PCT/US2005/019669, issued Dec. 4, 2006. |
International Search Report from International Application No. PCT/US2005 (date of completion of search and Sep. 7, 2005 (date of mailing of report). |
Jackson et al., "A Total Synthesis of Norhalichondrin B" Angew. Chem. Int. Ed. 48: 2346-2350 (2009). |
Jackson et al., "The Halichondrins and E7389," Chem. Rev. 109: 3044-3079 (2009). |
Jerry March, "Advanced Organic Chemistry," 4th Ed., pp. 348-357, John Wiley and Sons, N.Y. (1992). |
Jiang, L., et al., "A Novel Route to the F-Ring of Halichondrin B. Diastereoselection in Pd(0)-Mediated meso and C2 Diol Desymmetrization," Org. Lett., 4(20): 3411-3414 (2002). |
Jiang, L., et al., "A Practical Synthesis of the F-Ring of Halichondrin B via Ozonolytic Desymmetrization of a C2-Symmetric Dihydroxycyclohexene," J. Org. Chem., 68: 1150-1153 (2003). |
Kim, D. et al. "New Syntheses of E7389 C14-C35 and Halichondrin C14-C38 Building Blocks: Double-Inversion Approach" J. Am. Chem. Soc. 131: 15636-15641 (2009). |
Kurosu et al., "Fe/Cr- and Co/Cr-Mediated Catalytic Asymmetric 2-Haloallylations of Aldehydes," J. Am. Chem. Soc. 126: 12248-12249 (2004). |
Mattocks, "Novel Reactions of Some alpha-Acyloxy Acid Chlorides," J. Chem. Soc. 371: 1918-1930 (1964). |
Mattocks, "Novel Reactions of Some alpha-Acyloxy-acid Halides,"J. Chem. Soc. 932: 4840-4845 (1964). |
Mattocks, "Novel Reactions of Some α-Acyloxy Acid Chlorides," J. Chem. Soc. 371: 1918-1930 (1964). |
Mattocks, "Novel Reactions of Some α-Acyloxy-acid Halides,"J. Chem. Soc. 932: 4840-4845 (1964). |
Mitsunobu, "The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products," Synthesis. 1-28 (1981). |
Newman, "Drug Evaluation: Eribulin, a Simplified Ketone Analog of the Tubulin Inhibitor Halichondrin B. for the Potential Treatment of Cancer," Curr. Opin. Invest. Drugs. 8: 1057-1066 (2007). |
Office Action from the Canadian Intellectual Property Office for the counterpart Canadian Application No. 2,567,984, dated Oct. 7, 2011. |
RN: 185411-09-0; CN: L-arabino-D-allo-Dodeconic acid, 3,7:6, 10-dianhydro-8,9-O-cyclohexylidene-2,4,5-trideoxy-, methyl ester; Entered STN: Jan. 28, 1997. |
RN: 546141-26-8; CN: 1,2-Propaneldiol, 3-[(2R,3R,4R,5S)-tetrahydro-3-hydroxy-4-[(phenylsulfony)methyl]- 5-(2-propen-1-yl)-2-furanyl]-,1,2-dibenzoate, (2S)-; Entered STN: Jul. 11, 2003. |
RN: 546141-39-3; CN: 1,2-Propaneldiol, 3-[(2R,3R,4R,5S)-tetrahydro-3-methoxy-4-[(phenylsulfony)methyl]- 5-(2-propen-1-y1)-2-furanyl]-,1,2-dibenzoate, (2S); Entered STN: Jul. 11, 2003. |
RN: 546141-40-6; CN: 1,2-Propaneldiol, 3-[(2R,3R,4R,5S)-tetrahydro-3-methoxy-4-[(phenylsulfony)methyl]- 5-(2-propen-1-yl)-2-furanyl]-, (2S); Entered STN: Jul. 11, 2003. |
Sakamoto et al., "Stereoselective Ring Expansion via Bicyclooxonium Ion. A Novel Approach to Oxocanes," Org. Lett. 4(5):675-678 (2002). |
Schreiber, "Hydrogen Transfer from Tertiary Amines to Trifluoroacetic Anhydride," Tetrahedron Lett. 21: 1027-1030 (1980). |
Seletsky et al., "Structurally simplified macrolactone analogues of halichondrin B" Bioorg. Med. Chem. Lett. 14:5547 (2004). |
Stamos et al., "A Mild Preparation of Vinyliodides from Vinylsilanes," Tetrahedron Lett. 37(48), pp. 8647-8650 (1996). |
Stamos et al., "New Synthetic Route to the C.14-C.38 Segment of Halichondrins," J. Org. Chem. 62:7552-7553 (1997). |
Stamos et al., "Synthetic Studies on Halichondrins: A Practical Synthesis of the C.1-C.13 Segment," Tetrahedron Lett. 37(48): 8643-8646 (1996). |
Stamos, D.P., et al., "Ni(II)/Cr(II)-Mediated Coupling Reaction: Beneficial Effects of 4-Tert-Butylpyridine as an Additive and Development of New and Improved Workup Procedures," Tetrahedron Lett., 38(36): 6355-6358 (1997). |
Supporting Information for Wan et al., "Asymmetric Ni(II)/Cr(II)-Mediated Coupling Reaction: Stoichiometric Process," Organic Letters 4(25), pp. 4431-4434 (2002). |
Takai et al., "Reactions of Alkenylchromium reagents prepared from alkenyl trifluoromethanesulfonates (triflates) with chromium (II) chloride under nickel catalysis," J. Am. Chem. Soc. 108, pp. 6048-6050 (1986). |
Third party observation pursuant to Article 115 EPC relating to European Application EP 05760356.5, dated Jan. 9, 2013. |
Third party observation pursuant to Article 115 EPC relating to European Application No. EP 05760356.5, dated Mar. 26, 2012. |
Tokunaga et al., "Asymmetric Catalysis with Water: Efficient Kinetic Resolution of Terminal Exposides by Means of Catalytic Hydrolysis," Science 277: 936-938 (1997). |
Towle et al. "Hafichondrin B Macrocyclic Ketone Analog E7389: Medicinal Chemistry Repair of Lactone Ester Instability Generated During Structural Simplification to Clinical Candidate" Annual Meeting of the American of the American Association for Cancer Research, Apr. 6-10, 2002, 5721. |
Towle et al. "In Vitro and In Vivo Anticancer Activities of Synthetic Macrocyclic Ketone Analogues of Halichondrin B" Cancer Research 2001, 61:1013. |
U.S. Patent and Trademark Office, "Clarification of Criteria for Reissue Error in View of In re Tanaka," dated Aug. 1, 2011. |
Uemura et al., "Norhalichondrin A: An Antitumor Polyether Macrolide from a Marine Sponge," J. Am. Chem. Soc. 107: 4796-4798 (1985). |
Vandat et al., "Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients with Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane," J. Clin. Oncol. 27(18): 2954-2961 (2009). |
Wan et al., "Asymmetric Ni(II)/Cr(II)-Mediated Coupling Reaction: Stoichiometric Process," Org. Lett. 4(25): 4431-4434 (2002). |
Wan et al., "Asymmetric Ni(II)/Cr(II)-Mediated Coupling Reaction: Stoichiometric Process," Organic Letters 4(25), pp. 4431-4434 (2002). |
Wang et al. "Structure-Activity Relationships of Halichondrin B Analogues: Modifications at C.30-C.38" Bioorg. Med. Chem. Lett. 2000, 10:1029. |
Written Opinion from International Application No. PCT/US2005/019669, mailed Sep. 7, 2005. |
Xie, C., et al., "Synthesis of the C20-C26 Building Block of Halichondrins via a Regiospecific and Stereoselective SN2' Reaction," Org. Lett., 4(25): 4427-4429 (2002). |
Xie, C., et al., "Synthesis of the C20-C26 Building Block of Halichondrins via a Regiospecific and Stereoselective SN2′ Reaction," Org. Lett., 4(25): 4427-4429 (2002). |
Yang et al., "Second Generation Synthesis of C27-C35 Building Block of E7389, a Synthetic Halichondrin Analogue," Org. Lett. 11(20): 4516-4519 (2009). |
Yu et al., Anticancer Agents from Natural Products; CRC Press: Boca Raton, FL, 241-265. (2005). |
Yu et al., New Synthetic Route to the C.14-C.21 Fragment of Halichondrin B, Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, Mar. 26-30, 2000 (2000). |
Zheng et al., "Macrocyclic Ketone Analogues of Halichondrin B," Bioorg. Med. Chem. Lett. 14: 5551-5554 (2004). |
Zheng, W. et al. "Synthetic macrocyclic ketone analogs of halichondrin B: structure-activity relationships" American Association for Cancer Research, San Francisco, CA Apr. 1-5, 2000, 1915. |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46965E1 (en) | 2004-06-03 | 2018-07-24 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
USRE47797E1 (en) | 2004-06-03 | 2020-01-07 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of halichondrin B |
US9303050B2 (en) | 2004-06-03 | 2016-04-05 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of analogs of Halichondrin B |
US10717743B2 (en) | 2007-10-03 | 2020-07-21 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US9604993B2 (en) | 2007-10-03 | 2017-03-28 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US10214539B2 (en) | 2007-10-03 | 2019-02-26 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US9802953B2 (en) | 2007-10-03 | 2017-10-31 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
US9469651B2 (en) | 2008-04-04 | 2016-10-18 | Eisai R&D Management Co., Ltd. | Halichondrin B analogs |
US10494388B2 (en) | 2010-01-26 | 2019-12-03 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
US9382262B2 (en) | 2010-01-26 | 2016-07-05 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
US9856276B2 (en) | 2010-01-26 | 2018-01-02 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
US10611773B2 (en) | 2013-11-04 | 2020-04-07 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B |
US11643418B2 (en) | 2013-11-04 | 2023-05-09 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B |
US9783549B2 (en) | 2013-11-04 | 2017-10-10 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B |
US10221189B2 (en) | 2013-11-04 | 2019-03-05 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B |
US10934307B2 (en) | 2013-11-04 | 2021-03-02 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of analogs of halichondrin B |
US9303039B2 (en) | 2013-12-06 | 2016-04-05 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin B analogs |
US10450324B2 (en) | 2013-12-06 | 2019-10-22 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin B analogs |
US9695188B2 (en) | 2013-12-06 | 2017-07-04 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin B analogs |
US10030032B2 (en) | 2013-12-06 | 2018-07-24 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin B analogs |
US11155562B2 (en) | 2014-06-30 | 2021-10-26 | President And Fellows Of Harvard College | Synthesis of halichondrin analogs and uses thereof |
US10556910B2 (en) | 2014-06-30 | 2020-02-11 | President And Fellows Of Harvard College | Synthesis of halichondrin analogs and uses thereof |
US11220513B2 (en) | 2015-04-30 | 2022-01-11 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
US10633392B2 (en) | 2015-04-30 | 2020-04-28 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
US10344038B2 (en) | 2015-04-30 | 2019-07-09 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
US10913749B2 (en) | 2015-05-07 | 2021-02-09 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides |
US10308661B2 (en) | 2015-05-07 | 2019-06-04 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides |
US10676481B2 (en) | 2016-02-12 | 2020-06-09 | Eisai R&D Management Co., Ltd. | Intermediates in the synthesis of eribulin and related methods of synthesis |
US11136335B2 (en) | 2016-06-30 | 2021-10-05 | Eisai R&D Management Co., Ltd. | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof |
US10844073B2 (en) | 2016-11-11 | 2020-11-24 | President And Fellows Of Harvard College | Palladium-mediated ketolization |
US10392400B2 (en) | 2016-11-11 | 2019-08-27 | President And Fellows Of Harvard College | Palladium-mediated ketolization |
US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
US10954249B2 (en) | 2017-04-05 | 2021-03-23 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
EP4119563A2 (en) | 2017-04-05 | 2023-01-18 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
WO2018187331A1 (en) | 2017-04-05 | 2018-10-11 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
US11725015B2 (en) | 2017-04-05 | 2023-08-15 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
US11548898B2 (en) | 2017-07-06 | 2023-01-10 | President And Fellows Of Harvard College | Synthesis of halichondrins |
WO2019099646A1 (en) | 2017-11-15 | 2019-05-23 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
US11407762B2 (en) | 2017-11-15 | 2022-08-09 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
US11814398B2 (en) | 2017-11-15 | 2023-11-14 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
EP4403560A2 (en) | 2017-11-15 | 2024-07-24 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
US11542269B2 (en) | 2018-01-03 | 2023-01-03 | Eisai R&D Management Co., Ltd. | Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE47797E1 (en) | Intermediates for the preparation of analogs of halichondrin B | |
US20150175620A1 (en) | Compounds useful in the synthesis of halichondrin b analogs | |
CA2822994C (en) | Intermediates for the preparation of analogs of halichondrin b | |
US8580975B2 (en) | Synthesis of macrocyclic cancer chemotherapy agents and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
CC | Certificate of correction | ||
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |